0001193125-16-757218.txt : 20161102 0001193125-16-757218.hdr.sgml : 20161102 20161102170130 ACCESSION NUMBER: 0001193125-16-757218 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 55 CONFORMED PERIOD OF REPORT: 20160930 FILED AS OF DATE: 20161102 DATE AS OF CHANGE: 20161102 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HEALTHSTREAM INC CENTRAL INDEX KEY: 0001095565 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMPUTER PROGRAMMING, DATA PROCESSING, ETC. [7370] IRS NUMBER: 621443555 STATE OF INCORPORATION: TN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-27701 FILM NUMBER: 161968834 BUSINESS ADDRESS: STREET 1: 209 10TH AVE SOUTH STE 450 CITY: NASHVILLE STATE: TN ZIP: 37203 BUSINESS PHONE: 6153013100 MAIL ADDRESS: STREET 1: 209 10TH AVE SOUTH STE 450 CITY: NASHVILLE STATE: TN ZIP: 37203 10-Q 1 d267831d10q.htm FORM 10-Q Form 10-Q
Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 10-Q

 

 

Quarterly Report pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

For the quarterly period ended September 30, 2016

Commission File No.: 000-27701

 

 

HealthStream, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Tennessee   62-1443555

(State or other jurisdiction of

incorporation or organization)

  (I.R.S. Employer Identification No.)

209 10th Avenue South, Suite 450

Nashville, Tennessee

  37203
(Address of principal executive offices)   (Zip Code)

(615) 301-3100

(Registrant’s telephone number, including area code)

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  ☒    No  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer      Accelerated filer  
Non-accelerated filer   ☐  (Do not check if a smaller reporting company)    Smaller reporting company  

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes   ☐    No  ☒

As of November 2, 2016, there were 31,739,741 shares of the registrant’s common stock outstanding.

 

 

 


Table of Contents

Index to Form 10-Q

HEALTHSTREAM, INC.

 

         Page
Number
 

Part I.

 

Financial Information

  

Item 1.

 

Financial Statements

  
 

Condensed Consolidated Balance Sheets – September 30, 2016 (Unaudited) and December 31, 2015

     1   
 

Condensed Consolidated Statements of Income (Unaudited) – Three and Nine Months ended September 30, 2016 and 2015

     2   
 

Condensed Consolidated Statements of Comprehensive Income (Unaudited) – Three and Nine Months ended September 30, 2016 and 2015

     3   
 

Condensed Consolidated Statement of Shareholders’ Equity (Unaudited) – Nine Months ended September 30, 2016

     4   
 

Condensed Consolidated Statements of Cash Flows (Unaudited) – Nine Months ended September 30, 2016 and 2015

     5   
 

Notes to Condensed Consolidated Financial Statements (Unaudited)

     6   

Item 2.

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations

     16   

Item 3.

 

Quantitative and Qualitative Disclosures About Market Risk

     23   

Item 4.

 

Controls and Procedures

     23   

Part II.

 

Other Information

  

Item 2.

 

Unregistered Sales of Equity Securities and Use of Proceeds

     24   

Item 6.

 

Exhibits

     24   
 

Signature

     25   


Table of Contents

PART I. FINANCIAL INFORMATION

 

Item 1. Financial Statements

HEALTHSTREAM, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)

 

     September 30,
2016
    December 31,
2015
 
     (Unaudited)        
ASSETS     

Current assets:

    

Cash and cash equivalents

   $ 39,820      $ 82,010   

Marketable securities

     60,747        66,976   

Accounts receivable, net of allowance for doubtful accounts of $603 and $303 at September 30, 2016 and December 31, 2015, respectively

     46,166        36,348   

Accounts receivable – unbilled

     2,296        1,998   

Prepaid royalties, net of amortization

     16,466        14,036   

Other prepaid expenses and other current assets

     7,584        8,169   
  

 

 

   

 

 

 

Total current assets

     173,079        209,537   

Property and equipment, net

     10,403        12,471   

Capitalized software development, net of accumulated amortization of $29,717 and $24,130 at September 30, 2016 and December 31, 2015, respectively

     15,749        13,955   

Goodwill

     109,796        83,073   

Intangible assets, net of accumulated amortization of $14,038 and $8,685 at September 30, 2016 and December 31, 2015, respectively

     80,771        55,966   

Non-marketable equity investments

     3,289        3,640   

Other assets

     964        927   
  

 

 

   

 

 

 

Total assets

   $ 394,051      $ 379,569   
  

 

 

   

 

 

 
LIABILITIES AND SHAREHOLDERS’ EQUITY     

Current liabilities:

    

Accounts payable

   $ 3,675      $ 4,616   

Accrued royalties

     13,885        9,053   

Accrued liabilities

     10,623        7,003   

Accrued compensation and related expenses

     2,028        3,308   

Deferred revenue

     65,029        65,098   
  

 

 

   

 

 

 

Total current liabilities

     95,240        89,078   

Deferred tax liabilities

     4,909        4,763   

Deferred revenue, noncurrent

     6,735        4,350   

Other long term liabilities

     778        1,058   

Commitments and contingencies

     —          —     

Shareholders’ equity:

    

Common stock, no par value, 75,000 shares authorized; 31,739 and 31,647 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively

     280,759        278,799   

Retained earnings

     5,657        1,591   

Accumulated other comprehensive loss

     (27     (70
  

 

 

   

 

 

 

Total shareholders’ equity

     286,389        280,320   
  

 

 

   

 

 

 

Total liabilities and shareholders’ equity

   $ 394,051      $ 379,569   
  

 

 

   

 

 

 

See accompanying notes to the unaudited condensed consolidated financial statements.

 

1


Table of Contents

HEALTHSTREAM, INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)

(In thousands, except per share data)

 

     Three Months Ended
September 30,
     Nine Months Ended
September 30,
 
     2016      2015      2016      2015  

Revenues, net

   $ 58,367       $ 53,835       $ 167,237       $ 153,136   

Operating costs and expenses:

           

Cost of revenues (excluding depreciation and amortization)

     24,889         23,126         70,410         65,752   

Product development

     7,261         6,195         21,524         16,654   

Sales and marketing

     10,285         8,377         27,843         26,052   

Other general and administrative expenses

     8,891         7,173         25,396         20,851   

Depreciation and amortization

     5,755         4,639         15,976         12,148   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total operating costs and expenses

     57,081         49,510         161,149         141,457   

Operating income

     1,286         4,325         6,088         11,679   

Other income (expense), net

     337         28         465         (7
  

 

 

    

 

 

    

 

 

    

 

 

 

Income before income tax provision

     1,623         4,353         6,553         11,672   

Income tax provision

     461         1,739         2,487         4,862   
  

 

 

    

 

 

    

 

 

    

 

 

 

Net income

   $ 1,162       $ 2,614       $ 4,066       $ 6,810   
  

 

 

    

 

 

    

 

 

    

 

 

 

Earnings per share:

           

Basic

   $ 0.04       $ 0.08       $ 0.13       $ 0.23   
  

 

 

    

 

 

    

 

 

    

 

 

 

Diluted

   $ 0.04       $ 0.08       $ 0.13       $ 0.23   
  

 

 

    

 

 

    

 

 

    

 

 

 

Weighted average shares of common stock outstanding:

           

Basic

     31,739         31,643         31,714         29,527   
  

 

 

    

 

 

    

 

 

    

 

 

 

Diluted

     32,107         32,029         32,050         29,905   
  

 

 

    

 

 

    

 

 

    

 

 

 

See accompanying notes to the unaudited condensed consolidated financial statements.

 

2


Table of Contents

HEALTHSTREAM, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)

(In thousands)

 

     Three Months Ended
September 30,
     Nine Months Ended
September 30,
 
     2016     2015      2016      2015  

Net income

   $ 1,162      $ 2,614       $ 4,066       $ 6,810   

Other comprehensive income, net of taxes:

          

Unrealized gain (loss) on marketable securities

     (13     31         43         (10
  

 

 

   

 

 

    

 

 

    

 

 

 

Total other comprehensive income (loss)

     (13     31         43         (10
  

 

 

   

 

 

    

 

 

    

 

 

 

Comprehensive income

   $ 1,149      $ 2,645       $ 4,109       $ 6,800   
  

 

 

   

 

 

    

 

 

    

 

 

 

See accompanying notes to the unaudited condensed consolidated financial statements.

 

3


Table of Contents

HEALTHSTREAM, INC.

CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS’ EQUITY (UNAUDITED)

NINE MONTHS ENDED SEPTEMBER 30, 2016

(In thousands)

 

     Common Stock     Retained      Accumulated
Other
Comprehensive
    Total
Shareholders’
 
     Shares      Amount     Earnings      Loss     Equity  

Balance at December 31, 2015

     31,647       $ 278,799      $ 1,591       $ (70   $ 280,320   

Net income

     —           —          4,066         —          4,066   

Comprehensive income (loss)

     —           —          —           43        43   

Stock based compensation

     —           1,516        —           —          1,516   

Tax benefits from equity awards

     —           661        —           —          661   

Common stock issued under stock plans, net of shares withheld for employee taxes

     92         (217     —           —          (217
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

 

Balance at September 30, 2016

     31,739       $ 280,759      $ 5,657       $ (27   $ 286,389   
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

 

See accompanying notes to the unaudited condensed consolidated financial statements.

 

4


Table of Contents

HEALTHSTREAM, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

(In thousands)

 

     Nine Months Ended
September 30,
 
     2016     2015  

OPERATING ACTIVITIES:

    

Net income

   $ 4,066      $ 6,810   

Adjustments to reconcile net income to net cash provided by operating activities:

    

Depreciation and amortization

     15,976        12,148   

Deferred income taxes

     791        123   

Stock based compensation expense

     1,516        2,787   

Excess tax benefits from equity awards

     (661     (3,721

Provision for doubtful accounts

     340        184   

(Gain) loss on non-marketable equity investments

     (134     98   

Other

     846        938   

Changes in operating assets and liabilities:

    

Accounts and unbilled receivables

     (6,855     2,649   

Prepaid royalties

     (2,291     (946

Other prepaid expenses and other current assets

     (326     (595

Other assets

     (36     288   

Accounts payable

     (454     (2,501

Accrued royalties

     4,415        (1,251

Accrued liabilities and accrued compensation and related expenses and other long-term liabilities

     (444     3,082   

Deferred revenue

     (1,766     5,426   
  

 

 

   

 

 

 

Net cash provided by operating activities

     14,983        25,519   
  

 

 

   

 

 

 

INVESTING ACTIVITIES:

    

Business combinations, net of cash acquired

     (53,078     (88,075

Proceeds from maturities of marketable securities

     88,197        38,440   

Purchases of marketable securities

     (82,771     (77,774

Payments to acquire equity method investments

     —          (1,000

Payments to acquire cost method investments

     —          (1,000

Proceeds from sale of long lived assets

     975        —     

Payments associated with capitalized software development

     (7,070     (5,329

Purchases of property and equipment

     (3,870     (6,012
  

 

 

   

 

 

 

Net cash used in investing activities

     (57,617     (140,750
  

 

 

   

 

 

 

FINANCING ACTIVITIES:

    

Proceeds from issuance of common stock

     —          98,014   

Proceeds from exercise of stock options

     94        328   

Proceeds from borrowings under revolving line of credit facility

     —          28,000   

Repayments under revolving line of credit facility

     —          (28,000

Payment of earn-outs related to business combinations

     —          (633

Excess tax benefits from equity awards

     661        3,721   

Taxes paid related to net settlement of equity awards

     (311     (753
  

 

 

   

 

 

 

Net cash provided by financing activities

     444        100,677   
  

 

 

   

 

 

 

Net decrease in cash and cash equivalents

     (42,190     (14,554

Cash and cash equivalents at beginning of period

     82,010        81,995   
  

 

 

   

 

 

 

Cash and cash equivalents at end of period

   $ 39,820      $ 67,441   
  

 

 

   

 

 

 

See accompanying notes to the unaudited condensed consolidated financial statements.

 

5


Table of Contents

HEALTHSTREAM, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

1. BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, condensed consolidated financial statements do not include all of the information and footnotes required by US GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. All significant intercompany transactions have been eliminated in consolidation. Operating results for the three and nine months ended September 30, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016.

The balance sheet at December 31, 2015 is consistent with the audited financial statements at that date but does not include all of the information and footnotes required by US GAAP for a complete set of financial statements. For further information, refer to the consolidated financial statements and footnotes thereto for the year ended December 31, 2015 included in the Company’s Annual Report on Form 10-K (the “Form 10-K”), filed with the Securities and Exchange Commission on February 26, 2016.

Recently Adopted Accounting Standards

The Company has adopted Accounting Standards Update (“ASU”) 2015-16, Business Combinations (Topic 805). Under the provisions of the revised guidance, acquirers in a business combination must recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. The acquirer must record, in the same period’s financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the provisional amounts, calculated as if the accounting had been completed at the acquisition date. The Company recorded a measurement period adjustment during the period ended March 31, 2016. See Note 7 Business Combinations for further discussion.

2. RECENT ACCOUNTING PRONOUNCEMENTS

In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific revenue recognition guidance throughout the Industry Topics of the Accounting Standards Codification. The updated guidance states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also provides for additional disclosures with respect to revenues and cash flows arising from contracts with customers. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2017, and early adoption is permitted for the first interim period within annual reporting periods beginning after December 15, 2016. The Company is currently reviewing this standard to determine the method of adoption and to assess the impact on its future consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which requires lessees to recognize assets and liabilities for most leases. The recognition, measurement and presentation of expenses and cash flows arising from a lease by a lessee is not expected to significantly change under such guidance; however, the Company is currently reviewing this standard to determine the method of adoption and to assess the impact on its future consolidated financial statements. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2018, and early adoption is permitted.

In March 2016, the FASB issued ASU 2016-09, Compensation – Stock Compensation (Topic 718), which serves to simplify several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2016, and early adoption is permitted in any interim or annual period. The Company is currently reviewing this standard to determine the method of adoption and to assess the impact on its future consolidated financial statements.

In March 2016, the FASB issued ASU 2016-01, Financial Instruments – Overall (Sub Topic 825-10), which addresses certain aspects of the recognition, measurement, presentation, and disclosure of financial instruments. The guidance will, among other things, require equity method investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2017, and early adoption is permitted for only limited aspects of such guidance. The Company is currently reviewing this standard to determine the method of adoption and to assess the impact on its future consolidated financial statements.

 

6


Table of Contents

HEALTHSTREAM, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

 

3. INCOME TAXES

Income taxes are accounted for using the asset and liability method, whereby deferred tax assets and liabilities are determined based on the temporary differences between the financial statement and tax bases of assets and liabilities measured at tax rates that will be in effect for the year in which the differences are expected to affect taxable income.

During the nine months ended September 30, 2016 and 2015, the Company recorded a provision for income taxes of approximately $2.5 million and $4.9 million, respectively. The Company’s effective tax rate for the nine months ended September 30, 2016 and 2015 was 38.0% and 41.7%, respectively. The Company’s effective tax rate primarily reflects the statutory corporate income tax rate, the net effect of state taxes, and the effect of various permanent tax differences. During the nine months ended September 30, 2016, the Company recorded a reduction of approximately $300,000 to the liability for gross unrecognized tax benefits. During the nine months ended September 30, 2015, the Company recorded a reduction of approximately $1.8 million to the liability for gross unrecognized tax benefits, resulting from the filing of a change in tax accounting method with the IRS for tangible property and deferred revenue. Of this total reduction, approximately $115,000 had an impact on the effective tax rate for the third quarter of 2015.

4. STOCK BASED COMPENSATION

The Company has stock awards outstanding under three stock incentive plans, the Company’s 2010 Stock Incentive Plan, the Company’s 2000 Stock Incentive Plan, as amended, and the Company’s 2016 Omnibus Incentive Plan, which shareholders approved at the annual meeting of shareholders held on May 26, 2016. The Company accounts for its stock based compensation plans using the fair-value based method for costs related to share-based payments, including stock options and restricted share units (“RSUs”). During the nine months ended September 30, 2016, the Company issued 111,808 RSUs, subject to time-based vesting, with a weighted average grant date fair value of $20.49 per share, measured based on the closing fair market value of the Company’s stock on the date of grant. During the nine months ended September 30, 2015, the Company issued 80,355 RSUs with a weighted average grant date fair value of $25.56 per share, and the Company issued 49,310 stock awards with a weighted average grant date fair value of $30.42 per share. Both measurements were based on the closing fair market value of the Company’s stock on the date of grant.

During the three months ended September 30, 2015, the Company issued 30,000 performance-based RSUs, the vesting of which is contingent upon meeting certain performance criteria over a five year period. The measurement date for 8,750 of these performance-based RSUs was established during the three months ended September 30, 2015 with a grant-date fair value of $23.40 per share, and the measurement date for 5,000 of these awards was established during the three months ended March 31, 2016 with a grant-date fair value of $20.20 per share. Both measurements were based on the closing fair market value of the Company’s stock on the date of grant. The performance criteria for the remaining 16,250 performance-based RSUs will be established on an annual basis by the Company’s Compensation Committee; therefore, the measurement date and fair value of the awards cannot be determined until the performance criteria is established.

Total stock based compensation expense recorded for the three and nine months ended September 30, 2016 and 2015, which is recorded in the condensed consolidated statements of income, is as follows (in thousands):

 

     Three Months Ended
September 30,
     Nine Months Ended
September 30,
 
     2016      2015      2016      2015  

Cost of revenues (excluding depreciation and amortization)

   $ 35       $ 29       $ 110       $ 790   

Product development

     73         55         200         514   

Sales and marketing

     65         61         193         486   

Other general and administrative

     339         295         1,013         997   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total stock based compensation expense

   $ 512       $ 440       $ 1,516       $ 2,787   
  

 

 

    

 

 

    

 

 

    

 

 

 

7


Table of Contents

HEALTHSTREAM, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

 

4. STOCK BASED COMPENSATION (continued)

 

Stock Awards

During June 2015, the Company’s Chief Executive Officer (“CEO”), Robert A. Frist, Jr., entered into an agreement with the Company pursuant to which he contributed 54,241 of his personally owned shares of HealthStream, Inc. common stock to the Company, without any consideration paid to him. In connection with this contribution, the Company approved the grant of 49,310 shares of HealthStream, Inc. common stock to over 600 employees who were not otherwise eligible to receive equity awards and had at least one year of service with the Company. The Company recognized approximately $1.5 million of stock based compensation expense for these stock awards during the three months ended June 30, 2015 based on the closing fair market value of the Company’s stock on the date of the Company’s approval of these grants. In connection with these equity awards, effective in the second quarter of 2015, the Company withheld shares with value equivalent to the employees’ minimum statutory obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. The total shares withheld were 17,279, and were based on the value of the stock awards on the date of the Company’s approval of these grants, as determined by the Company’s closing stock price on that date. Total payments related to the employees’ tax obligations to taxing authorities for these stock awards were approximately $526,000, and are reflected as a financing activity within the condensed consolidated statements of cash flows for the nine months ended September 30, 2015. These share withholdings had the effect of share repurchases by the Company as they reduced and retired the number of shares otherwise issuable as a result of the stock awards and did not represent an expense to the Company.

5. EARNINGS PER SHARE

Basic earnings per share is computed by dividing the net income available to common shareholders for the period by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing the net income for the period by the weighted average number of potentially dilutive common and common equivalent shares outstanding during the period. Common equivalent shares are composed of incremental common shares issuable upon the exercise of stock options and RSUs subject to vesting. The dilutive effect of common equivalent shares is included in diluted earnings per share by application of the treasury stock method. The total number of common equivalent shares excluded from the calculations of diluted earnings per share, due to their anti-dilutive effect, was approximately 21,000 and 26,000 for the three months ended September 30, 2016 and 2015, respectively, and approximately 42,000 and 13,000 for the nine months ended September 30, 2016 and 2015, respectively.

The following table sets forth the computation of basic and diluted earnings per share for the three and nine months ended September 30, 2016 and 2015 (in thousands, except per share data):

 

     Three Months Ended
September 30,
     Nine Months Ended
September 30,
 
     2016      2015      2016      2015  

Numerator:

           

Net income

   $ 1,162       $ 2,614       $ 4,066       $ 6,810   
  

 

 

    

 

 

    

 

 

    

 

 

 

Denominator:

           

Weighted-average shares outstanding

     31,739         31,643         31,714         29,527   

Effect of dilutive shares

     368         386         336         378   
  

 

 

    

 

 

    

 

 

    

 

 

 

Weighted-average diluted shares

     32,107         32,029         32,050         29,905   
  

 

 

    

 

 

    

 

 

    

 

 

 

Basic earnings per share

   $ 0.04       $ 0.08       $ 0.13       $ 0.23   
  

 

 

    

 

 

    

 

 

    

 

 

 

Diluted earnings per share

   $ 0.04       $ 0.08       $ 0.13       $ 0.23   
  

 

 

    

 

 

    

 

 

    

 

 

 

8


Table of Contents

HEALTHSTREAM, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

 

6. MARKETABLE SECURITIES

At September 30, 2016 and December 31, 2015, the fair value of marketable securities, which were all classified as available for sale, included the following (in thousands):

 

     September 30, 2016  
     Adjusted
Cost
     Unrealized
Gains
     Unrealized
Losses
     Fair
Value
 

Level 2:

           

Corporate debt securities

   $ 43,720         3         (36    $ 43,687   

Government-sponsored enterprise debt securities

     17,054         6         —           17,060   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

   $ 60,774       $ 9       $ (36    $ 60,747   
  

 

 

    

 

 

    

 

 

    

 

 

 

 

     December 31, 2015  
     Adjusted
Cost
     Unrealized
Gains
     Unrealized
Losses
     Fair
Value
 

Level 2:

           

Certificates of deposit

   $ 1,000       $ —         $ —         $ 1,000   

Corporate debt securities

     66,046         —           (70      65,976   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

   $ 77,046       $ —         $ (70    $ 66,976   
  

 

 

    

 

 

    

 

 

    

 

 

 

The carrying amounts reported in the condensed consolidated balance sheet approximate the fair value based on quoted market prices or alternative pricing sources and models utilizing market observable inputs. As of September 30, 2016, the Company does not consider any of its marketable securities to be other than temporarily impaired. During the nine months ended September 30, 2016 and 2015, the Company did not reclassify any items out of accumulated other comprehensive income to net income. All investments in marketable securities are classified as a current asset on the balance sheet because the underlying securities mature within one year from the balance sheet date.

7. BUSINESS COMBINATIONS

Morrisey Associates, Inc.

On August 8, 2016, Echo, Inc. (“Echo”), a wholly owned subsidiary of the Company, acquired all of the outstanding stock of Morrisey Associates, Inc. (“MAI”), a Chicago, Illinois based company that provides credentialing and privileging software to healthcare professionals. The acquisition of MAI allows the Company to expand its credentialing and privileging product offerings and solutions to healthcare organizations. The consideration paid for MAI consisted of approximately $48.0 million in cash, which the Company funded with cash on hand, and was not subject to any post-closing working capital or similar adjustment. The Company incurred approximately $953,000 in transaction costs, of which $805,000 were incurred during the three months ended September 30, 2016 and $148,000 were incurred during the six months ended June 30, 2016. The transaction costs were recorded in other general and administrative expenses in the condensed consolidated statements of income for such periods. The results of operations for MAI have been included in the Company’s condensed consolidated financial statements from the date of acquisition, and are also included in the HealthStream Provider Solutions segment.

A summary of the purchase price is as follows (in thousands):

 

Cash paid at closing

   $ 44,120   

Cash held in escrow

     3,880   
  

 

 

 

Total consideration paid

   $ 48,000   
  

 

 

 

The following table summarizes the fair value of the assets acquired and liabilities assumed as of the date of acquisition (in thousands):

 

Accounts receivable, net

     3,402   

Prepaid royalties and other prepaid assets

     187   

Property and equipment

     75   

Deferred tax assets

     1,548   

Goodwill

     20,502   

Intangible assets

     27,400   

Accounts payable and accrued liabilities

     (913

Deferred revenue

     (4,201
  

 

 

 

Net assets acquired

   $ 48,000   
  

 

 

 

9


Table of Contents

HEALTHSTREAM, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

 

7. BUSINESS COMBINATIONS (continued)

 

The excess of preliminary purchase price over the preliminary fair values of net tangible and intangible assets will be recorded as goodwill. The preliminary fair values of tangible and identifiable intangible assets and deferred revenue are based on management’s estimates and assumptions. The preliminary fair values of assets acquired and liabilities assumed are considered preliminary and are based on the information that was available at the time of the acquisition. The preliminary fair values of assets acquired and liabilities assumed are subject to change during the measurement period (up to one year from the acquisition date) as the Company finalizes the valuation of these items. The goodwill balance is primarily attributed to the assembled workforce, additional market opportunities from offering MAI’s products, and expected synergies from integrating MAI with other products or other combined functional areas within the Company. The goodwill balance is deductible for U.S. income tax purposes. The net tangible assets include deferred revenue, which was preliminarily adjusted down from a book value at the acquisition date of $9.1 million to an estimated fair value of $4.2 million. The preliminary $4.9 million write-down of deferred revenue will result in lower revenues than would have otherwise been recognized for such services.

The following table sets forth the preliminary components of identifiable intangible assets and their estimated useful lives as of the acquisition date (in thousands):

 

     Preliminary
fair value
     Useful
life
 

Customer relationships

   $ 21,400         13 years   

Developed technology

     5,400         5 years   

Trade names

     600         6 years   
  

 

 

    

Total preliminary intangible assets subject to amortization

   $ 27,400      
  

 

 

    

The amounts of revenue and operating income (loss) of MAI included in the Company’s condensed consolidated statement of income from the date of acquisition of August 8, 2016 to the period ending September 30, 2016 are as follows (in thousands):

 

Total revenues

   $ 841   
  

 

 

 

Operating loss

   $ (1,023
  

 

 

 

The following unaudited pro forma financial information summarizes the combined results of operations of the Company and MAI, which was significant for purposes of the unaudited pro forma financial information disclosure, as though the companies were combined as of January 1, 2015 (in thousands, except per share data):

 

     Three Months Ended
September 30,
     Nine Months Ended
September 30,
 
     2016      2015      2016      2015  

Total revenues

   $ 60,711       $ 56,622       $ 176,401       $ 159,009   
  

 

 

    

 

 

    

 

 

    

 

 

 

Net income

   $ 2,275       $ 2,573       $ 5,764       $ 5,445   
  

 

 

    

 

 

    

 

 

    

 

 

 

Basic earnings per share

   $ 0.07       $ 0.08       $ 0.18       $ 0.18   
  

 

 

    

 

 

    

 

 

    

 

 

 

Diluted earnings per share

   $ 0.07       $ 0.08       $ 0.18       $ 0.18   
  

 

 

    

 

 

    

 

 

    

 

 

 

These unaudited pro forma combined results of operations include certain adjustments arising from the acquisition such as adjustment for amortization of intangible assets, depreciation of property and equipment, and fair value adjustments of acquired deferred revenue balances. The unaudited pro forma combined results of operations is for informational purposes only and is not indicative of what the Company’s results of operations would have been had the transaction occurred at the beginning of the period presented or to project the Company’s results of operations in any future period.

The unaudited pro forma financial information for the three and nine months ended September 30, 2016 and 2015 combines the historical results of the Company and MAI for the three and nine months ended September 30, 2016 and 2015 and the pro forma adjustments listed above.

10


Table of Contents

HEALTHSTREAM, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

 

7. BUSINESS COMBINATIONS (continued)

 

HealthLine Systems

On March 16, 2015, the Company acquired all of the membership interests of HealthLine Systems, LLC (“HLS”), a San Diego, California based company that specializes in credentialing, privileging, call center, and quality management solutions for the healthcare industry. The acquisition of HLS enabled the Company to provide a comprehensive solution set for healthcare provider credentialing, privileging, enrollment, referral, onboarding, and analytics in support of HealthStream’s approach to talent management for healthcare organizations. The consideration paid for HLS consisted of approximately $90.3 million in cash (taking into account an estimated closing working capital adjustment and amounts due to the seller as of September 30, 2016). The Company incurred approximately $1.3 million in transaction costs associated with the acquisition, of which $965,000 were incurred during the three months ended March 31, 2015 and $329,000 were incurred during the year ended December 31, 2014. The transaction costs were recorded in other general and administrative expenses in the condensed consolidated statements of income for such periods. The results of operations for HLS have been included in the Company’s condensed consolidated financial statements from the date of acquisition, and are also included in the HealthStream Provider Solutions segment.

A summary of the purchase price is as follows (in thousands):

 

Cash paid at closing

   $ 87,450   

Consideration due to the seller

     2,180   

Cash held in escrow

     679   
  

 

 

 

Total consideration paid

   $ 90,309   
  

 

 

 

The following table summarizes the fair value of the assets acquired and liabilities assumed as of the date of acquisition (in thousands):

 

Cash

   $ 54   

Accounts receivable, net

     3,052   

Prepaid assets

     546   

Property and equipment

     200   

Deferred tax assets

     2,523   

Goodwill

     43,798   

Intangible assets

     47,200   

Accounts payable and accrued liabilities

     (1,085

Deferred revenue

     (5,979
  

 

 

 

Net assets acquired

   $ 90,309   
  

 

 

 

The excess of purchase price over the fair values of net tangible and intangible assets has been recorded as goodwill. The fair values of tangible and identifiable intangible assets, deferred tax assets, deferred revenue, and other liabilities are based on management’s estimates and assumptions. Included in the assets and liabilities assumed is an estimated indemnification asset of $300,000 and a contingent liability of $700,000, both of which are associated with tax liabilities. The contingent liability is measured based on management’s estimate of a range of probable outcomes. The goodwill balance is primarily attributed to the assembled workforce, additional market opportunities from offering HLS’s products, and expected synergies from integrating HLS with other products or other combined functional areas within the Company. During the three months ended March 31, 2016, the Company received notice of an indemnification claim from the former owners of HLS pursuant to the terms of the membership interest purchase agreement. The terms of such agreement require the Company to indemnify such owners for incremental taxes incurred as the result of the structure of the acquisition, which had favorable tax aspects to the Company. The Company recorded a measurement period adjustment in relation to the claim that increased goodwill by approximately $2.2 million during the three months ended March 31, 2016. The additional goodwill is deductible for U.S. income tax purposes. The goodwill balance excluding such measurement period adjustment is also deductible for U.S. income tax purposes. During the three months ended September 30, 2016, the Company agreed to settle this indemnification claim for approximately $2.4 million in respect of such tax indemnification provision in the membership interest purchase agreement, a difference of approximately $200,000 from the aforementioned $2.2 million measurement period adjustment. The Company surpassed the one year measurement period as of the period ended March 31, 2016; accordingly, in accordance with requisite accounting guidance, the $200,000 difference has been reflected as a charge against net income for the period ended September 30, 2016. The net tangible assets include deferred revenue, which was adjusted down from a book value at the acquisition date of $15.0 million to an estimated fair value of $6.0 million. The $9.0 million write-down of deferred revenue will result in lower revenues than would have otherwise been recognized for such services.

11


Table of Contents

HEALTHSTREAM, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

 

7. BUSINESS COMBINATIONS (continued)

 

The following table sets forth the components of identifiable intangible assets and their estimated useful lives as of the acquisition date (in thousands):

 

     Fair value      Useful life  

Customer relationships

   $ 42,600         13 years   

Developed technology

     3,700         5 years   

Trade names

     900         6 years   
  

 

 

    

Total intangible assets subject to amortization

   $ 47,200      
  

 

 

    

The amounts of revenue and operating income (loss) of HLS included in the Company’s condensed consolidated statement of income from the date of acquisition of March 16, 2015 to the period ending September 30, 2015 are as follows (in thousands):

 

Total revenues

   $ 5,351   
  

 

 

 

Operating loss

   $ (1,899
  

 

 

 

The following unaudited pro forma financial information summarizes the combined results of operations of the Company and HLS, which was significant for purposes of the unaudited pro forma financial information disclosure, as though the companies were combined as of January 1, 2014 (in thousands, except per share data):

 

     Three Months Ended
September 30,
     Nine Months Ended
September 30,
 
     2016      2015      2016      2015  

Total revenues

   $ 58,644       $ 55,741       $ 168,908       $ 161,954   
  

 

 

    

 

 

    

 

 

    

 

 

 

Net income

   $ 1,361       $ 3,760       $ 5,090       $ 10,599   
  

 

 

    

 

 

    

 

 

    

 

 

 

Basic earnings per share

   $ 0.04       $ 0.12       $ 0.16       $ 0.36   
  

 

 

    

 

 

    

 

 

    

 

 

 

Diluted earnings per share

   $ 0.04       $ 0.12       $ 0.16       $ 0.35   
  

 

 

    

 

 

    

 

 

    

 

 

 

These unaudited pro forma combined results of operations include certain adjustments arising from the acquisition such as adjustment for amortization of intangible assets, depreciation of property and equipment, fair value adjustments of acquired deferred revenue balances, and interest expense associated with borrowings under a revolving credit facility by the Company to partially fund the acquisition. The unaudited pro forma combined results of operations is for informational purposes only and is not indicative of what the Company’s results of operations would have been had the transaction occurred at the beginning of the period presented or to project the Company’s results of operations in any future period.

The unaudited pro forma financial information for the three and nine months ended September 30, 2016 and 2015 combines the historical results of the Company and HLS for the three and nine months ended September 30, 2016 and 2015 and the pro forma adjustments listed above.

Other Business Combinations

On June 30, 2016, the Company acquired all of the stock of Performance Management Services, Inc. (“PMSI”), a Company based in Tustin, California focused on competency-based performance development for nurses, for $4.0 million in cash and up to an additional $500,000 of contingent consideration. The acquisition, including associated transaction costs, is not considered material to the Company’s financial statements. The Company accounted for the acquisition as a business combination and has allocated the purchase consideration based on preliminary estimates of fair value. The Company expects to finalize its estimates of fair value as soon as practicable, but not later than one year from the date of acquisition. The results of operations for PMSI are included in the Company’s condensed consolidated financial statements from the date of acquisition and are included in the HealthStream Workforce Solutions segment.

12


Table of Contents

HEALTHSTREAM, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

 

7. BUSINESS COMBINATIONS (continued)

 

On July 25, 2016, the Company purchased all of the outstanding stock of Nursing Registry Consultants Corporation (“Nurse Competency”) not previously held by the Company for approximately $1.0 million in cash and up to an additional $75,000 in contingent consideration. Nurse Competency provides SaaS-based clinical assessment and testing products to the healthcare industry. The Company previously held a 32% minority equity interest in Nurse Competency and had accounted for such interest as an equity method investment. The fair value of the minority equity interest as of the July 25, 2016 acquisition date was approximately $484,000 and was determined in accordance with the fair value of the controlling interest acquired with consideration given to acquisition premiums, where applicable. The Company recorded a gain of approximately $225,000 to account for the difference between the noted acquisition date fair value of the minority equity interest and the carrying value as of such date. The gain is included in other income (expense), net in the condensed consolidated statements of income for the three and nine months ended September 30, 2016. The Company accounted for the acquisition as a business combination and has allocated the purchase consideration based on preliminary estimates of fair value. The Company expects to finalize its estimates of fair value as soon as practicable, but not later than one year from the date of acquisition. The results of operations for Nurse Competency are included in the Company’s condensed consolidated financial statements from the date of acquisition and are included in the HealthStream Workforce Solutions segment.

Goodwill

The changes in the carrying amount of goodwill for the nine months ended September 30, 2016 are as follows (in thousands):

 

     Workforce      Patient
Experience
     Provider      Total  

Balance at January 1, 2016

   $ 12,336       $ 24,154       $ 46,583       $ 83,073   

Other business combinations

     4,041         —           —           4,041   

Acquisition of HealthLine Systems, LLC

     —           —           2,180         2,180   

Acquisition of Morrisey Associates, Inc.

     —           —           20,502         20,502   
  

 

 

    

 

 

    

 

 

    

 

 

 

Balance at September 30, 2016

   $ 16,377       $ 24,154       $ 69,265       $ 109,796   
  

 

 

    

 

 

    

 

 

    

 

 

 

During the three months ended March 31, 2016, the Company recorded approximately $2.2 million of additional goodwill in relation to the March 2015 acquisition of HealthLine Systems, LLC. Such amount relates to the measurement period adjustment previously discussed under the above caption “HealthLine Systems.

13


Table of Contents

HEALTHSTREAM, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

 

8. BUSINESS SEGMENTS

The Company provides services to healthcare organizations and other members within the healthcare industry. The Company’s services are focused on the delivery of workforce development products and services (HealthStream Workforce Solutions), survey and research services (HealthStream Patient Experience Solutions), and provider credentialing, privileging, call center and enrollment products and services (HealthStream Provider Solutions).

The Company measures segment performance based on operating income before income taxes and prior to the allocation of certain corporate overhead expenses, interest income, interest expense, and depreciation. The Unallocated component below includes corporate functions, such as accounting, human resources, legal, investor relations, administrative, and executive personnel, depreciation, a portion of amortization, and certain other expenses, which are not currently allocated in measuring segment performance. The following is the Company’s business segment information as of and for the three and nine months ended September 30, 2016 and 2015 (in thousands).

 

     Three Months Ended
September 30,
     Nine Months Ended
September 30,
 
     2016      2015      2016      2015  

Revenues, net:

           

Workforce

   $ 43,015       $ 41,092       $ 124,489       $ 118,488   

Patient Experience

     8,931         8,792         25,862         25,545   

Provider

     6,421         3,951         16,886         9,103   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total revenues, net

   $ 58,367       $ 53,835       $ 167,237       $ 153,136   
  

 

 

    

 

 

    

 

 

    

 

 

 

 

     Three Months Ended
September 30,
     Nine Months Ended
September 30,
 
     2016      2015      2016      2015  

Income from operations:

           

Workforce

   $ 9,386       $ 10,386       $ 29,034       $ 29,789   

Patient Experience

     471         807         (319      1,737   

Provider

     (959      (852      (681      (1,638

Unallocated

     (7,612      (6,016      (21,946      (18,209
  

 

 

    

 

 

    

 

 

    

 

 

 

Total income from operations

   $ 1,286       $ 4,325       $ 6,088       $ 11,679   
  

 

 

    

 

 

    

 

 

    

 

 

 

 

     September 30,
2016
     December 31,
2015
 

Segment assets *

     

Workforce

   $ 93,350       $ 82,375   

Patient Experience

     35,724         34,902   

Provider

     152,162         100,948   

Unallocated

     112,815         161,344   
  

 

 

    

 

 

 

Total assets

   $ 394,051       $ 379,569   
  

 

 

    

 

 

 

 

* Segment assets include accounts and unbilled receivables, prepaid and other current assets, other assets, capitalized software development, certain property and equipment, and intangible assets. Cash and cash equivalents and marketable securities are not allocated to individual segments, and are included within Unallocated. A significant portion of property and equipment assets are included within Unallocated.

14


Table of Contents

HEALTHSTREAM, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

 

9. DEBT

Revolving Credit Facility

The Company maintains a Loan Agreement (the “Revolving Credit Facility”) with SunTrust Bank (“SunTrust”) in the aggregate principal amount of $50.0 million, which matures on November 24, 2017. Under the Revolving Credit Facility, the Company may borrow up to $50.0 million, which includes a $5.0 million swing line subfacility and a $5.0 million letter of credit subfacility, as well as an accordion feature that allows the Company to increase the Revolving Credit Facility by a total of up to $25.0 million, subject to securing additional commitments from existing lenders or new lending institutions. The obligations under the Revolving Credit Facility are guaranteed by each of the Company’s subsidiaries. At the Company’s election, the borrowings under the Revolving Credit Facility bear interest at either (1) a rate per annum equal to the highest of SunTrust’s prime rate or 0.5% in excess of the Federal Funds Rate or 1.0% in excess of one-month LIBOR (the “Base Rate”), plus an applicable margin, or (2) the one, two, three, or six-month per annum LIBOR for deposits in the applicable currency (the “Eurocurrency Rate”), as selected by the Company, plus an applicable margin. The applicable margin for Eurocurrency Rate loans depends on the Company’s funded debt leverage ratio and varies from 1.50% to 2.00%. The applicable margin for Base Rate loans depends on the Company’s funded debt leverage ratio and varies from 0.50% to 1.50%. Commitment fees and letter of credit fees are also payable under the Revolving Credit Facility. Principal is payable in full at maturity on November 24, 2017, and there are no scheduled principal payments prior to maturity. The Company is required to pay a commitment fee ranging between 20 and 30 basis points per annum of the average daily unused portion of the Revolving Credit Facility, depending on the Company’s funded debt leverage ratio.

The purpose of the Revolving Credit Facility is for general working capital needs, permitted acquisitions (as defined in the Loan Agreement), and for stock repurchase and/or redemption transactions that the Company may authorize.

The Revolving Credit Facility contains certain covenants that, among other things, restrict additional indebtedness, liens and encumbrances, changes to the character of the Company’s business, acquisitions, asset dispositions, mergers and consolidations, sale or discount of receivables, creation or acquisitions of additional subsidiaries, and other matters customarily restricted in such agreements.

In addition, the Revolving Credit Facility requires the Company to meet certain financial tests, including, without limitation:

 

    a funded debt leverage ratio (consolidated debt/consolidated EBITDA) of not greater than 3.0 to 1.0; and

 

    an interest coverage ratio (consolidated EBITDA/consolidated interest expense) of not less than 3.0 to 1.0.

As of September 30, 2016, the Company was in material compliance with all covenants. There were no balances outstanding on the Revolving Credit Facility as of September 30, 2016. During the three months ended June 30, 2015, the Company repaid approximately $28.0 million of balances previously outstanding under the Revolving Credit Facility from proceeds received in the Company’s public offering of 3,869,750 shares which closed on May 28, 2015.

10. RELATED PARTY TRANSACTIONS

During the three months ended June 30, 2015, the Company’s CEO, Robert A. Frist, Jr., entered into an agreement with the Company pursuant to which he contributed 54,241 of his personally owned shares of HealthStream, Inc. common stock to the Company, without any consideration paid to him. In connection with this contribution, the Company approved the grant of 49,310 shares of common stock to over 600 employees, with a fair market value of approximately $1.5 million. Mr. Frist contributed 4,931 of the contributed shares noted above to take into account the estimated Company costs, such as administrative expenses and employer payroll taxes associated with the grants. (See Note 4 Stock Based Compensation).

15


Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Special Cautionary Notice Regarding Forward-Looking Statements

You should read the following discussion and analysis in conjunction with our condensed consolidated financial statements and related notes included elsewhere in this report and our audited consolidated financial statements and the notes thereto for the year ended December 31, 2015, appearing in our Annual Report on Form 10-K that was filed with the Securities and Exchange Commission (“SEC”) on February 26, 2016, (the “2015 Form 10-K”). Statements contained in this Quarterly Report on Form 10-Q that are not historical facts are forward-looking statements that the Company intends to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Statements that are predictive in nature, that depend on or refer to future events or conditions, or that include words such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “ projects,” “should,” “will,” “would,” and similar expressions are forward-looking statements.

The Company cautions that forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Forward-looking statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements.

In evaluating any forward-looking statement, you should specifically consider the information regarding forward-looking statements and the information set forth under the caption “Item 1A. Risk Factors” and other disclosures in our 2015 Form 10-K, and the information regarding forward-looking statements and other disclosures in our earnings releases, and other filings with the SEC from time to time, as well as other cautionary statements contained elsewhere in this report, including the matters discussed in “Critical Accounting Policies and Estimates.” We undertake no obligation beyond that required by law to update publicly any forward-looking statements for any reason, even if new information becomes available or other events occur in the future. You should read this report and the documents that we reference in this report and have filed as exhibits to this report completely and with the understanding that our actual future results may be materially different from our current expectations.

Overview

HealthStream provides workforce, patient experience, and provider solutions for healthcare organizations—all designed to assess and develop the people that deliver patient care which, in turn, supports the improvement of business and clinical outcomes. Our workforce products are used by healthcare organizations to meet a broad range of their training, certification, competency assessment, performance appraisal, and development needs. Our patient experience products provide our customers information about patients’ experiences and how to improve them, workforce engagement, physician relations, and community perceptions of their services. Our provider products are used by healthcare organizations for their provider credentialing, privileging, call center, and enrollment needs. HealthStream’s customers include healthcare organizations, pharmaceutical and medical device companies, and other participants in the healthcare industry.

Key financial indicators for the third quarter of 2016 include:

 

    Revenues of $58.4 million in the third quarter of 2016, up 8% from $53.8 million in the third quarter of 2015.

 

    Operating income of $1.2 million in the third quarter of 2016, down 70% from $4.3 million in the third quarter of 2015.

 

    Net income of $1.3 million in the third quarter of 2016, down 56% from $2.6 million in the third quarter of 2015, and earnings per share (EPS) of $0.04 per share (diluted) in the third quarter of 2016, compared to $0.08 per share (diluted) in the third quarter of 2015.

 

    Adjusted EBITDA1 of $7.8 million in the third quarter of 2016, down 17% from $9.3 million in the third quarter of 2015.

 

  (1) Adjusted EBITDA is a non-GAAP financial measure. A reconciliation of adjusted EBITDA to net income, and disclosure regarding why we believe Adjusted EBITDA provides useful information to investors is included later in this report.

Business Combinations

We acquired Morrisey Associates, Inc. (“MAI”), a Chicago, Illinois based company which provides credentialing and privileging software to healthcare professionals, in August 2016. The results of operations for MAI have been included in our condensed consolidated financial statements from the date of acquisition, and are also included in the HealthStream Provider Solutions segment. The purchase price for MAI was approximately $48 million, payable in cash at closing.

We acquired all of the remaining outstanding stock of Nursing Registry Consultants Corporation (“Nurse Competency”), a provider of SaaS-Based clinical assessment and testing products to the healthcare industry, in which we previously held a 32% minority equity interest. The results of operations for Nurse Competency are included in our condensed consolidated financial statements from the date of acquisition and are included in the HealthStream Workforce Solutions segment. The purchase price payable by us in connection with this acquisition was approximately $1.0 million in cash and up to an additional $75,000 in contingent consideration.

For additional information regarding these business combinations, please see Note 7 in the Notes to Condensed Consolidated Financial Statements.

 

16


Table of Contents

Critical Accounting Policies and Estimates

The Company’s condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”). These accounting principles require us to make certain estimates, judgments and assumptions during the preparation of our financial statements. We believe the estimates, judgments and assumptions upon which we rely are reasonable based upon information available to us at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities as of the date of the financial statements, as well as the reported amounts of revenues and expenses during the periods presented. To the extent there are material differences between these estimates, judgments or assumptions and actual results, our financial statements will be affected.

The accounting policies and estimates that we believe are the most critical in fully understanding and evaluating our reported financial results include the following:

 

    Revenue recognition

 

    Accounting for income taxes

 

    Software development costs

 

    Goodwill, intangibles, and other long-lived assets

 

    Allowance for doubtful accounts

 

    Stock based compensation

In many cases, the accounting treatment of a particular transaction is specifically dictated by US GAAP and does not require management’s judgment in its application. There are also areas where management’s judgment in selecting among available alternatives would not produce a materially different result. See Notes to Consolidated Financial Statements in our 2015 Form 10-K, which contains additional information regarding our accounting policies and other disclosures required by US GAAP. There have been no changes in our critical accounting policies and estimates from those reported in our 2015 Form 10-K.

Three Months Ended September 30, 2016 Compared to Three Months Ended September 30, 2015

Revenues, net. Revenues increased approximately $4.5 million, or 8%, to $58.4 million for the three months ended September 30, 2016 from $53.8 million for the three months ended September 30, 2015. A comparison of revenues by business segment is as follows (in thousands):

 

     Three Months Ended September 30,  
     2016     2015     Percentage
Change
 

Revenues by Business Segment:

      

Workforce

   $ 43,015      $ 41,092        5

Patient Experience

     8,931        8,792        2

Provider

     6,421        3,951        63
  

 

 

   

 

 

   

Total revenues, net

   $ 58,367      $ 53,835        8
  

 

 

   

 

 

   

% of Revenues

      

Workforce

     74     76  

Patient Experience

     15     17  

Provider

     11     7  

Revenues for HealthStream Workforce Solutions increased approximately $1.9 million, or 5%, over the third quarter of 2015. Revenues from our subscription-based workforce products increased approximately $1.8 million, or 5%, but were negatively impacted by a decline in ICD-10 readiness revenues. Revenues from ICD-10 readiness products declined by $5.0 million to $1.3 million in the third quarter of 2016 compared to $6.3 million in the prior year third quarter. The requirement mandated by CMS for healthcare organizations to transition to the ICD-10 coding system was effective in October 2015, and generated significant demand for our ICD-10 readiness training courseware from 2012 through 2015. However, as a result of the effectiveness of such mandate in October 2015, sales of that product have ceased and there will not be renewals of the specific ICD-10 readiness product. Accordingly, revenues and operating income contributions from this product will continue to significantly decline during 2016. In addition, revenues for the third quarter of 2016 were positively impacted by growth in our courseware subscriptions and our enterprise applications. Our Workforce Solutions annualized revenue per implemented subscriber metric was $37.80 per subscriber for the third quarter of 2016 compared to $35.82 per subscriber for the third quarter of 2015. Our implemented subscriber base decreased by 1% over the prior year third quarter to 4.39 million implemented subscribers at September 30, 2016 compared to 4.45 million implemented subscribers at September 30, 2015. The decrease is primarily due to expiration of subscriptions of ICD-10 readiness products. Additionally, total subscribers decreased by 1% over the prior year third quarter, with 4.47 million total subscribers at September 30, 2016 compared to 4.53 million total subscribers at September 30, 2015.

 

17


Table of Contents

Revenues for HealthStream Patient Experience Solutions increased approximately $139,000, or 2%, over the third quarter of 2015. Revenues from Patient Insights™ surveys, our survey research product that generates recurring revenues, decreased by $361,000, or 5%, over the prior year third quarter. This decline is partially due to changes in product mix, such as the adoption of our e-survey products, which have both lower revenue and cost per survey than our traditional phone survey products. Revenues from other products, including surveys conducted on annual or bi-annual cycles and consulting/coaching services, collectively increased by $500,000, or 27%, compared to the prior year third quarter due to more engagements.

Revenues for HealthStream Provider Solutions increased approximately $2.5 million, or 63%, over the third quarter of 2015. Revenues from both the HealthLine Systems, LLC (“HLS”) and MAI acquisitions, which were consummated in March 2015 and August 2016, respectively, accounted for the majority of the increase in revenues during the third quarter of 2016.

Cost of Revenues (excluding depreciation and amortization). Cost of revenues increased approximately $1.8 million, or 8%, to $24.9 million for the three months ended September 30, 2016 from $23.1 million for the three months ended September 30, 2015. Cost of revenues as a percentage of revenues was approximately 43% of revenues for both the three months ended September 30, 2016 and 2015. Cost of revenues for HealthStream Workforce Solutions increased approximately $868,000 to $17.4 million and approximated 41% and 40% of revenues for HealthStream Workforce Solutions for the three months ended September 30, 2016 and 2015, respectively. The increase in both amount and as a percentage of revenues is primarily associated with increased royalties paid by us resulting from growth in courseware subscription revenues, increased personnel costs, and other support costs. Cost of revenues for HealthStream Patient Experience Solutions decreased approximately $151,000 to $5.3 million and approximated 60% and 62% of revenues for HealthStream Patient Experience Solutions for the three months ended September 30, 2016 and 2015, respectively. The decrease in amount and as a percentage of revenues is primarily the result of lower personnel costs associated with a decline in phone based survey volumes. Cost of revenues for HealthStream Provider Solutions increased approximately $1.0 million to $2.1 million and approximated 33% and 28% of HealthStream Provider Solutions revenues for the three months ended September 30, 2016 and 2015, respectively. The increase in amount is primarily the result of increased personnel costs, including additional personnel from MAI.

Product Development. Product development expenses increased approximately $1.1 million, or 17%, to $7.3 million for the three months ended September 30, 2016 from $6.2 million for the three months ended September 30, 2015. Product development expenses as a percentage of revenues were approximately 12% of revenues for both the three months ended September 30, 2016 and 2015, respectively.

Product development expenses for HealthStream Workforce Solutions increased approximately $402,000 and approximated 12% of revenues for HealthStream Workforce Solutions for both the three months ended September 30, 2016 and 2015, respectively. The increase in amount is due to additional personnel and related expenses associated with new product development initiatives for our subscription-based products. Product development expenses for HealthStream Patient Experience Solutions increased approximately $399,000 and approximated 12% and 8% of revenues for HealthStream Patient Experience Solutions for the three months ended September 30, 2016 and 2015, respectively. The increase in both amount and as a percentage of revenues is due to additional personnel and related expenses associated with new product development initiatives. Product development expenses for HealthStream Provider Solutions increased approximately $266,000 and approximated 15% and 17% of revenues for HealthStream Provider Solutions for the three months ended September 30, 2016 and 2015, respectively. The increase in amount is primarily the result of increased personnel costs, including additional personnel from MAI.

Sales and Marketing. Sales and marketing expenses, including personnel costs, increased approximately $1.9 million, or 23%, to $10.3 million for the three months ended September 30, 2016 from $8.4 million for the three months ended September 30, 2015. Sales and marketing expenses were approximately 18% and 16% of revenues for the three months ended September 30, 2016 and 2015, respectively.

Sales and marketing expenses for HealthStream Workforce Solutions increased approximately $1.1 million and approximated 17% and 15% of revenues for HealthStream Workforce Solutions for the three months ended September 30, 2016 and 2015, respectively. The increase in both amount and as a percentage of revenues is primarily due to additional personnel and related expenses, sales commissions, and increased marketing spending. Sales and marketing expenses for HealthStream Patient Experience Solutions increased approximately $75,000, and approximated 12% and 11% of revenues for HealthStream Patient Experience Solutions for the three months ended September 30, 2016 and 2015, respectively. Sales and marketing expenses for HealthStream Provider Solutions increased approximately $634,000, and approximated 25% of revenues for HealthStream Provider Solutions for both the three months ended September 30, 2016 and 2015, respectively. The increase in amount is primarily associated with increased personnel costs, sales commissions, and marketing spending.

Other General and Administrative Expenses. Other general and administrative expenses increased approximately $1.7 million, or 24%, to $8.9 million for the three months ended September 30, 2016 from $7.2 million for the three months ended September 30, 2015. Other general and administrative expenses as a percentage of revenues were approximately 15% and 13% of revenues for the three months ended September 30, 2016 and 2015, respectively.

 

18


Table of Contents

Other general and administrative expenses for HealthStream Workforce Solutions increased approximately $298,000 compared to the prior year third quarter primarily as a result of increased technology infrastructure investments. Other general and administrative expenses for HealthStream Patient Experience Solutions increased approximately $125,000 over the prior year third quarter due to additional personnel and facility costs. Other general and administrative expenses for HealthStream Provider Solutions increased approximately $153,000 over the prior year third quarter primarily due to increased facility costs. The unallocated corporate portion of other general and administrative expenses increased approximately $1.1 million over the prior year third quarter, primarily related to due diligence costs and additional personnel expenses. During the third quarter of 2016, we incurred approximately $850,000 of expenses associated with the ongoing evaluation of business development opportunities, including the acquisitions of MAI and Nurse Competency.

Depreciation and Amortization. Depreciation and amortization increased approximately $1.1 million, or 24%, to $5.7 million for the three months ended September 30, 2016 from $4.6 million for the three months ended September 30, 2015. The increase primarily resulted from amortization of capitalized software development, amortization of intangible assets from recent acquisitions (including amortization of software acquired for resale), and depreciation expense associated with capital expenditures.

Other Income (Expense), Net. Other income (expense), net was approximately income of $337,000 for the three months ended September 30, 2016 compared to income of $28,000 for the three months ended September 30, 2015. The increase is primarily associated with a gain recorded in relation to the acquisition of all of the remaining outstanding stock of Nurse Competency. See Note 7 in the Notes to Condensed Consolidated Financial Statements for further discussion.

Income Tax Provision. The Company recorded a provision for income taxes of approximately $461,000 for the three months ended September 30, 2016 compared to $1.7 million for the three months ended September 30, 2015. The Company’s effective tax rate was approximately 28% for the three months ended September 30, 2016 compared to approximately 40% for the three months ended September 30, 2015. The effective tax rate for the third quarter of 2016 was positively influenced by certain tax benefits realized upon filing tax returns during the period as well as estimated increases in research and development tax credits for 2016.

Net Income. Net income decreased approximately $1.4 million, or 53%, to $1.2 million for the three months ended September 30, 2016 from $2.6 million for the three months ended September 30, 2015. Earnings per diluted share were $0.04 and $0.08 per share for the three months ended September 30, 2016 and 2015, respectively. The decline resulted from the factors mentioned above.

Adjusted EBITDA (which we define as net income before interest, income taxes, stock based compensation, and depreciation and amortization) decreased approximately 17% to approximately $7.8 million for the three months ended September 30, 2016 compared to $9.3 million for the three months ended September 30, 2015. This decline resulted from the factors mentioned above. See Reconciliation of Non-GAAP Financial Measures below for our reconciliation of this calculation to measures under US GAAP.

Nine Months Ended September 30, 2016 Compared to Nine Months Ended September 30, 2015

Revenues, net. Revenues increased approximately $14.1 million, or 9%, to $167.2 million for the nine months ended September 30, 2016 from $153.1 million for the nine months ended September 30, 2015. A comparison of revenues by business segment is as follows (in thousands):

 

     Nine Months Ended September 30,  
     2016     2015     Percentage
Change
 

Revenues by Business Segment:

      

Workforce

   $ 124,489      $ 118,488        5

Patient Experience

     25,862        25,545        1

Provider

     16,886        9,103        85
  

 

 

   

 

 

   

Total revenues, net

   $ 167,237      $ 153,136        9
  

 

 

   

 

 

   

% of Revenues

      

Workforce

     74     77  

Patient Experience

     16     17  

Provider

     10     6  

Revenues for HealthStream Workforce Solutions, which are primarily subscription-based, increased approximately $6.0 million, or 5%, over the first nine months of 2015. Revenues in 2016 were positively influenced by growth in courseware subscriptions and our enterprise applications, but were partially offset by an expected decline in ICD-10 readiness revenues. Revenues from ICD-10 readiness products declined by $12.8 million to $7.4 million in the first nine months of 2016 compared to $20.2 million in the first nine months of 2015.

Revenues for HealthStream Patient Experience Solutions increased approximately $317,000, or 1%, over the first nine months of 2015. Revenues from Patient Insights™ surveys, our survey research product that generates recurring revenues, were comparable between periods. Revenues from other products, including surveys conducted on annual or bi-annual cycles and consulting/coaching services, collectively increased by $319,000, or 6%, compared to the first nine months of 2015 due to more engagements.

 

19


Table of Contents

Revenues for HealthStream Provider Solutions increased approximately $7.8 million, or 85%, over the first nine months of 2015. The increase resulted primarily from the HLS acquisition, which was consummated on March 16, 2015.

Cost of Revenues (excluding depreciation and amortization). Cost of revenues increased approximately $4.7 million, or 7%, to $70.4 million for the nine months ended September 30, 2016 from $65.7 million for the nine months ended September 30, 2015. Cost of revenues as a percentage of revenues was approximately 42% of revenues for the nine months ended September 30, 2016 compared to approximately 43% of revenues for the nine months ended September 30, 2015. Cost of revenues for HealthStream Workforce Solutions increased approximately $2.6 million to $49.2 million and approximated 39% of revenues for HealthStream Workforce Solutions for both the nine months ended September 30, 2016 and 2015, respectively. The increase in amount is primarily associated with increased royalties paid by us resulting from growth in courseware subscription revenues, increased personnel costs, and other support costs. The increase was partially offset by a decrease in stock based compensation. Cost of revenues for HealthStream Patient Experience Solutions decreased approximately $91,000 to $16.6 million and approximated 64% and 65% of revenues for HealthStream Patient Experience Solutions for the nine months ended September 30, 2016 and 2015, respectively. Cost of revenues for HealthStream Provider Solutions increased approximately $2.1 million to $4.6 million and approximated 27% of HealthStream Provider Solutions revenues for both the nine months ended September 30, 2016 and 2015, respectively. The increase in amount is primarily the result of increased personnel and related costs, including additional personnel from MAI.

Product Development. Product development expenses increased approximately $4.9 million, or 29%, to $21.5 million for the nine months ended September 30, 2016 from $16.6 million for the nine months ended September 30, 2015. Product development expenses as a percentage of revenues were approximately 13% and 11% of revenues for the nine months ended September 30, 2016 and 2015, respectively.

Product development expenses for HealthStream Workforce Solutions increased approximately $1.4 million and approximated 12% of revenues for HealthStream Workforce Solutions for both the nine months ended September 30, 2016 and 2015, respectively. The increase in amount is due to additional personnel expenses associated with new product development initiatives for our subscription-based products. This increase was partially offset by lower stock based compensation. Product development expenses for HealthStream Patient Experience Solutions increased approximately $2.3 million and approximated 14% and 5% of revenues for HealthStream Patient Experience Solutions for the nine months ended September 30, 2016 and 2015, respectively. The increase in both amount and as a percentage of revenue is due to additional personnel expenses associated with new product development initiatives. Product development expenses for HealthStream Provider Solutions increased approximately $1.2 million and approximated 16% of revenues for HealthStream Provider Solutions for both the nine months ended September 30, 2016 and 2015, respectively. The increase in amount is primarily the result of increased personnel costs, including additional personnel from MAI.

Sales and Marketing. Sales and marketing expenses, including personnel costs, increased approximately $1.8 million, or 7%, to $27.8 million for the nine months ended September 30, 2016 from $26.0 million for the nine months ended September 30, 2015. Sales and marketing expenses were approximately 17% of revenues for both the nine months ended September 30, 2016 and 2015.

Sales and marketing expenses for HealthStream Workforce Solutions increased approximately $484,000 and approximated 16% and 17% of revenues for HealthStream Workforce Solutions for the nine months ended September 30, 2016 and 2015, respectively. The increase in amount is mainly due to additional personnel, sales commissions, and increased marketing spending. These expense increases were partially offset by a reduction of expenses associated with our annual customer Summit, which was held during the second quarter of 2015, but will be held during the fourth quarter of 2016. Sales and marketing expenses for HealthStream Patient Experience Solutions decreased approximately $299,000, and approximated 12% and 13% of revenues for HealthStream Patient Experience Solutions for the nine months ended September 30, 2016 and 2015, respectively. The decrease in amount and as a percentage of revenues is primarily due to reduced personnel costs. Sales and marketing expenses for HealthStream Provider Solutions increased approximately $1.2 million, and approximated 21% and 26% of revenues for HealthStream Provider Solutions for the nine months ended September 30, 2016 and 2015, respectively. The increase in amount is primarily the result of increased personnel costs, sales commissions, and marketing spending.

Other General and Administrative Expenses. Other general and administrative expenses increased approximately $4.5 million, or 22%, to $25.4 million for the nine months ended September 30, 2016 from $20.9 million for the nine months ended September 30, 2015. Other general and administrative expenses as a percentage of revenues were approximately 15% and 14% of revenues for the nine months ended September 30, 2016 and 2015, respectively.

Other general and administrative expenses for HealthStream Workforce Solutions increased approximately $1.1 million over the first nine months of 2015 primarily associated with increased technology infrastructure investments. Other general and administrative expenses for HealthStream Patient Experience Solutions increased approximately $388,000 over the first nine months of 2015 due to additional personnel and facility costs. Other general and administrative expenses for HealthStream Provider Solutions increased approximately $973,000 over the first nine months of 2015 primarily associated with increased personnel expenses and facility costs. The unallocated corporate portion of other general and administrative expenses increased approximately $2.1 million over the first nine months of 2015, primarily associated with additional personnel and related costs, due diligence costs of $300,000, and costs associated with the implementation of a new financial systems platform of $600,000, which was substantially completed during the second quarter of 2016.

 

20


Table of Contents

Depreciation and Amortization. Depreciation and amortization increased approximately $3.8 million, or 32%, to $16.0 million for the nine months ended September 30, 2016 from $12.2 million for the nine months ended September 30, 2015. The increase primarily resulted from amortization of capitalized software development, amortization of intangible assets from recent acquisitions (including amortization of software acquired for resale), and depreciation expense associated with capital expenditures.

Other Income (Expense), Net. Other income (expense), net was income of approximately $465,000 for the nine months ended September 30, 2016 compared to an expense of $7,000 for the nine months ended September 30, 2015. The increase is primarily associated with a gain recorded in relation to the acquisition of all of the remaining outstanding stock of Nurse Competency (See Note 7 in the Notes to Condensed Consolidated Financial Statements for further discussion), an increase in interest income from investments in marketable securities and lower interest expense.

Income Tax Provision. The Company recorded a provision for income taxes of approximately $2.5 million for the nine months ended September 30, 2016 compared to $4.9 million for the nine months ended September 30, 2015. The Company’s effective tax rate was approximately 38% for the nine months ended September 30, 2016 compared to approximately 42% for the nine months ended September 30, 2015.

Net Income. Net income decreased approximately $2.7 million, or 12%, to $4.1 million for the nine months ended September 30, 2016 compared to $6.8 million for the nine months ended September 30, 2015. Earnings per diluted share were $0.13 per share for the nine months ended September 30, 2016 compared to $0.23 per diluted share for the nine months ended September 30, 2015.

Adjusted EBITDA (which we define as net income before interest, income taxes, stock based compensation, and depreciation and amortization) decreased approximately 11% to approximately $23.7 million for the nine months ended September 30, 2016 compared to $26.5 million for the nine months ended September 30, 2015. The decrease resulted from the factors mentioned above. See Reconciliation of Non-GAAP Financial Measures below for our reconciliation of this calculation to measures under US GAAP.

Reconciliation of Non-GAAP Financial Measures

This report contains certain non-GAAP financial measures, including, non-GAAP net income, non-GAAP operating income, and adjusted EBITDA, which are used by management in analyzing its financial results and ongoing operational performance. These non-GAAP financial measures should not be considered as a substitute for, or superior to, measures of financial performance which are prepared in accordance with US GAAP and may be different from non-GAAP financial measures used by other companies.

In order to better assess the Company’s financial results, management believes that adjusted EBITDA is an appropriate measure for evaluating the operating performance of the Company and provides useful information to investors because adjusted EBITDA reflects net income adjusted for certain non-cash and non-operating items. We believe that adjusted EBITDA is also used by many investors and securities analysts to assess the Company’s results from current operations. Adjusted EBITDA is a non-GAAP financial measure and should not be considered as a measure of financial performance under US GAAP. Because adjusted EBITDA is not a measurement determined in accordance with US GAAP, it is susceptible to varying calculations. Accordingly, adjusted EBITDA, as presented, may not be comparable to other similarly titled measures of other companies.

The Company understands that, although adjusted EBITDA is frequently used by investors and securities analysts in their evaluation of companies, this measure has limitations as an analytical tool, and you should not consider it in isolation, or as a substitute for an analysis of the Company’s results as reported under US GAAP.

In recent years, including the March 2015 acquisition of HLS and the August 2016 acquisition of MAI, the Company has acquired businesses whose net tangible assets include deferred revenue. In accordance with GAAP reporting requirements, following the completion of any such acquisition, the Company may record a write-down of deferred revenue to fair value as defined in GAAP. If the Company is required to record a write-down of deferred revenue, it may result in lower recognized revenue, operating income and net income in subsequent periods.

In connection therewith, this report presents below non-GAAP operating income and non-GAAP net income, which in each such case reflects the corresponding GAAP figures adjusted to exclude the impact of the deferred revenue write-down associated with fair value accounting for acquired businesses as referenced above. Management believes that the presentation of these non-GAAP financial measures assists investors in understanding the Company’s performance between periods by excluding the impact of this deferred revenue write-down and provides a useful measure of the ongoing performance of the Company. Both on a quarterly and year-to-date basis, the revenue for the acquired business is deferred and typically recognized over a one-to-two year period following the completion of any particular acquisition, so our GAAP operating income and net income for this one-to-two year period will not reflect the full amount that would have been reported if the acquired deferred revenue was not written down to fair value. A reconciliation of these non-GAAP financial measures to the corresponding GAAP measures is set forth below.

 

21


Table of Contents
     Three Months Ended
September 30,
    Nine Months Ended
September 30,
 
     2016     2015     2016     2015  

GAAP net income

   $ 1,162      $ 2,614      $ 4,066      $ 6,810   

Interest income

     (153     (150     (418     (259

Interest expense

     26        26        76        162   

Income tax provision

     461        1,739        2,487        4,862   

Stock based compensation expense

     512        440        1,516        2,787   

Depreciation and amortization

     5,755        4,639        15,976        12,148   
  

 

 

   

 

 

   

 

 

   

 

 

 

Adjusted EBITDA

   $ 7,763      $ 9,308      $ 23,703      $ 26,510   
  

 

 

   

 

 

   

 

 

   

 

 

 

GAAP operating income

   $ 1,286      $ 4,325      $ 6,088      $ 11,679   

Adjustment for deferred revenue write-down

     1,183        2,099        2,577        5,341   
  

 

 

   

 

 

   

 

 

   

 

 

 

Non-GAAP operating income

   $ 2,469      $ 6,424      $ 8,665      $ 17,020   
  

 

 

   

 

 

   

 

 

   

 

 

 

GAAP net income

   $ 1,162      $ 2,614      $ 4,066      $ 6,810   

Adjustment for deferred revenue write-down, net of tax

     847        1,261        1,598        3,114   
  

 

 

   

 

 

   

 

 

   

 

 

 

Non-GAAP net income

   $ 2,009      $ 3,875      $ 5,664      $ 9,924   
  

 

 

   

 

 

   

 

 

   

 

 

 

Liquidity and Capital Resources

Net cash provided by operating activities was approximately $15.0 million and $25.5 million during the nine months ended September 30, 2016 and 2015, respectively. The decrease in cash flows from operating activities was significantly impacted by increases in accounts receivable, resulting from slower collections, as well as reduced deferred revenue balances compared to the prior year period. The number of days sales outstanding (“DSO”) was 68 days for the third quarter of 2016 compared to 57 days for the third quarter of 2015. The increase in DSO resulted primarily from slower collections in the Provider Solutions segment. The Company calculates DSO by dividing the average accounts receivable balance for the quarter by average daily revenues for the quarter. The Company’s primary sources of cash were receipts generated from the sales of our products and services. The primary uses of cash to fund operations included personnel expenses, sales commissions, royalty payments, payments for contract labor and other direct expenses associated with delivery of our products and services, and general corporate expenses.

Net cash used in investing activities was approximately $57.6 million and $140.7 million for the nine months ended September 30, 2016 and 2015, respectively. During 2016, the Company utilized $53.1 million (net of cash acquired) for acquisitions, purchased $82.8 million of marketable securities, purchased $3.9 million of property and equipment and spent $7.1 million for capitalized software development. These uses of cash were partially offset by maturities of marketable securities of $88.2 million and proceeds from the sale of long lived assets of $975,000. During 2015, the Company utilized $88.1 million (net of cash acquired) for acquisitions, purchased $77.8 million of marketable securities, purchased $6.0 million of property and equipment, spent $5.3 million for capitalized software development, and made $2.0 million in non-marketable equity investments. These uses of cash were partially offset by maturities of marketable securities of $38.4 million.

Cash provided by financing activities was approximately $444,000 and $100.7 million for the nine months ended September 30, 2016 and 2015, respectively. During 2016 the primary source of cash from financing activities resulted from $661,000 of excess tax benefits from equity awards and $94,000 of proceeds from the exercise of employee stock options. The primary uses of cash during 2016 related to $311,000 for payments of payroll taxes from stock based compensation arrangements. The primary sources of cash from financing activities for 2015 resulted from $98.0 million in proceeds from the issuance of 3.9 million shares of our common stock in our underwritten public offering that was completed on May 28, 2015, $3.7 million of excess tax benefits from equity awards, and $328,000 of proceeds from the exercise of employee stock options. The primary uses of cash during 2015 related to payments of payroll taxes from stock based compensation arrangements of $753,000, and earn-outs for prior business combinations of $633,000.

Our balance sheet reflects positive working capital of $77.8 million at September 30, 2016 compared to $120.4 million at December 31, 2015. The decrease in working capital was primarily due to the use of cash to fund acquisitions of approximately $53.1 million and slower collections from customers resulting in higher accounts receivable balances. The Company’s primary source of liquidity is $100.6 million of cash and cash equivalents and marketable securities. The Company also has a $50.0 million revolving credit facility, all of which was available for additional borrowing at September 30, 2016.

We believe that our existing cash and cash equivalents, marketable securities, cash generated from operations, and available borrowings under our revolving credit facility will be sufficient to meet anticipated cash needs for working capital, new product development and capital expenditures for at least the next 12 months. Over the past ten years, we have utilized our federal and state net operating loss carryforwards to offset taxable income, thereby reducing our tax liabilities. The federal net operating loss carryforwards have been fully utilized as of December 31, 2015; therefore, actual income tax payments are expected to increase significantly in the future and will more closely approximate the provision for income taxes.

 

22


Table of Contents

The Company’s growth strategy includes acquiring businesses that provide complementary products and services. It is anticipated that future acquisitions, if any, would be effected through cash consideration, stock consideration or a combination of both. The issuance of our stock as consideration for an acquisition or to raise additional capital could have a dilutive effect on earnings per share and could adversely affect our stock price. Our revolving credit facility contains financial covenants and availability calculations designed to set a maximum leverage ratio of outstanding debt to adjusted EBITDA and an interest coverage ratio of adjusted EBITDA to interest expense. Therefore, the maximum borrowings against our revolving credit facility would be dependent on the covenant values at the time of borrowing. As of September 30, 2016, we were in material compliance with all covenants. There can be no assurance that amounts available for borrowing under our revolving credit facility will be sufficient to consummate any possible acquisitions, and we cannot assure you that if we need additional financing that it will be available on terms favorable to us, or at all. Failure to generate sufficient cash flow from operations or raise additional capital when required in sufficient amounts and on terms acceptable to us could harm our business, financial condition and results of operations.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

The Company is exposed to market risk from changes in interest rates. We do not have any foreign currency exchange rate risk or commodity price risk. There were no balances outstanding on the Revolving Credit Facility as of or during the nine months ended September 30, 2016. We are subject to interest rate market risk associated with any borrowings under our revolving credit facility. The interest rate under the revolving credit facility varies depending on the interest rate option selected by the Company plus a margin determined in accordance with a pricing grid. We are also exposed to market risk with respect to our cash and investment balances, which approximated $100.6 million at September 30, 2016. Assuming a hypothetical 10% decrease in interest rates for invested balances, interest income from cash and investments would decrease on an annualized basis by approximately $68,000.

The Company’s investment policy and strategy is focused on investing in highly rated securities, with the objective of minimizing the potential risk of principal loss. The Company’s policy limits the amount of credit exposure to any single issuer and sets limits on the average portfolio maturity.

The above market risk discussion and the estimated amounts presented are forward-looking statements of market risk assuming the occurrence of certain adverse market conditions. Actual results in the future may differ materially from those projected as a result of actual developments in the market.

Item 4. Controls and Procedures

Changes in Internal Control Over Financial Reporting

The Company began using a new enterprise accounting system in the second quarter of 2016. The implementation of the new accounting system required the Company to modify various internal controls and processes. There have been no other changes in the Company’s internal control over financial reporting that occurred during the period covered by this Quarterly Report that have materially affected, or are likely to materially affect, the Company’s internal control over financial reporting.

Evaluation of Controls and Procedures

HealthStream’s chief executive officer and principal financial officer have reviewed and evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934 (the “Exchange Act”)) as of the end of the period covered by this Quarterly Report. Based on that evaluation, the chief executive officer and principal financial officer have concluded that HealthStream’s disclosure controls and procedures were effective to ensure that the information required to be disclosed by the Company in the reports the Company files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and the information required to be disclosed in the reports the Company files or submits under the Exchange Act was accumulated and communicated to the Company’s management, including its chief executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

23


Table of Contents

PART II - OTHER INFORMATION

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

On February 16, 2016, the Company announced a share repurchase program authorized by the Company’s Board of Directors under which the Company may purchase up to $25,000,000 of its common stock. The share repurchase program will terminate on the earlier of December 31, 2016 or when the maximum dollar amount has been expended. The table below sets forth activity under the stock repurchase plan for the three months ended September 30, 2016.

 

Period

  (a)
Total number of
shares (or units)
purchased  (1)
    (b)
Average price paid per
share (or unit)
    (c)
Total number of shares (or
units) purchased as part of
publicly  announced plans or
programs
    (d)
Maximum number (or
approximate dollar value) of
shares (or units) that  may
yet be purchased under the
plans or programs
 

Month #1 (July 1 – July 31)

    —          —          —          25,000,000   

Month #2 (August 1 – August 31)

    —          —          —          25,000,000   

Month #3 (September 1 – September 30)

    —          —          —          25,000,000   
 

 

 

   

 

 

   

 

 

   

 

 

 

Total

    —        $ —          —        $ 25,000,000   
 

 

 

   

 

 

   

 

 

   

 

 

 

Item 6. Exhibits

 

  (a) Exhibits

2.1 – Stock Purchase Agreement, by and between Echo, Inc. and Morrisey Holdings, Inc., dated August 8, 2016 (incorporated by reference from Exhibit 2.1 filed with HealthStream, Inc.’s Current Report on Form 8-K filed with the SEC on August 8, 2016)

31.1 – Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2 – Certification of the Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1 – Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2 – Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.1 INS – XBRL Instance Document

101.1 SCH – XBRL Taxonomy Extension Schema

101.1 CAL – XBRL Taxonomy Extension Calculation Linkbase

101.1 DEF – XBRL Taxonomy Extension Definition Linkbase

101.1 LAB – XBRL Taxonomy Extension Label Linkbase

101.1 PRE – XBRL Taxonomy Extension Presentation Linkbase

 

24


Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

    HEALTHSTREAM, INC.
November 2, 2016     By:   /S/ GERARD M. HAYDEN, JR.
      Gerard M. Hayden, Jr.
      Chief Financial Officer

 

25


Table of Contents

HEALTHSTREAM, INC.

EXHIBIT INDEX

 

2.1    Stock Purchase Agreement, by and between Echo, Inc. and Morrisey Holdings, Inc., dated August 8, 2016 (incorporated by reference from Exhibit 2.1 filed with HealthStream, Inc.’s Current Report on Form 8-K filed with the SEC on August 8, 2016)
31.1    Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2    Certification of the Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1    Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2    Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.1 INS    XBRL Instance Document
101.1 SCH    XBRL Taxonomy Extension Schema
101.1 CAL    XBRL Taxonomy Extension Calculation Linkbase
101.1 DEF    XBRL Taxonomy Extension Definition Linkbase
101.1 LAB    XBRL Taxonomy Extension Label Linkbase
101.1 PRE    XBRL Taxonomy Extension Presentation Linkbase
EX-31.1 2 d267831dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

I, Robert A. Frist, Jr., certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of HealthStream, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 2, 2016       /S/ ROBERT A. FRIST, JR.
      Robert A. Frist, Jr.
      Chief Executive Officer
EX-31.2 3 d267831dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

I, Gerard M. Hayden, Jr., certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of HealthStream, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 2, 2016       /S/ GERARD M. HAYDEN, JR.
      Gerard M. Hayden, Jr.
      Chief Financial Officer
EX-32.1 4 d267831dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of HealthStream, Inc. (the “Company”) on Form 10-Q for the period ending September 30, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Robert A. Frist, Jr., Chief Executive Officer of the Company, certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

  (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

/S/ ROBERT A. FRIST, JR.
Robert A. Frist, Jr.

Chief Executive Officer

November 2, 2016

 

EX-32.2 5 d267831dex322.htm EX-32.2 EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of HealthStream, Inc. (the “Company”) on Form 10-Q for the period ending September 30, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Gerard M. Hayden, Jr., Chief Financial Officer of the Company, certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

  (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

/S/ GERARD M. HAYDEN, JR.
Gerard M. Hayden, Jr.

Chief Financial Officer

November 2, 2016

 

EX-101.INS 6 hstm-20160930.xml XBRL INSTANCE DOCUMENT 3402000 27400000 1548000 75000 4201000 187000 48000000 913000 20502000 4200000 9100000 5400000 21400000 600000 31739741 3052000 47200000 2523000 200000 54000 5979000 546000 90309000 1085000 43798000 3700000 42600000 900000 500000 75000 484000 4931 67441000 115000 2028000 31739000 280759000 31739000 394051000 173079000 13885000 15749000 75000000 603000 60747000 39820000 46166000 6735000 3675000 65029000 -27000 29717000 4909000 10623000 14038000 7584000 394051000 80771000 109796000 778000 95240000 16466000 3289000 964000 10403000 286389000 5657000 2296000 112815000 93350000 35724000 152162000 36000 9000 60774000 60747000 36000 3000 43720000 43687000 6000 17054000 17060000 3.00 3.00 50000000 50000000 0 25000000 5000000 5000000 5979000 300000 700000 6000000 15000000 16377000 24154000 69265000 0.32 31739000 280759000 -27000 5657000 81995000 3308000 31647000 278799000 31647000 379569000 209537000 9053000 13955000 75000000 303000 66976000 82010000 36348000 4350000 4616000 65098000 -70000 24130000 4763000 7003000 8685000 8169000 379569000 55966000 83073000 1058000 89078000 14036000 3640000 927000 12471000 280320000 1591000 1998000 161344000 82375000 34902000 100948000 70000 77046000 66976000 70000 66046000 65976000 1000000 1000000 12336000 24154000 46583000 31647000 278799000 -70000 1591000 48000000 P1Y 4900000 3880000 44120000 P5Y P13Y P6Y 1000000 225000 148000 5351000 -1899000 3721000 13000 -14554000 2787000 65752000 0.23 12148000 0.23 6800000 141457000 0.417 3721000 123000 153136000 20851000 946000 -7000 3082000 -10000 1000000 6810000 77774000 184000 11672000 -2649000 -140750000 -10000 28000000 88075000 -2501000 595000 -288000 378000 11679000 -1251000 100677000 633000 5426000 753000 -98000 4862000 25519000 5329000 6012000 938000 98014000 30.42 29905000 38440000 -1800000 29527000 49310 16654000 328000 26052000 28000000 1000000 -18209000 118488000 29789000 25545000 1737000 9103000 -1638000 25.56 80355 526000 0.35 0.36 161954000 10599000 0.18 0.18 159009000 5445000 790000 997000 486000 514000 HEALTHSTREAM INC 661000 42000 10-Q 0001095565 <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>7. BUSINESS COMBINATIONS</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b><i>Morrisey Associates, Inc.</i></b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> On August&#xA0;8, 2016, Echo, Inc. (&#x201C;Echo&#x201D;), a wholly owned subsidiary of the Company, acquired all of the outstanding stock of Morrisey Associates, Inc. (&#x201C;MAI&#x201D;), a Chicago, Illinois based company that provides credentialing and privileging software to healthcare professionals. The acquisition of MAI allows the Company to expand its credentialing and privileging product offerings and solutions to healthcare organizations. The consideration paid for MAI consisted of approximately $48.0 million in cash, which the Company funded with cash on hand, and was not subject to any post-closing working capital or similar adjustment. The Company incurred approximately $953,000 in transaction costs, of which $805,000 were incurred during the three months ended September&#xA0;30, 2016 and $148,000 were incurred during the six months ended June&#xA0;30, 2016. The transaction costs were recorded in other general and administrative expenses in the condensed consolidated statements of income for such periods. The results of operations for MAI have been included in the Company&#x2019;s condensed consolidated financial statements from the date of acquisition, and are also included in the HealthStream Provider Solutions segment.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> A summary of the purchase price is as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="88%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Cash paid at closing</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">44,120</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Cash held in escrow</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,880</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total consideration paid</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">48,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The following table summarizes the fair value of the assets acquired and liabilities assumed as of the date of acquisition (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="88%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Accounts receivable, net</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,402</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Prepaid royalties and other prepaid assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">187</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Property and equipment</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">75</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Deferred tax assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,548</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Goodwill</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">20,502</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Intangible assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">27,400</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Accounts payable and accrued liabilities</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(913</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Deferred revenue</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(4,201</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Net assets acquired</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">48,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" align="center">9</p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The excess of preliminary purchase price over the preliminary fair values of net tangible and intangible assets will be recorded as goodwill. The preliminary fair values of tangible and identifiable intangible assets and deferred revenue are based on management&#x2019;s estimates and assumptions. The preliminary fair values of assets acquired and liabilities assumed are considered preliminary and are based on the information that was available at the time of the acquisition. The preliminary fair values of assets acquired and liabilities assumed are subject to change during the measurement period (up to one year from the acquisition date) as the Company finalizes the valuation of these items. The goodwill balance is primarily attributed to the assembled workforce, additional market opportunities from offering MAI&#x2019;s products, and expected synergies from integrating MAI with other products or other combined functional areas within the Company. The goodwill balance is deductible for U.S. income tax purposes. The net tangible assets include deferred revenue, which was preliminarily adjusted down from a book value at the acquisition date of $9.1 million to an estimated fair value of $4.2 million. The preliminary $4.9 million write-down of deferred revenue will result in lower revenues than would have otherwise been recognized for such services.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The following table sets forth the preliminary components of identifiable intangible assets and their estimated useful lives as of the acquisition date (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="78%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Preliminary<br /> fair value</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Useful<br /> life</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Customer relationships</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">21,400</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">13&#xA0;years</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Developed technology</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,400</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5&#xA0;years</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Trade names</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">600</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6&#xA0;years</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total preliminary intangible assets subject to amortization</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">27,400</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The amounts of revenue and operating income (loss) of MAI included in the Company&#x2019;s condensed consolidated statement of income from the date of acquisition of August&#xA0;8, 2016 to the period ending September&#xA0;30, 2016 are as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="88%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total revenues</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">841</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Operating loss</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1,023</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The following unaudited pro forma financial information summarizes the combined results of operations of the Company and MAI, which was significant for purposes of the unaudited pro forma financial information disclosure, as though the companies were combined as of January&#xA0;1, 2015 (in thousands, except per share data):</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Three Months Ended</b><br /> <b>September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Nine Months Ended</b><br /> <b>September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total revenues</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">60,711</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">56,622</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">176,401</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">159,009</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Net income</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,275</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,573</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,764</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,445</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Basic earnings per share</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.07</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.08</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.18</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.18</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Diluted earnings per share</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.07</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.08</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.18</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.18</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> These unaudited pro forma combined results of operations include certain adjustments arising from the acquisition such as adjustment for amortization of intangible assets, depreciation of property and equipment, and fair value adjustments of acquired deferred revenue balances. The unaudited pro forma combined results of operations is for informational purposes only and is not indicative of what the Company&#x2019;s results of operations would have been had the transaction occurred at the beginning of the period presented or to project the Company&#x2019;s results of operations in any future period.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The unaudited pro forma financial information for the three and nine months ended September&#xA0;30, 2016 and 2015 combines the historical results of the Company and MAI for the three and nine months ended September&#xA0;30, 2016 and 2015 and the pro forma adjustments listed above.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" align="center">10</p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b><i>HealthLine Systems</i></b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> On March&#xA0;16, 2015, the Company acquired all of the membership interests of HealthLine Systems, LLC (&#x201C;HLS&#x201D;), a San Diego, California based company that specializes in credentialing, privileging, call center, and quality management solutions for the healthcare industry. The acquisition of HLS enabled the Company to provide a comprehensive solution set for healthcare provider credentialing, privileging, enrollment, referral, onboarding, and analytics in support of HealthStream&#x2019;s approach to talent management for healthcare organizations. The consideration paid for HLS consisted of approximately $90.3 million in cash (taking into account an estimated closing working capital adjustment and amounts due to the seller as of September&#xA0;30, 2016). The Company incurred approximately $1.3 million in transaction costs associated with the acquisition, of which $965,000 were incurred during the three months ended March&#xA0;31, 2015 and $329,000 were incurred during the year ended December&#xA0;31, 2014. The transaction costs were recorded in other general and administrative expenses in the condensed consolidated statements of income for such periods. The results of operations for HLS have been included in the Company&#x2019;s condensed consolidated financial statements from the date of acquisition, and are also included in the HealthStream Provider Solutions segment.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> A summary of the purchase price is as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="88%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Cash paid at closing</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">87,450</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Consideration due to the seller</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,180</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Cash held in escrow</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">679</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total consideration paid</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">90,309</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The following table summarizes the fair value of the assets acquired and liabilities assumed as of the date of acquisition (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="88%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Cash</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">54</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Accounts receivable, net</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,052</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Prepaid assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">546</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Property and equipment</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">200</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Deferred tax assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,523</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Goodwill</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">43,798</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Intangible assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">47,200</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Accounts payable and accrued liabilities</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(1,085</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Deferred revenue</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(5,979</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Net assets acquired</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">90,309</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The excess of purchase price over the fair values of net tangible and intangible assets has been recorded as goodwill. The fair values of tangible and identifiable intangible assets, deferred tax assets, deferred revenue, and other liabilities are based on management&#x2019;s estimates and assumptions. Included in the assets and liabilities assumed is an estimated indemnification asset of $300,000 and a contingent liability of $700,000, both of which are associated with tax liabilities. The contingent liability is measured based on management&#x2019;s estimate of a range of probable outcomes. The goodwill balance is primarily attributed to the assembled workforce, additional market opportunities from offering HLS&#x2019;s products, and expected synergies from integrating HLS with other products or other combined functional areas within the Company. During the three months ended March&#xA0;31, 2016, the Company received notice of an indemnification claim from the former owners of HLS pursuant to the terms of the membership interest purchase agreement. The terms of such agreement require the Company to indemnify such owners for incremental taxes incurred as the result of the structure of the acquisition, which had favorable tax aspects to the Company. The Company recorded a measurement period adjustment in relation to the claim that increased goodwill by approximately $2.2 million during the three months ended March&#xA0;31, 2016. The additional goodwill is deductible for U.S. income tax purposes. The goodwill balance excluding such measurement period adjustment is also deductible for U.S. income tax purposes. During the three months ended September&#xA0;30, 2016, the Company agreed to settle this indemnification claim for approximately $2.4 million in respect of such tax indemnification provision in the membership interest purchase agreement, a difference of approximately $200,000 from the aforementioned $2.2 million measurement period adjustment. The Company surpassed the one year measurement period as of the period ended March&#xA0;31, 2016; accordingly, in accordance with requisite accounting guidance, the $200,000 difference has been reflected as a charge against net income for the period ended September&#xA0;30, 2016. The net tangible assets include deferred revenue, which was adjusted down from a book value at the acquisition date of $15.0 million to an estimated fair value of $6.0 million. The $9.0 million write-down of deferred revenue will result in lower revenues than would have otherwise been recognized for such services.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" align="center">11</p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The following table sets forth the components of identifiable intangible assets and their estimated useful lives as of the acquisition date (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="78%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Fair&#xA0;value</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Useful&#xA0;life</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Customer relationships</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">42,600</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">13&#xA0;years</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Developed technology</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,700</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5 years</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Trade names</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">900</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6 years</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total intangible assets subject to amortization</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">47,200</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The amounts of revenue and operating income (loss) of HLS included in the Company&#x2019;s condensed consolidated statement of income from the date of acquisition of March&#xA0;16, 2015 to the period ending September&#xA0;30, 2015 are as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="88%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total revenues</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,351</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Operating loss</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1,899</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The following unaudited pro forma financial information summarizes the combined results of operations of the Company and HLS, which was significant for purposes of the unaudited pro forma financial information disclosure, as though the companies were combined as of January&#xA0;1, 2014 (in thousands, except per share data):</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Three Months Ended</b><br /> <b>September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Nine Months Ended</b><br /> <b>September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total revenues</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">58,644</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">55,741</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">168,908</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">161,954</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Net income</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,361</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,760</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,090</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">10,599</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Basic earnings per share</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.04</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.12</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.16</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.36</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Diluted earnings per share</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.04</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.12</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.16</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.35</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> These unaudited pro forma combined results of operations include certain adjustments arising from the acquisition such as adjustment for amortization of intangible assets, depreciation of property and equipment, fair value adjustments of acquired deferred revenue balances, and interest expense associated with borrowings under a revolving credit facility by the Company to partially fund the acquisition. The unaudited pro forma combined results of operations is for informational purposes only and is not indicative of what the Company&#x2019;s results of operations would have been had the transaction occurred at the beginning of the period presented or to project the Company&#x2019;s results of operations in any future period.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The unaudited pro forma financial information for the three and nine months ended September&#xA0;30, 2016 and 2015 combines the historical results of the Company and HLS for the three and nine months ended September&#xA0;30, 2016 and 2015 and the pro forma adjustments listed above.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b><i>Other Business Combinations</i></b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> On June&#xA0;30, 2016, the Company acquired all of the stock of Performance Management Services, Inc. (&#x201C;PMSI&#x201D;), a Company based in Tustin, California focused on competency-based performance development for nurses, for $4.0 million in cash and up to an additional $500,000 of contingent consideration. The acquisition, including associated transaction costs, is not considered material to the Company&#x2019;s financial statements. The Company accounted for the acquisition as a business combination and has allocated the purchase consideration based on preliminary estimates of fair value. The Company expects to finalize its estimates of fair value as soon as practicable, but not later than one year from the date of acquisition. The results of operations for PMSI are included in the Company&#x2019;s condensed consolidated financial statements from the date of acquisition and are included in the HealthStream Workforce Solutions segment.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" align="center">12</p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> On July&#xA0;25, 2016, the Company purchased all of the outstanding stock of Nursing Registry Consultants Corporation (&#x201C;Nurse Competency&#x201D;) not previously held by the Company for approximately $1.0 million in cash and up to an additional $75,000 in contingent consideration. Nurse Competency provides SaaS-based clinical assessment and testing products to the healthcare industry. The Company previously held a 32% minority equity interest in Nurse Competency and had accounted for such interest as an equity method investment. The fair value of the minority equity interest as of the July&#xA0;25, 2016 acquisition date was approximately $484,000 and was determined in accordance with the fair value of the controlling interest acquired with consideration given to acquisition premiums, where applicable. The Company recorded a gain of approximately $225,000 to account for the difference between the noted acquisition date fair value of the minority equity interest and the carrying value as of such date. The gain is included in other income (expense), net in the condensed consolidated statements of income for the three and nine months ended September&#xA0;30, 2016. The Company accounted for the acquisition as a business combination and has allocated the purchase consideration based on preliminary estimates of fair value. The Company expects to finalize its estimates of fair value as soon as practicable, but not later than one year from the date of acquisition. The results of operations for Nurse Competency are included in the Company&#x2019;s condensed consolidated financial statements from the date of acquisition and are included in the HealthStream Workforce Solutions segment.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b><i>Goodwill</i></b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The changes in the carrying amount of goodwill for the nine months ended September&#xA0;30, 2016 are as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="63%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Workforce</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Patient</b><br /> <b>Experience</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Provider</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Balance at January&#xA0;1, 2016</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">12,336</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">24,154</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">46,583</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">83,073</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Other business combinations</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,041</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,041</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Acquisition of HealthLine Systems, LLC</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,180</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,180</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Acquisition of Morrisey Associates, Inc.</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">20,502</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">20,502</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Balance at September&#xA0;30, 2016</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">16,377</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">24,154</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">69,265</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">109,796</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> During the three months ended March&#xA0;31, 2016, the Company recorded approximately $2.2 million of additional goodwill in relation to the March 2015 acquisition of HealthLine Systems, LLC. Such amount relates to the measurement period adjustment previously discussed under the above caption &#x201C;<i>HealthLine Systems.</i>&#x201D;</p> <p><br class="Apple-interchange-newline" /> &#xA0;</p> </div> <div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>9. DEBT</b></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <u>Revolving Credit Facility</u></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> The Company maintains a Loan Agreement (the &#x201C;Revolving Credit Facility&#x201D;) with SunTrust Bank (&#x201C;SunTrust&#x201D;) in the aggregate principal amount of $50.0 million, which matures on November&#xA0;24, 2017. Under the Revolving Credit Facility, the Company may borrow up to $50.0 million, which includes a $5.0 million swing line subfacility and a $5.0 million letter of credit subfacility, as well as an accordion feature that allows the Company to increase the Revolving Credit Facility by a total of up to $25.0 million, subject to securing additional commitments from existing lenders or new lending institutions. The obligations under the Revolving Credit Facility are guaranteed by each of the Company&#x2019;s subsidiaries. At the Company&#x2019;s election, the borrowings under the Revolving Credit Facility bear interest at either (1)&#xA0;a rate per annum equal to the highest of SunTrust&#x2019;s prime rate or 0.5% in excess of the Federal Funds Rate or 1.0% in excess of one-month LIBOR (the &#x201C;Base Rate&#x201D;), plus an applicable margin, or (2)&#xA0;the one, two, three, or six-month per annum LIBOR for deposits in the applicable currency (the &#x201C;Eurocurrency Rate&#x201D;), as selected by the Company, plus an applicable margin. The applicable margin for Eurocurrency Rate loans depends on the Company&#x2019;s funded debt leverage ratio and varies from 1.50% to 2.00%. The applicable margin for Base Rate loans depends on the Company&#x2019;s funded debt leverage ratio and varies from 0.50% to 1.50%. Commitment fees and letter of credit fees are also payable under the Revolving Credit Facility. Principal is payable in full at maturity on November&#xA0;24, 2017, and there are no scheduled principal payments prior to maturity. The Company is required to pay a commitment fee ranging between 20 and 30 basis points per annum of the average daily unused portion of the Revolving Credit Facility, depending on the Company&#x2019;s funded debt leverage ratio.</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> The purpose of the Revolving Credit Facility is for general working capital needs, permitted acquisitions (as defined in the Loan Agreement), and for stock repurchase and/or redemption transactions that the Company may authorize.</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> The Revolving Credit Facility contains certain covenants that, among other things, restrict additional indebtedness, liens and encumbrances, changes to the character of the Company&#x2019;s business, acquisitions, asset dispositions, mergers and consolidations, sale or discount of receivables, creation or acquisitions of additional subsidiaries, and other matters customarily restricted in such agreements.</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> In addition, the Revolving Credit Facility requires the Company to meet certain financial tests, including, without limitation:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="1%">&#xA0;</td> <td width="2%" valign="top" align="left">&#x2022;</td> <td width="1%" valign="top">&#xA0;</td> <td align="left" valign="top">a funded debt leverage ratio (consolidated debt/consolidated EBITDA) of not greater than 3.0 to 1.0; and</td> </tr> </table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="1%">&#xA0;</td> <td width="2%" valign="top" align="left">&#x2022;</td> <td width="1%" valign="top">&#xA0;</td> <td align="left" valign="top">an interest coverage ratio (consolidated EBITDA/consolidated interest expense) of not less than 3.0 to 1.0.</td> </tr> </table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> As of September&#xA0;30, 2016, the Company was in material compliance with all covenants. There were no balances outstanding on the Revolving Credit Facility as of September&#xA0;30, 2016. During the three months ended June&#xA0;30, 2015, the Company repaid approximately $28.0 million of balances previously outstanding under the Revolving Credit Facility from proceeds received in the Company&#x2019;s public offering of 3,869,750 shares which closed on May&#xA0;28, 2015.</p> </div> 1516000 2016-09-30 -42190000 1516000 <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>1. BASIS OF PRESENTATION</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#x201C;US GAAP&#x201D;) for interim financial information and with the instructions to<font style="WHITE-SPACE: nowrap">Form&#xA0;10-Q</font>&#xA0;and Article 10 of Regulation&#xA0;<font style="WHITE-SPACE: nowrap">S-X.</font>&#xA0;Accordingly, condensed consolidated financial statements do not include all of the information and footnotes required by US&#xA0;GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. All significant intercompany transactions have been eliminated in consolidation. Operating results for the three and nine months ended September&#xA0;30, 2016 are not necessarily indicative of the results that may be expected for the year ending December&#xA0;31, 2016.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The balance sheet at December&#xA0;31, 2015 is consistent with the audited financial statements at that date but does not include all of the information and footnotes required by US&#xA0;GAAP for a complete set of financial statements. For further information, refer to the consolidated financial statements and footnotes thereto for the year ended December&#xA0;31, 2015 included in the Company&#x2019;s Annual Report on Form 10-K (the &#x201C;Form 10-K&#x201D;), filed with the Securities and Exchange Commission on February&#xA0;26, 2016.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b><i>Recently Adopted Accounting Standards</i></b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The Company has adopted Accounting Standards Update (&#x201C;ASU&#x201D;) 2015-16,&#xA0;<i>Business Combinations (Topic 805)</i>. Under the provisions of the revised guidance, acquirers in a business combination must recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. The acquirer must record, in the same period&#x2019;s financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the provisional amounts, calculated as if the accounting had been completed at the acquisition date. The Company recorded a measurement period adjustment during the period ended March&#xA0;31, 2016. See Note 7 Business Combinations for further discussion.</p> </div> 2016 false --12-31 70410000 0.13 15976000 <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>4. STOCK BASED COMPENSATION</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The Company has stock awards outstanding under three stock incentive plans, the Company&#x2019;s 2010 Stock Incentive Plan, the Company&#x2019;s 2000 Stock Incentive Plan, as amended, and the Company&#x2019;s 2016 Omnibus Incentive Plan, which shareholders approved at the annual meeting of shareholders held on May&#xA0;26, 2016. The Company accounts for its stock based compensation plans using the fair-value based method for costs related to share-based payments, including stock options and restricted share units (&#x201C;RSUs&#x201D;). During the nine months ended September&#xA0;30, 2016, the Company issued 111,808 RSUs, subject to time-based vesting, with a weighted average grant date fair value of $20.49 per share, measured based on the closing fair market value of the Company&#x2019;s stock on the date of grant. During the nine months ended September&#xA0;30, 2015, the Company issued 80,355 RSUs with a weighted average grant date fair value of $25.56 per share, and the Company issued 49,310 stock awards with a weighted average grant date fair value of $30.42 per share. Both measurements were based on the closing fair market value of the Company&#x2019;s stock on the date of grant.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> During the three months ended September&#xA0;30, 2015, the Company issued 30,000 performance-based RSUs, the vesting of which is contingent upon meeting certain performance criteria over a five year period. The measurement date for 8,750 of these performance-based RSUs was established during the three months ended September&#xA0;30, 2015 with a grant-date fair value of $23.40 per share, and the measurement date for 5,000 of these awards was established during the three months ended March&#xA0;31, 2016 with a grant-date fair value of $20.20 per share. Both measurements were based on the closing fair market value of the Company&#x2019;s stock on the date of grant. The performance criteria for the remaining 16,250 performance-based RSUs will be established on an annual basis by the Company&#x2019;s Compensation Committee; therefore, the measurement date and fair value of the awards cannot be determined until the performance criteria is established.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Total stock based compensation expense recorded for the three and nine months ended September&#xA0;30, 2016 and 2015, which is recorded in the condensed consolidated statements of income, is as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"> <b>Three&#xA0;Months&#xA0;Ended</b><br /> <b>September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Nine&#xA0;Months&#xA0;Ended</b><br /> <b>September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Cost of revenues (excluding depreciation and amortization)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">35</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">29</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">110</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">790</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Product development</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">73</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">55</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">200</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">514</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Sales and marketing</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">65</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">61</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">193</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">486</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Other general and administrative</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">339</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">295</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,013</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">997</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total stock based compensation expense</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">512</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">440</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,516</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,787</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" align="center">7</p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <i><u>Stock Awards</u></i></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> During June 2015, the Company&#x2019;s Chief Executive Officer (&#x201C;CEO&#x201D;), Robert A. Frist, Jr., entered into an agreement with the Company pursuant to which he contributed 54,241 of his personally owned shares of HealthStream, Inc. common stock to the Company, without any consideration paid to him. In connection with this contribution, the Company approved the grant of 49,310 shares of HealthStream, Inc. common stock to over 600 employees who were not otherwise eligible to receive equity awards and had at least one year of service with the Company. The Company recognized approximately $1.5 million of stock based compensation expense for these stock awards during the three months ended June&#xA0;30, 2015 based on the closing fair market value of the Company&#x2019;s stock on the date of the Company&#x2019;s approval of these grants. In connection with these equity awards, effective in the second quarter of 2015, the Company withheld shares with value equivalent to the employees&#x2019; minimum statutory obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. The total shares withheld were 17,279, and were based on the value of the stock awards on the date of the Company&#x2019;s approval of these grants, as determined by the Company&#x2019;s closing stock price on that date. Total payments related to the employees&#x2019; tax obligations to taxing authorities for these stock awards were approximately $526,000, and are reflected as a financing activity within the condensed consolidated statements of cash flows for the nine months ended September&#xA0;30, 2015. These share withholdings had the effect of share repurchases by the Company as they reduced and retired the number of shares otherwise issuable as a result of the stock awards and did not represent an expense to the Company.</p> </div> Q3 0.13 4109000 161149000 Large Accelerated Filer <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>5. EARNINGS PER SHARE</b></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Basic earnings per share is computed by dividing the net income available to common shareholders for the period by the <font style="white-space:nowrap">weighted-average</font> number of common shares outstanding during the period. Diluted earnings per share is computed by dividing the net income for the period by the weighted average number of potentially dilutive common and common equivalent shares outstanding during the period. Common equivalent shares are composed of incremental common shares issuable upon the exercise of stock options and RSUs subject to vesting. The dilutive effect of common equivalent shares is included in diluted earnings per share by application of the treasury stock method. The total number of common equivalent shares excluded from the calculations of diluted earnings per share, due to their anti-dilutive effect, was approximately 21,000 and 26,000 for the three months ended September&#xA0;30, 2016 and 2015, respectively, and approximately 42,000 and 13,000 for the nine months ended September&#xA0;30, 2016 and 2015, respectively.</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> The following table sets forth the computation of basic and diluted earnings per share for the three and nine months ended September&#xA0;30, 2016 and 2015 (in thousands, except per share data):</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="72%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"><b>Three Months Ended</b><br /> <b>September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"><b>Nine Months Ended</b><br /> <b>September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Numerator:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Net income</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,162</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,614</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,066</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,810</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Denominator:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Weighted-average shares outstanding</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">31,739</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">31,643</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">31,714</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">29,527</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Effect of dilutive shares</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">368</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">386</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">336</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">378</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"> &#xA0;</p> </td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"> &#xA0;</p> </td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"> &#xA0;</p> </td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"> &#xA0;</p> </td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Weighted-average diluted shares</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">32,107</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">32,029</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">32,050</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">29,905</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Basic earnings per share</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.04</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.08</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.13</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.23</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Diluted earnings per share</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.04</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.08</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.13</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.23</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> 0.380 661000 661000 791000 167237000 25396000 2291000 465000 -444000 <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>3. INCOME TAXES</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Income taxes are accounted for using the asset and liability method, whereby deferred tax assets and liabilities are determined based on the temporary differences between the financial statement and tax bases of assets and liabilities measured at tax rates that will be in effect for the year in which the differences are expected to affect taxable income.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> During the nine months ended September&#xA0;30, 2016 and 2015, the Company recorded a provision for income taxes of approximately $2.5 million and $4.9 million, respectively. The Company&#x2019;s effective tax rate for the nine months ended September&#xA0;30, 2016 and 2015 was 38.0% and 41.7%, respectively. The Company&#x2019;s effective tax rate primarily reflects the statutory corporate income tax rate, the net effect of state taxes, and the effect of various permanent tax differences. During the nine months ended September&#xA0;30, 2016, the Company recorded a reduction of approximately $300,000 to the liability for gross unrecognized tax benefits. During the nine months ended September&#xA0;30, 2015, the Company recorded a reduction of approximately $1.8 million to the liability for gross unrecognized tax benefits, resulting from the filing of a change in tax accounting method with the IRS for tangible property and deferred revenue. Of this total reduction, approximately $115,000 had an impact on the effective tax rate for the third quarter of 2015.</p> </div> 43000 4066000 82771000 340000 6553000 6855000 -57617000 43000 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The following is the Company&#x2019;s business segment information as of and for the three and nine months ended September&#xA0;30, 2016 and 2015 (in thousands).</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Three Months Ended</b><br /> <b>September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Nine Months Ended</b><br /> <b>September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Revenues, net:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Workforce</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">43,015</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">41,092</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">124,489</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">118,488</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Patient Experience</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">8,931</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">8,792</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">25,862</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">25,545</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Provider</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6,421</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,951</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">16,886</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">9,103</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total revenues, net</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">58,367</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">53,835</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">167,237</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">153,136</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> 975000 53078000 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>2. RECENT ACCOUNTING PRONOUNCEMENTS</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> In May 2014, the Financial Accounting Standards Board (&#x201C;FASB&#x201D;) issued ASU 2014-09, <i>Revenue from Contracts with Customers (Topic 606)</i>, which supersedes the revenue recognition requirements in Topic 605, <i>Revenue Recognition</i>, and most industry-specific revenue recognition guidance throughout the Industry Topics of the Accounting Standards Codification. The updated guidance states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also provides for additional disclosures with respect to revenues and cash flows arising from contracts with customers. The standard will be effective for the first interim period within annual reporting periods beginning after December&#xA0;15, 2017, and early adoption is permitted for the first interim period within annual reporting periods beginning after December&#xA0;15, 2016. The Company is currently reviewing this standard to determine the method of adoption and to assess the impact on its future consolidated financial statements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> In February 2016, the FASB issued ASU 2016-02, <i>Leases (Topic 842)</i>, which requires lessees to recognize assets and liabilities for most leases. The recognition, measurement and presentation of expenses and cash flows arising from a lease by a lessee is not expected to significantly change under such guidance; however, the Company is currently reviewing this standard to determine the method of adoption and to assess the impact on its future consolidated financial statements. The standard will be effective for the first interim period within annual reporting periods beginning after December&#xA0;15, 2018, and early adoption is permitted.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> In March 2016, the FASB issued ASU 2016-09, <i>Compensation &#x2013; Stock Compensation (Topic 718)</i>, which serves to simplify several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The standard will be effective for the first interim period within annual reporting periods beginning after December&#xA0;15, 2016, and early adoption is permitted in any interim or annual period. The Company is currently reviewing this standard to determine the method of adoption and to assess the impact on its future consolidated financial statements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> In March 2016, the FASB issued ASU 2016-01, <i>Financial Instruments &#x2013; Overall (Sub Topic 825-10)</i>, which addresses certain aspects of the recognition, measurement, presentation, and disclosure of financial instruments. The guidance will, among other things, require equity method investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income. The standard will be effective for the first interim period within annual reporting periods beginning after December&#xA0;15, 2017, and early adoption is permitted for only limited aspects of such guidance. The Company is currently reviewing this standard to determine the method of adoption and to assess the impact on its future consolidated financial statements.</p> </div> -454000 326000 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Recently Adopted Accounting Standards</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The Company has adopted Accounting Standards Update (&#x201C;ASU&#x201D;) 2015-16, <i>Business Combinations (Topic 805)</i>. Under the provisions of the revised guidance, acquirers in a business combination must recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. The acquirer must record, in the same period&#x2019;s financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the provisional amounts, calculated as if the accounting had been completed at the acquisition date. The Company recorded a measurement period adjustment during the period ended March&#xA0;31, 2016. See Note 7 Business Combinations for further discussion.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> <strong>RECENT ACCOUNTING PRONOUNCEMENTS</strong></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> In May 2014, the Financial Accounting Standards Board (&#x201C;FASB&#x201D;) issued ASU 2014-09, <i>Revenue from Contracts with Customers (Topic 606)</i>, which supersedes the revenue recognition requirements in Topic 605, <i>Revenue Recognition</i>, and most industry-specific revenue recognition guidance throughout the Industry Topics of the Accounting Standards Codification. The updated guidance states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also provides for additional disclosures with respect to revenues and cash flows arising from contracts with customers. The standard will be effective for the first interim period within annual reporting periods beginning after December&#xA0;15, 2017, and early adoption is permitted for the first interim period within annual reporting periods beginning after December&#xA0;15, 2016. The Company is currently reviewing this standard to determine the method of adoption and to assess the impact on its future consolidated financial statements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> In February 2016, the FASB issued ASU 2016-02, <i>Leases (Topic 842)</i>, which requires lessees to recognize assets and liabilities for most leases. The recognition, measurement and presentation of expenses and cash flows arising from a lease by a lessee is not expected to significantly change under such guidance; however, the Company is currently reviewing this standard to determine the method of adoption and to assess the impact on its future consolidated financial statements. The standard will be effective for the first interim period within annual reporting periods beginning after December&#xA0;15, 2018, and early adoption is permitted.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> In March 2016, the FASB issued ASU 2016-09, <i>Compensation &#x2013; Stock Compensation (Topic 718)</i>, which serves to simplify several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The standard will be effective for the first interim period within annual reporting periods beginning after December&#xA0;15, 2016, and early adoption is permitted in any interim or annual period. The Company is currently reviewing this standard to determine the method of adoption and to assess the impact on its future consolidated financial statements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> In March 2016, the FASB issued ASU 2016-01, <i>Financial Instruments &#x2013; Overall (Sub Topic 825-10)</i>, which addresses certain aspects of the recognition, measurement, presentation, and disclosure of financial instruments. The guidance will, among other things, require equity method investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income. The standard will be effective for the first interim period within annual reporting periods beginning after December&#xA0;15, 2017, and early adoption is permitted for only limited aspects of such guidance. The Company is currently reviewing this standard to determine the method of adoption and to assess the impact on its future consolidated financial statements.</p> </div> 36000 336000 6088000 4415000 444000 -1766000 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <b>6. MARKETABLE SECURITIES</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> At September&#xA0;30, 2016 and December&#xA0;31, 2015, the fair value of marketable securities, which were all classified as available for sale, included the following (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>September&#xA0;30, 2016</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Adjusted<br /> Cost</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Unrealized<br /> Gains</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Unrealized<br /> Losses</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Fair<br /> Value</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Level 2:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Corporate debt securities</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">43,720</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(36</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">43,687</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Government-sponsored enterprise debt securities</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">17,054</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">17,060</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">60,774</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">9</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(36</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">60,747</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="64%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>December&#xA0;31, 2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Adjusted<br /> Cost</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Unrealized<br /> Gains</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Unrealized<br /> Losses</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Fair<br /> Value</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Level 2:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Certificates of deposit</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Corporate debt securities</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">66,046</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(70</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">65,976</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">77,046</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(70</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">66,976</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> The carrying amounts reported in the condensed consolidated balance sheet approximate the fair value based on quoted market prices or alternative pricing sources and models utilizing market observable inputs. As of September&#xA0;30, 2016, the Company does not consider any of its marketable securities to be other than temporarily impaired. During the nine months ended September&#xA0;30, 2016 and 2015, the Company did not reclassify any items out of accumulated other comprehensive income to net income. All investments in marketable securities are classified as a current asset on the balance sheet because the underlying securities mature within one year from the balance sheet date.</p> </div> 311000 134000 2487000 14983000 7070000 3870000 846000 <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="65%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Three Months Ended</b><br /> <b>September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Nine Months Ended</b><br /> <b>September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Income from operations:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Workforce</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,386</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">10,386</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">29,034</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">29,789</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Patient Experience</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">471</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">807</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(319</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,737</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Provider</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(959</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(852</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(681</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(1,638</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Unallocated</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(7,612</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(6,016</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(21,946</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(18,209</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total income from operations</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,286</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,325</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,088</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,679</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> -217000 32050000 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> At September&#xA0;30, 2016 and December&#xA0;31, 2015, the fair value of marketable securities, which were all classified as available for sale, included the following (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>September&#xA0;30, 2016</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Adjusted<br /> Cost</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Unrealized<br /> Gains</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Unrealized<br /> Losses</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Fair<br /> Value</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Level 2:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Corporate debt securities</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">43,720</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(36</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">43,687</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Government-sponsored enterprise debt securities</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">17,054</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">17,060</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">60,774</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">9</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(36</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">60,747</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="64%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>December&#xA0;31, 2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Adjusted<br /> Cost</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Unrealized<br /> Gains</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Unrealized<br /> Losses</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Fair<br /> Value</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Level 2:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Certificates of deposit</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Corporate debt securities</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">66,046</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(70</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">65,976</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">77,046</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(70</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">66,976</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> The following table sets forth the computation of basic and diluted earnings per share for the three and nine months ended September&#xA0;30, 2016 and 2015 (in thousands, except per share data):</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="72%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"><b>Three Months Ended</b><br /> <b>September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"><b>Nine Months Ended</b><br /> <b>September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Numerator:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Net income</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,162</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,614</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,066</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,810</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Denominator:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Weighted-average shares outstanding</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">31,739</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">31,643</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">31,714</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">29,527</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Effect of dilutive shares</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">368</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">386</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">336</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">378</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"> &#xA0;</p> </td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"> &#xA0;</p> </td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"> &#xA0;</p> </td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"> &#xA0;</p> </td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Weighted-average diluted shares</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">32,107</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">32,029</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">32,050</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">29,905</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Basic earnings per share</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.04</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.08</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.13</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.23</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Diluted earnings per share</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.04</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.08</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.13</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.23</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> Total stock based compensation expense recorded for the three and nine months ended September&#xA0;30, 2016 and 2015, which is recorded in the condensed consolidated statements of income, is as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> <b>Three&#xA0;Months&#xA0;Ended</b><br /> <b>September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Nine&#xA0;Months&#xA0;Ended</b><br /> <b>September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Cost of revenues (excluding depreciation and amortization)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">35</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">29</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">110</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">790</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Product development</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">73</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">55</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">200</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">514</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Sales and marketing</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">65</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">61</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">193</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">486</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Other general and administrative</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">339</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">295</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,013</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">997</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total stock based compensation expense</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">512</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">440</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,516</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,787</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>September&#xA0;30,<br /> 2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br /> 2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Segment assets *</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Workforce</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">93,350</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">82,375</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Patient Experience</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">35,724</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">34,902</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Provider</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">152,162</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">100,948</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Unallocated</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">112,815</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">161,344</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">394,051</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">379,569</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="2%" align="left">*</td> <td valign="top" align="left">Segment assets include accounts and unbilled receivables, prepaid and other current assets, other assets, capitalized software development, certain property and equipment, and intangible assets. Cash and cash equivalents and marketable securities are not allocated to individual segments, and are included within Unallocated. A significant portion of property and equipment assets are included within Unallocated.</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The changes in the carrying amount of goodwill for the nine months ended September&#xA0;30, 2016 are as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="63%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Workforce</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Patient</b><br /> <b>Experience</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Provider</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Balance at January&#xA0;1, 2016</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">12,336</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">24,154</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">46,583</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">83,073</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Other business combinations</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,041</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,041</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Acquisition of HealthLine Systems, LLC</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,180</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,180</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Acquisition of Morrisey Associates, Inc.</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">20,502</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">20,502</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Balance at September&#xA0;30, 2016</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">16,377</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">24,154</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">69,265</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">109,796</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /> </div> 88197000 -300000 31714000 HSTM 21524000 94000 <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>8. BUSINESS SEGMENTS</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The Company provides services to healthcare organizations and other members within the healthcare industry. The Company&#x2019;s services are focused on the delivery of workforce development products and services (HealthStream Workforce Solutions), survey and research services (HealthStream Patient Experience Solutions), and provider credentialing, privileging, call center and enrollment products and services (HealthStream Provider Solutions).</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The Company measures segment performance based on operating income before income taxes and prior to the allocation of certain corporate overhead expenses, interest income, interest expense, and depreciation. The Unallocated component below includes corporate functions, such as accounting, human resources, legal, investor relations, administrative, and executive personnel, depreciation, a portion of amortization, and certain other expenses, which are not currently allocated in measuring segment performance. The following is the Company&#x2019;s business segment information as of and for the three and nine months ended September&#xA0;30, 2016 and 2015 (in thousands).</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Three Months Ended</b><br /> <b>September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Nine Months Ended</b><br /> <b>September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Revenues, net:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Workforce</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">43,015</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">41,092</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">124,489</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">118,488</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Patient Experience</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">8,931</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">8,792</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">25,862</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">25,545</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Provider</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6,421</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,951</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">16,886</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">9,103</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total revenues, net</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">58,367</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">53,835</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">167,237</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">153,136</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="65%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Three Months Ended</b><br /> <b>September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Nine Months Ended</b><br /> <b>September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Income from operations:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Workforce</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,386</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">10,386</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">29,034</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">29,789</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Patient Experience</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">471</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">807</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(319</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,737</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Provider</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(959</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(852</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(681</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(1,638</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Unallocated</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(7,612</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(6,016</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(21,946</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(18,209</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total income from operations</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,286</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,325</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,088</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,679</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>September&#xA0;30,<br /> 2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br /> 2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Segment assets *</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Workforce</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">93,350</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">82,375</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Patient Experience</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">35,724</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">34,902</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Provider</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">152,162</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">100,948</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Unallocated</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">112,815</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">161,344</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">394,051</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">379,569</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="2%" align="left">*</td> <td valign="top" align="left">Segment assets include accounts and unbilled receivables, prepaid and other current assets, other assets, capitalized software development, certain property and equipment, and intangible assets. Cash and cash equivalents and marketable securities are not allocated to individual segments, and are included within Unallocated. A significant portion of property and equipment assets are included within Unallocated.</td> </tr> </table> </div> 27843000 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>10. RELATED PARTY TRANSACTIONS</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> During the three months ended June&#xA0;30, 2015, the Company&#x2019;s CEO, Robert A. Frist, Jr., entered into an agreement with the Company pursuant to which he contributed 54,241 of his personally owned shares of HealthStream, Inc. common stock to the Company, without any consideration paid to him. In connection with this contribution, the Company approved the grant of 49,310 shares of common stock to over 600 employees, with a fair market value of approximately $1.5&#xA0;million. Mr.&#xA0;Frist contributed 4,931 of the contributed shares noted above to take into account the estimated Company costs, such as administrative expenses and employer payroll taxes associated with the grants. (See Note&#xA0;4 Stock Based Compensation).</p> </div> 3 -21946000 124489000 29034000 25862000 -319000 16886000 -681000 0.0150 0.0050 0.0200 0.0150 0 2017-11-24 The borrowings under the Revolving Credit Facility bear interest at either (1) a rate per annum equal to the highest of SunTrust’s prime rate or 0.5% in excess of the Federal Funds Rate or 1.0% in excess of one-month LIBOR (the “Base Rate”), plus an applicable margin, or (2) the one, two, three, or six-month per annum LIBOR for deposits in the applicable currency (the “Eurocurrency Rate”), as selected by the Company, plus an applicable margin. The applicable margin for Eurocurrency Rate loans depends on the Company’s funded debt leverage ratio and varies from 1.50% to 2.00%. The applicable margin for Base Rate loans depends on the Company’s funded debt leverage ratio and varies from 0.50% to 1.50% 0.005 0.010 20.49 111808 4041000 4041000 0.16 0.16 168908000 2015-03-16 5090000 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> The amounts of revenue and operating income (loss) of HLS included in the Company&#x2019;s condensed consolidated statement of income from the date of acquisition of March&#xA0;16, 2015 to the period ending September&#xA0;30, 2015 are as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="88%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total revenues</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,351</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Operating loss</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1,899</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> The following unaudited pro forma financial information summarizes the combined results of operations of the Company and HLS, which was significant for purposes of the unaudited pro forma financial information disclosure, as though the companies were combined as of January&#xA0;1, 2014 (in thousands, except per share data):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Three Months Ended</b><br /> <b>September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Nine Months Ended</b><br /> <b>September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total revenues</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">58,644</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">55,741</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">168,908</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">161,954</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Net income</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,361</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,760</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,090</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">10,599</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Basic earnings per share</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.04</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.12</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.16</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.36</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Diluted earnings per share</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.04</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.12</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.16</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.35</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> 90309000 2180000 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> A summary of the purchase price is as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="88%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Cash paid at closing</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">87,450</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Consideration due to the seller</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,180</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Cash held in escrow</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">679</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total consideration paid</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">90,309</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> The following table sets forth the components of identifiable intangible assets and their estimated useful lives as of the acquisition date (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="78%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Fair&#xA0;value</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Useful&#xA0;life</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Customer relationships</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">42,600</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">13&#xA0;years</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Developed technology</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,700</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5 years</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Trade names</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">900</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6 years</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total intangible assets subject to amortization</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">47,200</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> The following table summarizes the fair value of the assets acquired and liabilities assumed as of the date of acquisition (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="88%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Cash</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">54</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Accounts receivable, net</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,052</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Prepaid assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">546</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Property and equipment</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">200</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Deferred tax assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,523</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Goodwill</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">43,798</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Intangible assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">47,200</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Accounts payable and accrued liabilities</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(1,085</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Deferred revenue</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(5,979</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Net assets acquired</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">90,309</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> P1Y 9000000 200000 2180000 679000 87450000 P5Y P13Y P6Y 2180000 0.18 0.18 176401000 2016-08-08 953000 5764000 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> The amounts of revenue and operating income (loss) of MAI included in the Company&#x2019;s condensed consolidated statement of income from the date of acquisition of August&#xA0;8, 2016 to the period ending September&#xA0;30, 2016 are as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="88%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total revenues</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">841</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Operating loss</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1,023</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> The following unaudited pro forma financial information summarizes the combined results of operations of the Company and MAI, which was significant for purposes of the unaudited pro forma financial information disclosure, as though the companies were combined as of January&#xA0;1, 2015 (in thousands, except per share data):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Three Months Ended</b><br /> <b>September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Nine Months Ended</b><br /> <b>September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total revenues</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">60,711</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">56,622</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">176,401</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">159,009</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Net income</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,275</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,573</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,764</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,445</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Basic earnings per share</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.07</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.08</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.18</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.18</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Diluted earnings per share</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.07</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.08</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.18</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.18</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> 20502000 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> A summary of the purchase price is as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="88%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Cash paid at closing</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">44,120</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Cash held in escrow</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,880</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total consideration paid</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">48,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> The following table sets forth the preliminary components of identifiable intangible assets and their estimated useful lives as of the acquisition date (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="78%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Preliminary<br /> fair value</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Useful<br /> life</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Customer relationships</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">21,400</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">13&#xA0;years</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Developed technology</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,400</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5&#xA0;years</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Trade names</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">600</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6&#xA0;years</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total preliminary intangible assets subject to amortization</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">27,400</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> The following table summarizes the fair value of the assets acquired and liabilities assumed as of the date of acquisition (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="88%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Accounts receivable, net</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,402</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Prepaid royalties and other prepaid assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">187</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Property and equipment</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">75</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Deferred tax assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,548</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Goodwill</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">20,502</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Intangible assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">27,400</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Accounts payable and accrued liabilities</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(913</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Deferred revenue</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(4,201</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Net assets acquired</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">48,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> 20502000 0.002 0.003 110000 1013000 193000 200000 A funded debt leverage ratio (consolidated debt/consolidated EBITDA) of not greater than 3.0 to 1.0 and an interest coverage ratio (consolidated EBITDA/consolidated interest expense) of not less than 3.0 to 1.0. 1516000 661000 -217000 92000 43000 4066000 4000000 600 P1Y 54241 49310 329000 1300000 841000 -1023000 965000 3869750 28000000 1500000 17279 1500000 54241 49310 600 20.20 16250 5000 2200000 26000 440000 23126000 0.08 4639000 0.08 2645000 49510000 53835000 7173000 28000 31000 2614000 4353000 31000 386000 4325000 1739000 32029000 31643000 6195000 8377000 -6016000 41092000 10386000 8792000 807000 3951000 -852000 23.40 P5Y 30000 16250 8750 0.12 0.12 55741000 3760000 0.08 0.08 56622000 2573000 29000 295000 61000 55000 21000 512000 24889000 0.04 5755000 0.04 1149000 57081000 58367000 8891000 337000 -13000 1162000 1623000 -13000 368000 1286000 461000 32107000 31739000 7261000 10285000 -7612000 43015000 9386000 8931000 471000 6421000 -959000 0.04 0.04 58644000 1361000 2200000 2400000 200000 0.07 0.07 60711000 805000 2275000 35000 339000 65000 73000 0001095565 hstm:ProductDevelopmentMember 2016-07-01 2016-09-30 0001095565 us-gaap:SellingAndMarketingExpenseMember 2016-07-01 2016-09-30 0001095565 us-gaap:GeneralAndAdministrativeExpenseMember 2016-07-01 2016-09-30 0001095565 us-gaap:CostOfSalesMember 2016-07-01 2016-09-30 0001095565 hstm:MorriseyAssociatesIncMember 2016-07-01 2016-09-30 0001095565 hstm:HealthlineSystemsMember 2016-07-01 2016-09-30 0001095565 us-gaap:OperatingSegmentsMember hstm:HealthstreamProviderSolutionsMember 2016-07-01 2016-09-30 0001095565 us-gaap:OperatingSegmentsMember hstm:PatientExperienceSolutionsMember 2016-07-01 2016-09-30 0001095565 us-gaap:OperatingSegmentsMember hstm:HealthstreamWorkforceSolutionsMember 2016-07-01 2016-09-30 0001095565 us-gaap:MaterialReconcilingItemsMember 2016-07-01 2016-09-30 0001095565 2016-07-01 2016-09-30 0001095565 hstm:ProductDevelopmentMember 2015-07-01 2015-09-30 0001095565 us-gaap:SellingAndMarketingExpenseMember 2015-07-01 2015-09-30 0001095565 us-gaap:GeneralAndAdministrativeExpenseMember 2015-07-01 2015-09-30 0001095565 us-gaap:CostOfSalesMember 2015-07-01 2015-09-30 0001095565 hstm:MorriseyAssociatesIncMember 2015-07-01 2015-09-30 0001095565 hstm:HealthlineSystemsMember 2015-07-01 2015-09-30 0001095565 hstm:PerformanceBasedRestrictedShareUnitsMember 2015-07-01 2015-09-30 0001095565 us-gaap:OperatingSegmentsMember hstm:HealthstreamProviderSolutionsMember 2015-07-01 2015-09-30 0001095565 us-gaap:OperatingSegmentsMember hstm:PatientExperienceSolutionsMember 2015-07-01 2015-09-30 0001095565 us-gaap:OperatingSegmentsMember hstm:HealthstreamWorkforceSolutionsMember 2015-07-01 2015-09-30 0001095565 us-gaap:MaterialReconcilingItemsMember 2015-07-01 2015-09-30 0001095565 2015-07-01 2015-09-30 0001095565 hstm:HealthlineSystemsMember 2016-01-01 2016-03-31 0001095565 hstm:PerformanceBasedRestrictedShareUnitsMember 2016-01-01 2016-03-31 0001095565 us-gaap:ChiefExecutiveOfficerMember 2015-04-01 2015-06-30 0001095565 hstm:StockAwardsMember 2015-04-01 2015-06-30 0001095565 us-gaap:RevolvingCreditFacilityMember hstm:SunTrustBankMember 2015-04-01 2015-06-30 0001095565 hstm:HealthlineSystemsMember 2015-01-01 2015-03-31 0001095565 hstm:MorriseyAssociatesIncMember 2016-08-09 2016-09-30 0001095565 hstm:HealthlineSystemsMember 2014-01-01 2015-03-31 0001095565 hstm:HealthlineSystemsMember 2014-01-01 2014-12-31 0001095565 hstm:StockAwardsMember us-gaap:ChiefExecutiveOfficerMember 2015-06-01 2015-06-30 0001095565 hstm:StockAwardsMember 2015-06-01 2015-06-30 0001095565 hstm:OtherBusinessCombinationMember 2016-06-01 2016-06-30 0001095565 us-gaap:RetainedEarningsMember 2016-01-01 2016-09-30 0001095565 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-01-01 2016-09-30 0001095565 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2016-01-01 2016-09-30 0001095565 hstm:SunTrustBankMember 2016-01-01 2016-09-30 0001095565 hstm:ProductDevelopmentMember 2016-01-01 2016-09-30 0001095565 us-gaap:SellingAndMarketingExpenseMember 2016-01-01 2016-09-30 0001095565 us-gaap:GeneralAndAdministrativeExpenseMember 2016-01-01 2016-09-30 0001095565 us-gaap:CostOfSalesMember 2016-01-01 2016-09-30 0001095565 hstm:SunTrustBankMember us-gaap:MaximumMember 2016-01-01 2016-09-30 0001095565 hstm:SunTrustBankMember us-gaap:MinimumMember 2016-01-01 2016-09-30 0001095565 hstm:MorriseyAssociatesIncMember hstm:HealthstreamProviderSolutionsMember 2016-01-01 2016-09-30 0001095565 hstm:MorriseyAssociatesIncMember 2016-01-01 2016-09-30 0001095565 hstm:HealthlineSystemsMember hstm:HealthstreamProviderSolutionsMember 2016-01-01 2016-09-30 0001095565 hstm:HealthlineSystemsMember us-gaap:TradeNamesMember 2016-01-01 2016-09-30 0001095565 hstm:HealthlineSystemsMember us-gaap:CustomerRelationshipsMember 2016-01-01 2016-09-30 0001095565 hstm:HealthlineSystemsMember us-gaap:DevelopedTechnologyRightsMember 2016-01-01 2016-09-30 0001095565 hstm:HealthlineSystemsMember hstm:NonEscrowMember 2016-01-01 2016-09-30 0001095565 hstm:HealthlineSystemsMember hstm:EscrowMember 2016-01-01 2016-09-30 0001095565 hstm:HealthlineSystemsMember hstm:ConsiderationDueSellerMember 2016-01-01 2016-09-30 0001095565 hstm:HealthlineSystemsMember 2016-01-01 2016-09-30 0001095565 hstm:OtherBusinessCombinationMember hstm:HealthstreamWorkforceSolutionsMember 2016-01-01 2016-09-30 0001095565 hstm:OtherBusinessCombinationMember 2016-01-01 2016-09-30 0001095565 us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-09-30 0001095565 us-gaap:RevolvingCreditFacilityMember hstm:SunTrustBankMember us-gaap:BaseRateMember 2016-01-01 2016-09-30 0001095565 us-gaap:RevolvingCreditFacilityMember hstm:SunTrustBankMember us-gaap:FederalFundsEffectiveSwapRateMember 2016-01-01 2016-09-30 0001095565 us-gaap:RevolvingCreditFacilityMember hstm:SunTrustBankMember 2016-01-01 2016-09-30 0001095565 us-gaap:RevolvingCreditFacilityMember hstm:SunTrustBankMember us-gaap:MaximumMember us-gaap:BaseRateMember 2016-01-01 2016-09-30 0001095565 us-gaap:RevolvingCreditFacilityMember hstm:SunTrustBankMember us-gaap:MaximumMember us-gaap:EurodollarMember 2016-01-01 2016-09-30 0001095565 us-gaap:RevolvingCreditFacilityMember hstm:SunTrustBankMember us-gaap:MinimumMember us-gaap:BaseRateMember 2016-01-01 2016-09-30 0001095565 us-gaap:RevolvingCreditFacilityMember hstm:SunTrustBankMember us-gaap:MinimumMember us-gaap:EurodollarMember 2016-01-01 2016-09-30 0001095565 us-gaap:OperatingSegmentsMember hstm:HealthstreamProviderSolutionsMember 2016-01-01 2016-09-30 0001095565 us-gaap:OperatingSegmentsMember hstm:PatientExperienceSolutionsMember 2016-01-01 2016-09-30 0001095565 us-gaap:OperatingSegmentsMember hstm:HealthstreamWorkforceSolutionsMember 2016-01-01 2016-09-30 0001095565 us-gaap:MaterialReconcilingItemsMember 2016-01-01 2016-09-30 0001095565 2016-01-01 2016-09-30 0001095565 hstm:ProductDevelopmentMember 2015-01-01 2015-09-30 0001095565 us-gaap:SellingAndMarketingExpenseMember 2015-01-01 2015-09-30 0001095565 us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-09-30 0001095565 us-gaap:CostOfSalesMember 2015-01-01 2015-09-30 0001095565 hstm:MorriseyAssociatesIncMember 2015-01-01 2015-09-30 0001095565 hstm:HealthlineSystemsMember 2015-01-01 2015-09-30 0001095565 hstm:StockAwardsMember 2015-01-01 2015-09-30 0001095565 us-gaap:RestrictedStockUnitsRSUMember 2015-01-01 2015-09-30 0001095565 us-gaap:OperatingSegmentsMember hstm:HealthstreamProviderSolutionsMember 2015-01-01 2015-09-30 0001095565 us-gaap:OperatingSegmentsMember hstm:PatientExperienceSolutionsMember 2015-01-01 2015-09-30 0001095565 us-gaap:OperatingSegmentsMember hstm:HealthstreamWorkforceSolutionsMember 2015-01-01 2015-09-30 0001095565 us-gaap:MaterialReconcilingItemsMember 2015-01-01 2015-09-30 0001095565 2015-01-01 2015-09-30 0001095565 hstm:HealthlineSystemsMember 2015-03-17 2015-09-30 0001095565 hstm:MorriseyAssociatesIncMember 2016-01-01 2016-06-30 0001095565 hstm:NursingRegistryConsultantsCorporationMember 2016-07-25 2016-07-25 0001095565 hstm:MorriseyAssociatesIncMember us-gaap:TradeNamesMember 2016-08-08 2016-08-08 0001095565 hstm:MorriseyAssociatesIncMember us-gaap:CustomerRelationshipsMember 2016-08-08 2016-08-08 0001095565 hstm:MorriseyAssociatesIncMember us-gaap:DevelopedTechnologyRightsMember 2016-08-08 2016-08-08 0001095565 hstm:MorriseyAssociatesIncMember hstm:NonEscrowMember 2016-08-08 2016-08-08 0001095565 hstm:MorriseyAssociatesIncMember hstm:EscrowMember 2016-08-08 2016-08-08 0001095565 hstm:MorriseyAssociatesIncMember 2016-08-08 2016-08-08 0001095565 us-gaap:RetainedEarningsMember 2015-12-31 0001095565 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-12-31 0001095565 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2015-12-31 0001095565 hstm:HealthstreamProviderSolutionsMember 2015-12-31 0001095565 hstm:PatientExperienceSolutionsMember 2015-12-31 0001095565 hstm:HealthstreamWorkforceSolutionsMember 2015-12-31 0001095565 us-gaap:FairValueInputsLevel2Member us-gaap:CertificatesOfDepositMember 2015-12-31 0001095565 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2015-12-31 0001095565 us-gaap:FairValueInputsLevel2Member 2015-12-31 0001095565 us-gaap:OperatingSegmentsMember hstm:HealthstreamProviderSolutionsMember 2015-12-31 0001095565 us-gaap:OperatingSegmentsMember hstm:PatientExperienceSolutionsMember 2015-12-31 0001095565 us-gaap:OperatingSegmentsMember hstm:HealthstreamWorkforceSolutionsMember 2015-12-31 0001095565 us-gaap:MaterialReconcilingItemsMember 2015-12-31 0001095565 2015-12-31 0001095565 2014-12-31 0001095565 us-gaap:RetainedEarningsMember 2016-09-30 0001095565 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-09-30 0001095565 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2016-09-30 0001095565 hstm:NursingRegistryConsultantsCorporationMember 2016-09-30 0001095565 hstm:HealthstreamProviderSolutionsMember 2016-09-30 0001095565 hstm:PatientExperienceSolutionsMember 2016-09-30 0001095565 hstm:HealthstreamWorkforceSolutionsMember 2016-09-30 0001095565 hstm:HealthlineSystemsMember 2016-09-30 0001095565 us-gaap:RevolvingCreditFacilityMember hstm:SunTrustBankMember hstm:LetterOfCreditSubfacilityMember 2016-09-30 0001095565 us-gaap:RevolvingCreditFacilityMember hstm:SunTrustBankMember hstm:SwinglineSubFacilityMember 2016-09-30 0001095565 us-gaap:RevolvingCreditFacilityMember hstm:SunTrustBankMember 2016-09-30 0001095565 us-gaap:RevolvingCreditFacilityMember hstm:SunTrustBankMember us-gaap:MaximumMember 2016-09-30 0001095565 us-gaap:RevolvingCreditFacilityMember hstm:SunTrustBankMember us-gaap:MinimumMember 2016-09-30 0001095565 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2016-09-30 0001095565 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2016-09-30 0001095565 us-gaap:FairValueInputsLevel2Member 2016-09-30 0001095565 us-gaap:OperatingSegmentsMember hstm:HealthstreamProviderSolutionsMember 2016-09-30 0001095565 us-gaap:OperatingSegmentsMember hstm:PatientExperienceSolutionsMember 2016-09-30 0001095565 us-gaap:OperatingSegmentsMember hstm:HealthstreamWorkforceSolutionsMember 2016-09-30 0001095565 us-gaap:MaterialReconcilingItemsMember 2016-09-30 0001095565 2016-09-30 0001095565 2015-09-30 0001095565 us-gaap:ChiefExecutiveOfficerMember 2015-06-30 0001095565 hstm:NursingRegistryConsultantsCorporationMember 2016-07-25 0001095565 hstm:NursingRegistryConsultantsCorporationMember 2016-07-25 0001095565 hstm:OtherBusinessCombinationMember 2016-06-30 0001095565 hstm:HealthlineSystemsMember us-gaap:TradeNamesMember 2015-03-16 0001095565 hstm:HealthlineSystemsMember us-gaap:CustomerRelationshipsMember 2015-03-16 0001095565 hstm:HealthlineSystemsMember us-gaap:DevelopedTechnologyRightsMember 2015-03-16 0001095565 hstm:HealthlineSystemsMember 2015-03-16 0001095565 2016-11-02 0001095565 hstm:MorriseyAssociatesIncMember us-gaap:TradeNamesMember 2016-08-08 0001095565 hstm:MorriseyAssociatesIncMember us-gaap:CustomerRelationshipsMember 2016-08-08 0001095565 hstm:MorriseyAssociatesIncMember us-gaap:DevelopedTechnologyRightsMember 2016-08-08 0001095565 hstm:MorriseyAssociatesIncMember 2016-08-08 iso4217:USD shares iso4217:USD shares pure hstm:Incentive_Plan hstm:Employees EX-101.SCH 7 hstm-20160930.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Condensed Consolidated Statements of Income (Unaudited) link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited) link:calculationLink link:presentationLink link:definitionLink 107 - Statement - Condensed Consolidated Statement of Shareholders' Equity (Unaudited) link:calculationLink link:presentationLink link:definitionLink 108 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Recent Accounting Pronouncements link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Stock Based Compensation link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Earnings Per Share link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Marketable Securities link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Business Combinations link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Business Segments link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Debt link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Related Party Transactions link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Recent Accounting Pronouncements (Policies) link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Stock Based Compensation (Tables) link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Earnings Per Share (Tables) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Marketable Securities (Tables) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Business Combinations (Tables) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Business Segments (Tables) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Income Taxes - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Stock Based Compensation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Stock Based Compensation - Stock Based Compensation Expense Recorded in Condensed Consolidated Statements of Income (Detail) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Earnings Per Share - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Earnings Per Share - Computation of Basic and Diluted Earnings Per Share (Detail) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Marketable Securities - Fair Value of Available for Sale Marketable Securities (Detail) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - Business Combinations - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - Business Combinations - Summary of Purchase Price (Detail) link:calculationLink link:presentationLink link:definitionLink 133 - Disclosure - Business Combinations - Summary of Fair Value of Assets Acquired and Liabilities Assumed (Detail) link:calculationLink link:presentationLink link:definitionLink 134 - Disclosure - Business Combinations - Components of Identifiable Intangible Assets and Estimated Useful Lives (Detail) link:calculationLink link:presentationLink link:definitionLink 135 - Disclosure - Business Combinations - Summary of Unaudited ProForma Financial Information (Detail) link:calculationLink link:presentationLink link:definitionLink 136 - Disclosure - Business Combinations - Changes In Carrying Amount of Goodwill (Detail) link:calculationLink link:presentationLink link:definitionLink 137 - Disclosure - Business Segments - Business Segment Information Based on Net Revenues and Operating Income (Detail) link:calculationLink link:presentationLink link:definitionLink 138 - Disclosure - Business Segments - Business Segment Information Based on Assets (Detail) link:calculationLink link:presentationLink link:definitionLink 139 - Disclosure - Debt - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 140 - Disclosure - Related Party Transactions - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 8 hstm-20160930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 hstm-20160930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 hstm-20160930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 11 hstm-20160930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.5.0.2
Document and Entity Information - shares
9 Months Ended
Sep. 30, 2016
Nov. 02, 2016
Document And Entity Information [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Sep. 30, 2016  
Document Fiscal Year Focus 2016  
Document Fiscal Period Focus Q3  
Trading Symbol HSTM  
Entity Registrant Name HEALTHSTREAM INC  
Entity Central Index Key 0001095565  
Current Fiscal Year End Date --12-31  
Entity Filer Category Large Accelerated Filer  
Entity Common Stock, Shares Outstanding   31,739,741
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2016
Dec. 31, 2015
Current assets:    
Cash and cash equivalents $ 39,820 $ 82,010
Marketable securities 60,747 66,976
Accounts receivable, net of allowance for doubtful accounts of $603 and $303 at September 30, 2016 and December 31, 2015, respectively 46,166 36,348
Accounts receivable - unbilled 2,296 1,998
Prepaid royalties, net of amortization 16,466 14,036
Other prepaid expenses and other current assets 7,584 8,169
Total current assets 173,079 209,537
Property and equipment, net 10,403 12,471
Capitalized software development, net of accumulated amortization of $29,717 and $24,130 at September 30, 2016 and December 31, 2015, respectively 15,749 13,955
Goodwill 109,796 83,073
Intangible assets, net of accumulated amortization of $14,038 and $8,685 at September 30, 2016 and December 31, 2015, respectively 80,771 55,966
Non-marketable equity investments 3,289 3,640
Other assets 964 927
Total assets 394,051 379,569
Current liabilities:    
Accounts payable 3,675 4,616
Accrued royalties 13,885 9,053
Accrued liabilities 10,623 7,003
Accrued compensation and related expenses 2,028 3,308
Deferred revenue 65,029 65,098
Total current liabilities 95,240 89,078
Deferred tax liabilities 4,909 4,763
Deferred revenue, noncurrent 6,735 4,350
Other long term liabilities 778 1,058
Commitments and contingencies
Shareholders' equity:    
Common stock, no par value, 75,000 shares authorized; 31,739 and 31,647 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively 280,759 278,799
Retained earnings 5,657 1,591
Accumulated other comprehensive loss (27) (70)
Total shareholders' equity 286,389 280,320
Total liabilities and shareholders' equity $ 394,051 $ 379,569
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Sep. 30, 2016
Dec. 31, 2015
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts, net $ 603 $ 303
Accumulated amortization on capitalized software development 29,717 24,130
Accumulated amortization on intangible assets $ 14,038 $ 8,685
Common stock, no par value
Common stock, shares authorized 75,000,000 75,000,000
Common stock, shares issued 31,739,000 31,647,000
Common stock, shares outstanding 31,739,000 31,647,000
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Income Statement [Abstract]        
Revenues, net $ 58,367 $ 53,835 $ 167,237 $ 153,136
Operating costs and expenses:        
Cost of revenues (excluding depreciation and amortization) 24,889 23,126 70,410 65,752
Product development 7,261 6,195 21,524 16,654
Sales and marketing 10,285 8,377 27,843 26,052
Other general and administrative expenses 8,891 7,173 25,396 20,851
Depreciation and amortization 5,755 4,639 15,976 12,148
Total operating costs and expenses 57,081 49,510 161,149 141,457
Operating income 1,286 4,325 6,088 11,679
Other income (expense), net 337 28 465 (7)
Income before income tax provision 1,623 4,353 6,553 11,672
Income tax provision 461 1,739 2,487 4,862
Net income $ 1,162 $ 2,614 $ 4,066 $ 6,810
Earnings per share:        
Basic $ 0.04 $ 0.08 $ 0.13 $ 0.23
Diluted $ 0.04 $ 0.08 $ 0.13 $ 0.23
Weighted average shares of common stock outstanding:        
Basic 31,739 31,643 31,714 29,527
Diluted 32,107 32,029 32,050 29,905
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Statement of Comprehensive Income [Abstract]        
Net income $ 1,162 $ 2,614 $ 4,066 $ 6,810
Other comprehensive income, net of taxes:        
Unrealized gain (loss) on marketable securities (13) 31 43 (10)
Total other comprehensive income (loss) (13) 31 43 (10)
Comprehensive income $ 1,149 $ 2,645 $ 4,109 $ 6,800
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Statement of Shareholders' Equity (Unaudited) - 9 months ended Sep. 30, 2016 - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock [Member]
Retained Earnings [Member]
Accumulated Other Comprehensive Loss [Member]
Beginning balance at Dec. 31, 2015 $ 280,320 $ 278,799 $ 1,591 $ (70)
Beginning balance, shares at Dec. 31, 2015 31,647 31,647    
Net income $ 4,066   4,066  
Comprehensive income (loss) 43     43
Stock based compensation 1,516 $ 1,516    
Tax benefits from equity awards 661 661    
Common stock issued under stock plans, net of shares withheld for employee taxes (217) $ (217)    
Common stock issued under stock plans, net of shares withheld for employee taxes, shares   92    
Ending balance at Sep. 30, 2016 $ 286,389 $ 280,759 $ 5,657 $ (27)
Ending balance, shares at Sep. 30, 2016 31,739 31,739    
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
OPERATING ACTIVITIES:    
Net income $ 4,066 $ 6,810
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 15,976 12,148
Deferred income taxes 791 123
Stock based compensation expense 1,516 2,787
Excess tax benefits from equity awards (661) (3,721)
Provision for doubtful accounts 340 184
(Gain) loss on non-marketable equity investments (134) 98
Other 846 938
Changes in operating assets and liabilities:    
Accounts and unbilled receivables (6,855) 2,649
Prepaid royalties (2,291) (946)
Other prepaid expenses and other current assets (326) (595)
Other assets (36) 288
Accounts payable (454) (2,501)
Accrued royalties 4,415 (1,251)
Accrued liabilities and accrued compensation and related expenses and other long-term liabilities (444) 3,082
Deferred revenue (1,766) 5,426
Net cash provided by operating activities 14,983 25,519
INVESTING ACTIVITIES:    
Business combinations, net of cash acquired (53,078) (88,075)
Proceeds from maturities of marketable securities 88,197 38,440
Purchases of marketable securities (82,771) (77,774)
Payments to acquire equity method investments   (1,000)
Payments to acquire cost method investments   (1,000)
Proceeds from sale of long lived assets 975  
Payments associated with capitalized software development (7,070) (5,329)
Purchases of property and equipment (3,870) (6,012)
Net cash used in investing activities (57,617) (140,750)
FINANCING ACTIVITIES:    
Proceeds from issuance of common stock   98,014
Proceeds from exercise of stock options 94 328
Proceeds from borrowings under revolving line of credit facility   28,000
Repayments under revolving line of credit facility   (28,000)
Payment of earn-outs related to business combinations   (633)
Excess tax benefits from equity awards 661 3,721
Taxes paid related to net settlement of equity awards (311) (753)
Net cash provided by financing activities 444 100,677
Net decrease in cash and cash equivalents (42,190) (14,554)
Cash and cash equivalents at beginning of period 82,010 81,995
Cash and cash equivalents at end of period $ 39,820 $ 67,441
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.5.0.2
Basis of Presentation
9 Months Ended
Sep. 30, 2016
Accounting Policies [Abstract]  
Basis of Presentation

1. BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) for interim financial information and with the instructions toForm 10-Q and Article 10 of Regulation S-X. Accordingly, condensed consolidated financial statements do not include all of the information and footnotes required by US GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. All significant intercompany transactions have been eliminated in consolidation. Operating results for the three and nine months ended September 30, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016.

The balance sheet at December 31, 2015 is consistent with the audited financial statements at that date but does not include all of the information and footnotes required by US GAAP for a complete set of financial statements. For further information, refer to the consolidated financial statements and footnotes thereto for the year ended December 31, 2015 included in the Company’s Annual Report on Form 10-K (the “Form 10-K”), filed with the Securities and Exchange Commission on February 26, 2016.

Recently Adopted Accounting Standards

The Company has adopted Accounting Standards Update (“ASU”) 2015-16, Business Combinations (Topic 805). Under the provisions of the revised guidance, acquirers in a business combination must recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. The acquirer must record, in the same period’s financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the provisional amounts, calculated as if the accounting had been completed at the acquisition date. The Company recorded a measurement period adjustment during the period ended March 31, 2016. See Note 7 Business Combinations for further discussion.

XML 20 R9.htm IDEA: XBRL DOCUMENT v3.5.0.2
Recent Accounting Pronouncements
9 Months Ended
Sep. 30, 2016
Accounting Changes and Error Corrections [Abstract]  
Recent Accounting Pronouncements

2. RECENT ACCOUNTING PRONOUNCEMENTS

In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific revenue recognition guidance throughout the Industry Topics of the Accounting Standards Codification. The updated guidance states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also provides for additional disclosures with respect to revenues and cash flows arising from contracts with customers. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2017, and early adoption is permitted for the first interim period within annual reporting periods beginning after December 15, 2016. The Company is currently reviewing this standard to determine the method of adoption and to assess the impact on its future consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which requires lessees to recognize assets and liabilities for most leases. The recognition, measurement and presentation of expenses and cash flows arising from a lease by a lessee is not expected to significantly change under such guidance; however, the Company is currently reviewing this standard to determine the method of adoption and to assess the impact on its future consolidated financial statements. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2018, and early adoption is permitted.

In March 2016, the FASB issued ASU 2016-09, Compensation – Stock Compensation (Topic 718), which serves to simplify several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2016, and early adoption is permitted in any interim or annual period. The Company is currently reviewing this standard to determine the method of adoption and to assess the impact on its future consolidated financial statements.

In March 2016, the FASB issued ASU 2016-01, Financial Instruments – Overall (Sub Topic 825-10), which addresses certain aspects of the recognition, measurement, presentation, and disclosure of financial instruments. The guidance will, among other things, require equity method investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2017, and early adoption is permitted for only limited aspects of such guidance. The Company is currently reviewing this standard to determine the method of adoption and to assess the impact on its future consolidated financial statements.

XML 21 R10.htm IDEA: XBRL DOCUMENT v3.5.0.2
Income Taxes
9 Months Ended
Sep. 30, 2016
Income Tax Disclosure [Abstract]  
Income Taxes

3. INCOME TAXES

Income taxes are accounted for using the asset and liability method, whereby deferred tax assets and liabilities are determined based on the temporary differences between the financial statement and tax bases of assets and liabilities measured at tax rates that will be in effect for the year in which the differences are expected to affect taxable income.

During the nine months ended September 30, 2016 and 2015, the Company recorded a provision for income taxes of approximately $2.5 million and $4.9 million, respectively. The Company’s effective tax rate for the nine months ended September 30, 2016 and 2015 was 38.0% and 41.7%, respectively. The Company’s effective tax rate primarily reflects the statutory corporate income tax rate, the net effect of state taxes, and the effect of various permanent tax differences. During the nine months ended September 30, 2016, the Company recorded a reduction of approximately $300,000 to the liability for gross unrecognized tax benefits. During the nine months ended September 30, 2015, the Company recorded a reduction of approximately $1.8 million to the liability for gross unrecognized tax benefits, resulting from the filing of a change in tax accounting method with the IRS for tangible property and deferred revenue. Of this total reduction, approximately $115,000 had an impact on the effective tax rate for the third quarter of 2015.

XML 22 R11.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stock Based Compensation
9 Months Ended
Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock Based Compensation

4. STOCK BASED COMPENSATION

The Company has stock awards outstanding under three stock incentive plans, the Company’s 2010 Stock Incentive Plan, the Company’s 2000 Stock Incentive Plan, as amended, and the Company’s 2016 Omnibus Incentive Plan, which shareholders approved at the annual meeting of shareholders held on May 26, 2016. The Company accounts for its stock based compensation plans using the fair-value based method for costs related to share-based payments, including stock options and restricted share units (“RSUs”). During the nine months ended September 30, 2016, the Company issued 111,808 RSUs, subject to time-based vesting, with a weighted average grant date fair value of $20.49 per share, measured based on the closing fair market value of the Company’s stock on the date of grant. During the nine months ended September 30, 2015, the Company issued 80,355 RSUs with a weighted average grant date fair value of $25.56 per share, and the Company issued 49,310 stock awards with a weighted average grant date fair value of $30.42 per share. Both measurements were based on the closing fair market value of the Company’s stock on the date of grant.

During the three months ended September 30, 2015, the Company issued 30,000 performance-based RSUs, the vesting of which is contingent upon meeting certain performance criteria over a five year period. The measurement date for 8,750 of these performance-based RSUs was established during the three months ended September 30, 2015 with a grant-date fair value of $23.40 per share, and the measurement date for 5,000 of these awards was established during the three months ended March 31, 2016 with a grant-date fair value of $20.20 per share. Both measurements were based on the closing fair market value of the Company’s stock on the date of grant. The performance criteria for the remaining 16,250 performance-based RSUs will be established on an annual basis by the Company’s Compensation Committee; therefore, the measurement date and fair value of the awards cannot be determined until the performance criteria is established.

Total stock based compensation expense recorded for the three and nine months ended September 30, 2016 and 2015, which is recorded in the condensed consolidated statements of income, is as follows (in thousands):

 

     Three Months Ended
September 30,
     Nine Months Ended
September 30,
 
     2016      2015      2016      2015  

Cost of revenues (excluding depreciation and amortization)

   $ 35       $ 29       $ 110       $ 790   

Product development

     73         55         200         514   

Sales and marketing

     65         61         193         486   

Other general and administrative

     339         295         1,013         997   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total stock based compensation expense

   $ 512       $ 440       $ 1,516       $ 2,787   
  

 

 

    

 

 

    

 

 

    

 

 

 

7

 

Stock Awards

During June 2015, the Company’s Chief Executive Officer (“CEO”), Robert A. Frist, Jr., entered into an agreement with the Company pursuant to which he contributed 54,241 of his personally owned shares of HealthStream, Inc. common stock to the Company, without any consideration paid to him. In connection with this contribution, the Company approved the grant of 49,310 shares of HealthStream, Inc. common stock to over 600 employees who were not otherwise eligible to receive equity awards and had at least one year of service with the Company. The Company recognized approximately $1.5 million of stock based compensation expense for these stock awards during the three months ended June 30, 2015 based on the closing fair market value of the Company’s stock on the date of the Company’s approval of these grants. In connection with these equity awards, effective in the second quarter of 2015, the Company withheld shares with value equivalent to the employees’ minimum statutory obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. The total shares withheld were 17,279, and were based on the value of the stock awards on the date of the Company’s approval of these grants, as determined by the Company’s closing stock price on that date. Total payments related to the employees’ tax obligations to taxing authorities for these stock awards were approximately $526,000, and are reflected as a financing activity within the condensed consolidated statements of cash flows for the nine months ended September 30, 2015. These share withholdings had the effect of share repurchases by the Company as they reduced and retired the number of shares otherwise issuable as a result of the stock awards and did not represent an expense to the Company.

XML 23 R12.htm IDEA: XBRL DOCUMENT v3.5.0.2
Earnings Per Share
9 Months Ended
Sep. 30, 2016
Earnings Per Share [Abstract]  
Earnings Per Share

5. EARNINGS PER SHARE

Basic earnings per share is computed by dividing the net income available to common shareholders for the period by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing the net income for the period by the weighted average number of potentially dilutive common and common equivalent shares outstanding during the period. Common equivalent shares are composed of incremental common shares issuable upon the exercise of stock options and RSUs subject to vesting. The dilutive effect of common equivalent shares is included in diluted earnings per share by application of the treasury stock method. The total number of common equivalent shares excluded from the calculations of diluted earnings per share, due to their anti-dilutive effect, was approximately 21,000 and 26,000 for the three months ended September 30, 2016 and 2015, respectively, and approximately 42,000 and 13,000 for the nine months ended September 30, 2016 and 2015, respectively.

The following table sets forth the computation of basic and diluted earnings per share for the three and nine months ended September 30, 2016 and 2015 (in thousands, except per share data):

 

     Three Months Ended
September 30,
     Nine Months Ended
September 30,
 
     2016      2015      2016      2015  

Numerator:

           

Net income

   $ 1,162       $ 2,614       $ 4,066       $ 6,810   
  

 

 

    

 

 

    

 

 

    

 

 

 

Denominator:

           

Weighted-average shares outstanding

     31,739         31,643         31,714         29,527   

Effect of dilutive shares

     368         386         336         378   
  

 

 

    

 

 

    

 

 

    

 

 

 

Weighted-average diluted shares

     32,107         32,029         32,050         29,905   
  

 

 

    

 

 

    

 

 

    

 

 

 

Basic earnings per share

   $ 0.04       $ 0.08       $ 0.13       $ 0.23   
  

 

 

    

 

 

    

 

 

    

 

 

 

Diluted earnings per share

   $ 0.04       $ 0.08       $ 0.13       $ 0.23   
  

 

 

    

 

 

    

 

 

    

 

 

 
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.5.0.2
Marketable Securities
9 Months Ended
Sep. 30, 2016
Investments, Debt and Equity Securities [Abstract]  
Marketable Securities

6. MARKETABLE SECURITIES

At September 30, 2016 and December 31, 2015, the fair value of marketable securities, which were all classified as available for sale, included the following (in thousands):

 

     September 30, 2016  
     Adjusted
Cost
     Unrealized
Gains
     Unrealized
Losses
     Fair
Value
 

Level 2:

           

Corporate debt securities

   $ 43,720         3         (36    $ 43,687   

Government-sponsored enterprise debt securities

     17,054         6         —           17,060   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

   $ 60,774       $ 9       $ (36    $ 60,747   
  

 

 

    

 

 

    

 

 

    

 

 

 

 

     December 31, 2015  
     Adjusted
Cost
     Unrealized
Gains
     Unrealized
Losses
     Fair
Value
 

Level 2:

           

Certificates of deposit

   $ 1,000       $ —         $ —         $ 1,000   

Corporate debt securities

     66,046         —           (70      65,976   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

   $ 77,046       $ —         $ (70    $ 66,976   
  

 

 

    

 

 

    

 

 

    

 

 

 

The carrying amounts reported in the condensed consolidated balance sheet approximate the fair value based on quoted market prices or alternative pricing sources and models utilizing market observable inputs. As of September 30, 2016, the Company does not consider any of its marketable securities to be other than temporarily impaired. During the nine months ended September 30, 2016 and 2015, the Company did not reclassify any items out of accumulated other comprehensive income to net income. All investments in marketable securities are classified as a current asset on the balance sheet because the underlying securities mature within one year from the balance sheet date.

XML 25 R14.htm IDEA: XBRL DOCUMENT v3.5.0.2
Business Combinations
9 Months Ended
Sep. 30, 2016
Business Combinations [Abstract]  
Business Combinations

7. BUSINESS COMBINATIONS

Morrisey Associates, Inc.

On August 8, 2016, Echo, Inc. (“Echo”), a wholly owned subsidiary of the Company, acquired all of the outstanding stock of Morrisey Associates, Inc. (“MAI”), a Chicago, Illinois based company that provides credentialing and privileging software to healthcare professionals. The acquisition of MAI allows the Company to expand its credentialing and privileging product offerings and solutions to healthcare organizations. The consideration paid for MAI consisted of approximately $48.0 million in cash, which the Company funded with cash on hand, and was not subject to any post-closing working capital or similar adjustment. The Company incurred approximately $953,000 in transaction costs, of which $805,000 were incurred during the three months ended September 30, 2016 and $148,000 were incurred during the six months ended June 30, 2016. The transaction costs were recorded in other general and administrative expenses in the condensed consolidated statements of income for such periods. The results of operations for MAI have been included in the Company’s condensed consolidated financial statements from the date of acquisition, and are also included in the HealthStream Provider Solutions segment.

A summary of the purchase price is as follows (in thousands):

 

Cash paid at closing

   $ 44,120   

Cash held in escrow

     3,880   
  

 

 

 

Total consideration paid

   $ 48,000   
  

 

 

 

The following table summarizes the fair value of the assets acquired and liabilities assumed as of the date of acquisition (in thousands):

 

Accounts receivable, net

     3,402   

Prepaid royalties and other prepaid assets

     187   

Property and equipment

     75   

Deferred tax assets

     1,548   

Goodwill

     20,502   

Intangible assets

     27,400   

Accounts payable and accrued liabilities

     (913

Deferred revenue

     (4,201
  

 

 

 

Net assets acquired

   $ 48,000   
  

 

 

 

9

 

The excess of preliminary purchase price over the preliminary fair values of net tangible and intangible assets will be recorded as goodwill. The preliminary fair values of tangible and identifiable intangible assets and deferred revenue are based on management’s estimates and assumptions. The preliminary fair values of assets acquired and liabilities assumed are considered preliminary and are based on the information that was available at the time of the acquisition. The preliminary fair values of assets acquired and liabilities assumed are subject to change during the measurement period (up to one year from the acquisition date) as the Company finalizes the valuation of these items. The goodwill balance is primarily attributed to the assembled workforce, additional market opportunities from offering MAI’s products, and expected synergies from integrating MAI with other products or other combined functional areas within the Company. The goodwill balance is deductible for U.S. income tax purposes. The net tangible assets include deferred revenue, which was preliminarily adjusted down from a book value at the acquisition date of $9.1 million to an estimated fair value of $4.2 million. The preliminary $4.9 million write-down of deferred revenue will result in lower revenues than would have otherwise been recognized for such services.

The following table sets forth the preliminary components of identifiable intangible assets and their estimated useful lives as of the acquisition date (in thousands):

 

     Preliminary
fair value
     Useful
life
 

Customer relationships

   $ 21,400         13 years   

Developed technology

     5,400         5 years   

Trade names

     600         6 years   
  

 

 

    

Total preliminary intangible assets subject to amortization

   $ 27,400      
  

 

 

    

The amounts of revenue and operating income (loss) of MAI included in the Company’s condensed consolidated statement of income from the date of acquisition of August 8, 2016 to the period ending September 30, 2016 are as follows (in thousands):

 

Total revenues

   $ 841   
  

 

 

 

Operating loss

   $ (1,023
  

 

 

 

The following unaudited pro forma financial information summarizes the combined results of operations of the Company and MAI, which was significant for purposes of the unaudited pro forma financial information disclosure, as though the companies were combined as of January 1, 2015 (in thousands, except per share data):

 

     Three Months Ended
September 30,
     Nine Months Ended
September 30,
 
     2016      2015      2016      2015  

Total revenues

   $ 60,711       $ 56,622       $ 176,401       $ 159,009   
  

 

 

    

 

 

    

 

 

    

 

 

 

Net income

   $ 2,275       $ 2,573       $ 5,764       $ 5,445   
  

 

 

    

 

 

    

 

 

    

 

 

 

Basic earnings per share

   $ 0.07       $ 0.08       $ 0.18       $ 0.18   
  

 

 

    

 

 

    

 

 

    

 

 

 

Diluted earnings per share

   $ 0.07       $ 0.08       $ 0.18       $ 0.18   
  

 

 

    

 

 

    

 

 

    

 

 

 

These unaudited pro forma combined results of operations include certain adjustments arising from the acquisition such as adjustment for amortization of intangible assets, depreciation of property and equipment, and fair value adjustments of acquired deferred revenue balances. The unaudited pro forma combined results of operations is for informational purposes only and is not indicative of what the Company’s results of operations would have been had the transaction occurred at the beginning of the period presented or to project the Company’s results of operations in any future period.

The unaudited pro forma financial information for the three and nine months ended September 30, 2016 and 2015 combines the historical results of the Company and MAI for the three and nine months ended September 30, 2016 and 2015 and the pro forma adjustments listed above.

10

 

HealthLine Systems

On March 16, 2015, the Company acquired all of the membership interests of HealthLine Systems, LLC (“HLS”), a San Diego, California based company that specializes in credentialing, privileging, call center, and quality management solutions for the healthcare industry. The acquisition of HLS enabled the Company to provide a comprehensive solution set for healthcare provider credentialing, privileging, enrollment, referral, onboarding, and analytics in support of HealthStream’s approach to talent management for healthcare organizations. The consideration paid for HLS consisted of approximately $90.3 million in cash (taking into account an estimated closing working capital adjustment and amounts due to the seller as of September 30, 2016). The Company incurred approximately $1.3 million in transaction costs associated with the acquisition, of which $965,000 were incurred during the three months ended March 31, 2015 and $329,000 were incurred during the year ended December 31, 2014. The transaction costs were recorded in other general and administrative expenses in the condensed consolidated statements of income for such periods. The results of operations for HLS have been included in the Company’s condensed consolidated financial statements from the date of acquisition, and are also included in the HealthStream Provider Solutions segment.

A summary of the purchase price is as follows (in thousands):

 

Cash paid at closing

   $ 87,450   

Consideration due to the seller

     2,180   

Cash held in escrow

     679   
  

 

 

 

Total consideration paid

   $ 90,309   
  

 

 

 

The following table summarizes the fair value of the assets acquired and liabilities assumed as of the date of acquisition (in thousands):

 

Cash

   $ 54   

Accounts receivable, net

     3,052   

Prepaid assets

     546   

Property and equipment

     200   

Deferred tax assets

     2,523   

Goodwill

     43,798   

Intangible assets

     47,200   

Accounts payable and accrued liabilities

     (1,085

Deferred revenue

     (5,979
  

 

 

 

Net assets acquired

   $ 90,309   
  

 

 

 

The excess of purchase price over the fair values of net tangible and intangible assets has been recorded as goodwill. The fair values of tangible and identifiable intangible assets, deferred tax assets, deferred revenue, and other liabilities are based on management’s estimates and assumptions. Included in the assets and liabilities assumed is an estimated indemnification asset of $300,000 and a contingent liability of $700,000, both of which are associated with tax liabilities. The contingent liability is measured based on management’s estimate of a range of probable outcomes. The goodwill balance is primarily attributed to the assembled workforce, additional market opportunities from offering HLS’s products, and expected synergies from integrating HLS with other products or other combined functional areas within the Company. During the three months ended March 31, 2016, the Company received notice of an indemnification claim from the former owners of HLS pursuant to the terms of the membership interest purchase agreement. The terms of such agreement require the Company to indemnify such owners for incremental taxes incurred as the result of the structure of the acquisition, which had favorable tax aspects to the Company. The Company recorded a measurement period adjustment in relation to the claim that increased goodwill by approximately $2.2 million during the three months ended March 31, 2016. The additional goodwill is deductible for U.S. income tax purposes. The goodwill balance excluding such measurement period adjustment is also deductible for U.S. income tax purposes. During the three months ended September 30, 2016, the Company agreed to settle this indemnification claim for approximately $2.4 million in respect of such tax indemnification provision in the membership interest purchase agreement, a difference of approximately $200,000 from the aforementioned $2.2 million measurement period adjustment. The Company surpassed the one year measurement period as of the period ended March 31, 2016; accordingly, in accordance with requisite accounting guidance, the $200,000 difference has been reflected as a charge against net income for the period ended September 30, 2016. The net tangible assets include deferred revenue, which was adjusted down from a book value at the acquisition date of $15.0 million to an estimated fair value of $6.0 million. The $9.0 million write-down of deferred revenue will result in lower revenues than would have otherwise been recognized for such services.

11

 

The following table sets forth the components of identifiable intangible assets and their estimated useful lives as of the acquisition date (in thousands):

 

     Fair value      Useful life  

Customer relationships

   $ 42,600         13 years   

Developed technology

     3,700         5 years   

Trade names

     900         6 years   
  

 

 

    

Total intangible assets subject to amortization

   $ 47,200      
  

 

 

    

The amounts of revenue and operating income (loss) of HLS included in the Company’s condensed consolidated statement of income from the date of acquisition of March 16, 2015 to the period ending September 30, 2015 are as follows (in thousands):

 

Total revenues

   $ 5,351   
  

 

 

 

Operating loss

   $ (1,899
  

 

 

 

The following unaudited pro forma financial information summarizes the combined results of operations of the Company and HLS, which was significant for purposes of the unaudited pro forma financial information disclosure, as though the companies were combined as of January 1, 2014 (in thousands, except per share data):

 

     Three Months Ended
September 30,
     Nine Months Ended
September 30,
 
     2016      2015      2016      2015  

Total revenues

   $ 58,644       $ 55,741       $ 168,908       $ 161,954   
  

 

 

    

 

 

    

 

 

    

 

 

 

Net income

   $ 1,361       $ 3,760       $ 5,090       $ 10,599   
  

 

 

    

 

 

    

 

 

    

 

 

 

Basic earnings per share

   $ 0.04       $ 0.12       $ 0.16       $ 0.36   
  

 

 

    

 

 

    

 

 

    

 

 

 

Diluted earnings per share

   $ 0.04       $ 0.12       $ 0.16       $ 0.35   
  

 

 

    

 

 

    

 

 

    

 

 

 

These unaudited pro forma combined results of operations include certain adjustments arising from the acquisition such as adjustment for amortization of intangible assets, depreciation of property and equipment, fair value adjustments of acquired deferred revenue balances, and interest expense associated with borrowings under a revolving credit facility by the Company to partially fund the acquisition. The unaudited pro forma combined results of operations is for informational purposes only and is not indicative of what the Company’s results of operations would have been had the transaction occurred at the beginning of the period presented or to project the Company’s results of operations in any future period.

The unaudited pro forma financial information for the three and nine months ended September 30, 2016 and 2015 combines the historical results of the Company and HLS for the three and nine months ended September 30, 2016 and 2015 and the pro forma adjustments listed above.

Other Business Combinations

On June 30, 2016, the Company acquired all of the stock of Performance Management Services, Inc. (“PMSI”), a Company based in Tustin, California focused on competency-based performance development for nurses, for $4.0 million in cash and up to an additional $500,000 of contingent consideration. The acquisition, including associated transaction costs, is not considered material to the Company’s financial statements. The Company accounted for the acquisition as a business combination and has allocated the purchase consideration based on preliminary estimates of fair value. The Company expects to finalize its estimates of fair value as soon as practicable, but not later than one year from the date of acquisition. The results of operations for PMSI are included in the Company’s condensed consolidated financial statements from the date of acquisition and are included in the HealthStream Workforce Solutions segment.

12

 

On July 25, 2016, the Company purchased all of the outstanding stock of Nursing Registry Consultants Corporation (“Nurse Competency”) not previously held by the Company for approximately $1.0 million in cash and up to an additional $75,000 in contingent consideration. Nurse Competency provides SaaS-based clinical assessment and testing products to the healthcare industry. The Company previously held a 32% minority equity interest in Nurse Competency and had accounted for such interest as an equity method investment. The fair value of the minority equity interest as of the July 25, 2016 acquisition date was approximately $484,000 and was determined in accordance with the fair value of the controlling interest acquired with consideration given to acquisition premiums, where applicable. The Company recorded a gain of approximately $225,000 to account for the difference between the noted acquisition date fair value of the minority equity interest and the carrying value as of such date. The gain is included in other income (expense), net in the condensed consolidated statements of income for the three and nine months ended September 30, 2016. The Company accounted for the acquisition as a business combination and has allocated the purchase consideration based on preliminary estimates of fair value. The Company expects to finalize its estimates of fair value as soon as practicable, but not later than one year from the date of acquisition. The results of operations for Nurse Competency are included in the Company’s condensed consolidated financial statements from the date of acquisition and are included in the HealthStream Workforce Solutions segment.

Goodwill

The changes in the carrying amount of goodwill for the nine months ended September 30, 2016 are as follows (in thousands):

 

     Workforce      Patient
Experience
     Provider      Total  

Balance at January 1, 2016

   $ 12,336       $ 24,154       $ 46,583       $ 83,073   

Other business combinations

     4,041         —           —           4,041   

Acquisition of HealthLine Systems, LLC

     —           —           2,180         2,180   

Acquisition of Morrisey Associates, Inc.

     —           —           20,502         20,502   
  

 

 

    

 

 

    

 

 

    

 

 

 

Balance at September 30, 2016

   $ 16,377       $ 24,154       $ 69,265       $ 109,796   
  

 

 

    

 

 

    

 

 

    

 

 

 

During the three months ended March 31, 2016, the Company recorded approximately $2.2 million of additional goodwill in relation to the March 2015 acquisition of HealthLine Systems, LLC. Such amount relates to the measurement period adjustment previously discussed under the above caption “HealthLine Systems.


 

XML 26 R15.htm IDEA: XBRL DOCUMENT v3.5.0.2
Business Segments
9 Months Ended
Sep. 30, 2016
Segment Reporting [Abstract]  
Business Segments

8. BUSINESS SEGMENTS

The Company provides services to healthcare organizations and other members within the healthcare industry. The Company’s services are focused on the delivery of workforce development products and services (HealthStream Workforce Solutions), survey and research services (HealthStream Patient Experience Solutions), and provider credentialing, privileging, call center and enrollment products and services (HealthStream Provider Solutions).

The Company measures segment performance based on operating income before income taxes and prior to the allocation of certain corporate overhead expenses, interest income, interest expense, and depreciation. The Unallocated component below includes corporate functions, such as accounting, human resources, legal, investor relations, administrative, and executive personnel, depreciation, a portion of amortization, and certain other expenses, which are not currently allocated in measuring segment performance. The following is the Company’s business segment information as of and for the three and nine months ended September 30, 2016 and 2015 (in thousands).

 

     Three Months Ended
September 30,
     Nine Months Ended
September 30,
 
     2016      2015      2016      2015  

Revenues, net:

           

Workforce

   $ 43,015       $ 41,092       $ 124,489       $ 118,488   

Patient Experience

     8,931         8,792         25,862         25,545   

Provider

     6,421         3,951         16,886         9,103   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total revenues, net

   $ 58,367       $ 53,835       $ 167,237       $ 153,136   
  

 

 

    

 

 

    

 

 

    

 

 

 

 

     Three Months Ended
September 30,
     Nine Months Ended
September 30,
 
     2016      2015      2016      2015  

Income from operations:

           

Workforce

   $ 9,386       $ 10,386       $ 29,034       $ 29,789   

Patient Experience

     471         807         (319      1,737   

Provider

     (959      (852      (681      (1,638

Unallocated

     (7,612      (6,016      (21,946      (18,209
  

 

 

    

 

 

    

 

 

    

 

 

 

Total income from operations

   $ 1,286       $ 4,325       $ 6,088       $ 11,679   
  

 

 

    

 

 

    

 

 

    

 

 

 

 

     September 30,
2016
     December 31,
2015
 

Segment assets *

     

Workforce

   $ 93,350       $ 82,375   

Patient Experience

     35,724         34,902   

Provider

     152,162         100,948   

Unallocated

     112,815         161,344   
  

 

 

    

 

 

 

Total assets

   $ 394,051       $ 379,569   
  

 

 

    

 

 

 

 

* Segment assets include accounts and unbilled receivables, prepaid and other current assets, other assets, capitalized software development, certain property and equipment, and intangible assets. Cash and cash equivalents and marketable securities are not allocated to individual segments, and are included within Unallocated. A significant portion of property and equipment assets are included within Unallocated.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.5.0.2
Debt
9 Months Ended
Sep. 30, 2016
Debt Disclosure [Abstract]  
Debt

9. DEBT

Revolving Credit Facility

The Company maintains a Loan Agreement (the “Revolving Credit Facility”) with SunTrust Bank (“SunTrust”) in the aggregate principal amount of $50.0 million, which matures on November 24, 2017. Under the Revolving Credit Facility, the Company may borrow up to $50.0 million, which includes a $5.0 million swing line subfacility and a $5.0 million letter of credit subfacility, as well as an accordion feature that allows the Company to increase the Revolving Credit Facility by a total of up to $25.0 million, subject to securing additional commitments from existing lenders or new lending institutions. The obligations under the Revolving Credit Facility are guaranteed by each of the Company’s subsidiaries. At the Company’s election, the borrowings under the Revolving Credit Facility bear interest at either (1) a rate per annum equal to the highest of SunTrust’s prime rate or 0.5% in excess of the Federal Funds Rate or 1.0% in excess of one-month LIBOR (the “Base Rate”), plus an applicable margin, or (2) the one, two, three, or six-month per annum LIBOR for deposits in the applicable currency (the “Eurocurrency Rate”), as selected by the Company, plus an applicable margin. The applicable margin for Eurocurrency Rate loans depends on the Company’s funded debt leverage ratio and varies from 1.50% to 2.00%. The applicable margin for Base Rate loans depends on the Company’s funded debt leverage ratio and varies from 0.50% to 1.50%. Commitment fees and letter of credit fees are also payable under the Revolving Credit Facility. Principal is payable in full at maturity on November 24, 2017, and there are no scheduled principal payments prior to maturity. The Company is required to pay a commitment fee ranging between 20 and 30 basis points per annum of the average daily unused portion of the Revolving Credit Facility, depending on the Company’s funded debt leverage ratio.

The purpose of the Revolving Credit Facility is for general working capital needs, permitted acquisitions (as defined in the Loan Agreement), and for stock repurchase and/or redemption transactions that the Company may authorize.

The Revolving Credit Facility contains certain covenants that, among other things, restrict additional indebtedness, liens and encumbrances, changes to the character of the Company’s business, acquisitions, asset dispositions, mergers and consolidations, sale or discount of receivables, creation or acquisitions of additional subsidiaries, and other matters customarily restricted in such agreements.

In addition, the Revolving Credit Facility requires the Company to meet certain financial tests, including, without limitation:

 

    a funded debt leverage ratio (consolidated debt/consolidated EBITDA) of not greater than 3.0 to 1.0; and

 

    an interest coverage ratio (consolidated EBITDA/consolidated interest expense) of not less than 3.0 to 1.0.

As of September 30, 2016, the Company was in material compliance with all covenants. There were no balances outstanding on the Revolving Credit Facility as of September 30, 2016. During the three months ended June 30, 2015, the Company repaid approximately $28.0 million of balances previously outstanding under the Revolving Credit Facility from proceeds received in the Company’s public offering of 3,869,750 shares which closed on May 28, 2015.

XML 28 R17.htm IDEA: XBRL DOCUMENT v3.5.0.2
Related Party Transactions
9 Months Ended
Sep. 30, 2016
Related Party Transactions [Abstract]  
Related Party Transactions

10. RELATED PARTY TRANSACTIONS

During the three months ended June 30, 2015, the Company’s CEO, Robert A. Frist, Jr., entered into an agreement with the Company pursuant to which he contributed 54,241 of his personally owned shares of HealthStream, Inc. common stock to the Company, without any consideration paid to him. In connection with this contribution, the Company approved the grant of 49,310 shares of common stock to over 600 employees, with a fair market value of approximately $1.5 million. Mr. Frist contributed 4,931 of the contributed shares noted above to take into account the estimated Company costs, such as administrative expenses and employer payroll taxes associated with the grants. (See Note 4 Stock Based Compensation).

XML 29 R18.htm IDEA: XBRL DOCUMENT v3.5.0.2
Recent Accounting Pronouncements (Policies)
9 Months Ended
Sep. 30, 2016
Accounting Changes and Error Corrections [Abstract]  
RECENT ACCOUNTING PRONOUNCEMENTS

Recently Adopted Accounting Standards

The Company has adopted Accounting Standards Update (“ASU”) 2015-16, Business Combinations (Topic 805). Under the provisions of the revised guidance, acquirers in a business combination must recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. The acquirer must record, in the same period’s financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the provisional amounts, calculated as if the accounting had been completed at the acquisition date. The Company recorded a measurement period adjustment during the period ended March 31, 2016. See Note 7 Business Combinations for further discussion.

RECENT ACCOUNTING PRONOUNCEMENTS

In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific revenue recognition guidance throughout the Industry Topics of the Accounting Standards Codification. The updated guidance states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also provides for additional disclosures with respect to revenues and cash flows arising from contracts with customers. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2017, and early adoption is permitted for the first interim period within annual reporting periods beginning after December 15, 2016. The Company is currently reviewing this standard to determine the method of adoption and to assess the impact on its future consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which requires lessees to recognize assets and liabilities for most leases. The recognition, measurement and presentation of expenses and cash flows arising from a lease by a lessee is not expected to significantly change under such guidance; however, the Company is currently reviewing this standard to determine the method of adoption and to assess the impact on its future consolidated financial statements. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2018, and early adoption is permitted.

In March 2016, the FASB issued ASU 2016-09, Compensation – Stock Compensation (Topic 718), which serves to simplify several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2016, and early adoption is permitted in any interim or annual period. The Company is currently reviewing this standard to determine the method of adoption and to assess the impact on its future consolidated financial statements.

In March 2016, the FASB issued ASU 2016-01, Financial Instruments – Overall (Sub Topic 825-10), which addresses certain aspects of the recognition, measurement, presentation, and disclosure of financial instruments. The guidance will, among other things, require equity method investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2017, and early adoption is permitted for only limited aspects of such guidance. The Company is currently reviewing this standard to determine the method of adoption and to assess the impact on its future consolidated financial statements.

XML 30 R19.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stock Based Compensation (Tables)
9 Months Ended
Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock Based Compensation Expense Recorded in Condensed Consolidated Statements of Income

Total stock based compensation expense recorded for the three and nine months ended September 30, 2016 and 2015, which is recorded in the condensed consolidated statements of income, is as follows (in thousands):

 

     Three Months Ended
September 30,
     Nine Months Ended
September 30,
 
     2016      2015      2016      2015  

Cost of revenues (excluding depreciation and amortization)

   $ 35       $ 29       $ 110       $ 790   

Product development

     73         55         200         514   

Sales and marketing

     65         61         193         486   

Other general and administrative

     339         295         1,013         997   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total stock based compensation expense

   $ 512       $ 440       $ 1,516       $ 2,787   
  

 

 

    

 

 

    

 

 

    

 

 

 
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.5.0.2
Earnings Per Share (Tables)
9 Months Ended
Sep. 30, 2016
Earnings Per Share [Abstract]  
Computation of Basic and Diluted Earnings Per Share

The following table sets forth the computation of basic and diluted earnings per share for the three and nine months ended September 30, 2016 and 2015 (in thousands, except per share data):

 

     Three Months Ended
September 30,
     Nine Months Ended
September 30,
 
     2016      2015      2016      2015  

Numerator:

           

Net income

   $ 1,162       $ 2,614       $ 4,066       $ 6,810   
  

 

 

    

 

 

    

 

 

    

 

 

 

Denominator:

           

Weighted-average shares outstanding

     31,739         31,643         31,714         29,527   

Effect of dilutive shares

     368         386         336         378   
  

 

 

    

 

 

    

 

 

    

 

 

 

Weighted-average diluted shares

     32,107         32,029         32,050         29,905   
  

 

 

    

 

 

    

 

 

    

 

 

 

Basic earnings per share

   $ 0.04       $ 0.08       $ 0.13       $ 0.23   
  

 

 

    

 

 

    

 

 

    

 

 

 

Diluted earnings per share

   $ 0.04       $ 0.08       $ 0.13       $ 0.23   
  

 

 

    

 

 

    

 

 

    

 

 

 
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.5.0.2
Marketable Securities (Tables)
9 Months Ended
Sep. 30, 2016
Investments, Debt and Equity Securities [Abstract]  
Fair Value of Available for Sale Marketable Securities

At September 30, 2016 and December 31, 2015, the fair value of marketable securities, which were all classified as available for sale, included the following (in thousands):

 

     September 30, 2016  
     Adjusted
Cost
     Unrealized
Gains
     Unrealized
Losses
     Fair
Value
 

Level 2:

           

Corporate debt securities

   $ 43,720         3         (36    $ 43,687   

Government-sponsored enterprise debt securities

     17,054         6         —           17,060   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

   $ 60,774       $ 9       $ (36    $ 60,747   
  

 

 

    

 

 

    

 

 

    

 

 

 

 

     December 31, 2015  
     Adjusted
Cost
     Unrealized
Gains
     Unrealized
Losses
     Fair
Value
 

Level 2:

           

Certificates of deposit

   $ 1,000       $ —         $ —         $ 1,000   

Corporate debt securities

     66,046         —           (70      65,976   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

   $ 77,046       $ —         $ (70    $ 66,976   
  

 

 

    

 

 

    

 

 

    

 

 

 
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.5.0.2
Business Combinations (Tables)
9 Months Ended
Sep. 30, 2016
Changes in the Carrying Amount of Goodwill

The changes in the carrying amount of goodwill for the nine months ended September 30, 2016 are as follows (in thousands):

 

     Workforce      Patient
Experience
     Provider      Total  

Balance at January 1, 2016

   $ 12,336       $ 24,154       $ 46,583       $ 83,073   

Other business combinations

     4,041         —           —           4,041   

Acquisition of HealthLine Systems, LLC

     —           —           2,180         2,180   

Acquisition of Morrisey Associates, Inc.

     —           —           20,502         20,502   
  

 

 

    

 

 

    

 

 

    

 

 

 

Balance at September 30, 2016

   $ 16,377       $ 24,154       $ 69,265       $ 109,796   
  

 

 

    

 

 

    

 

 

    

 

 

 

HealthLine Systems LLC [Member]  
Summary of Purchase Price

A summary of the purchase price is as follows (in thousands):

 

Cash paid at closing

   $ 87,450   

Consideration due to the seller

     2,180   

Cash held in escrow

     679   
  

 

 

 

Total consideration paid

   $ 90,309   
  

 

 

 
Summary of Fair Value of Assets Acquired and Liabilities Assumed

The following table summarizes the fair value of the assets acquired and liabilities assumed as of the date of acquisition (in thousands):

 

Cash

   $ 54   

Accounts receivable, net

     3,052   

Prepaid assets

     546   

Property and equipment

     200   

Deferred tax assets

     2,523   

Goodwill

     43,798   

Intangible assets

     47,200   

Accounts payable and accrued liabilities

     (1,085

Deferred revenue

     (5,979
  

 

 

 

Net assets acquired

   $ 90,309   
  

 

 

 
Components of Identifiable Intangible Assets and Estimated Useful Lives

The following table sets forth the components of identifiable intangible assets and their estimated useful lives as of the acquisition date (in thousands):

 

     Fair value      Useful life  

Customer relationships

   $ 42,600         13 years   

Developed technology

     3,700         5 years   

Trade names

     900         6 years   
  

 

 

    

Total intangible assets subject to amortization

   $ 47,200      
  

 

 

    
Summary of Unaudited ProForma Financial Information

The amounts of revenue and operating income (loss) of HLS included in the Company’s condensed consolidated statement of income from the date of acquisition of March 16, 2015 to the period ending September 30, 2015 are as follows (in thousands):

 

Total revenues

   $ 5,351   
  

 

 

 

Operating loss

   $ (1,899
  

 

 

 

The following unaudited pro forma financial information summarizes the combined results of operations of the Company and HLS, which was significant for purposes of the unaudited pro forma financial information disclosure, as though the companies were combined as of January 1, 2014 (in thousands, except per share data):

 

     Three Months Ended
September 30,
     Nine Months Ended
September 30,
 
     2016      2015      2016      2015  

Total revenues

   $ 58,644       $ 55,741       $ 168,908       $ 161,954   
  

 

 

    

 

 

    

 

 

    

 

 

 

Net income

   $ 1,361       $ 3,760       $ 5,090       $ 10,599   
  

 

 

    

 

 

    

 

 

    

 

 

 

Basic earnings per share

   $ 0.04       $ 0.12       $ 0.16       $ 0.36   
  

 

 

    

 

 

    

 

 

    

 

 

 

Diluted earnings per share

   $ 0.04       $ 0.12       $ 0.16       $ 0.35   
  

 

 

    

 

 

    

 

 

    

 

 

 
Morrisey Associates Inc [Member]  
Summary of Purchase Price

A summary of the purchase price is as follows (in thousands):

 

Cash paid at closing

   $ 44,120   

Cash held in escrow

     3,880   
  

 

 

 

Total consideration paid

   $ 48,000   
  

 

 

 
Summary of Fair Value of Assets Acquired and Liabilities Assumed

The following table summarizes the fair value of the assets acquired and liabilities assumed as of the date of acquisition (in thousands):

 

Accounts receivable, net

     3,402   

Prepaid royalties and other prepaid assets

     187   

Property and equipment

     75   

Deferred tax assets

     1,548   

Goodwill

     20,502   

Intangible assets

     27,400   

Accounts payable and accrued liabilities

     (913

Deferred revenue

     (4,201
  

 

 

 

Net assets acquired

   $ 48,000   
  

 

 

 
Components of Identifiable Intangible Assets and Estimated Useful Lives

The following table sets forth the preliminary components of identifiable intangible assets and their estimated useful lives as of the acquisition date (in thousands):

 

     Preliminary
fair value
     Useful
life
 

Customer relationships

   $ 21,400         13 years   

Developed technology

     5,400         5 years   

Trade names

     600         6 years   
  

 

 

    

Total preliminary intangible assets subject to amortization

   $ 27,400      
  

 

 

    
Summary of Unaudited ProForma Financial Information

The amounts of revenue and operating income (loss) of MAI included in the Company’s condensed consolidated statement of income from the date of acquisition of August 8, 2016 to the period ending September 30, 2016 are as follows (in thousands):

 

Total revenues

   $ 841   
  

 

 

 

Operating loss

   $ (1,023
  

 

 

 

The following unaudited pro forma financial information summarizes the combined results of operations of the Company and MAI, which was significant for purposes of the unaudited pro forma financial information disclosure, as though the companies were combined as of January 1, 2015 (in thousands, except per share data):

 

     Three Months Ended
September 30,
     Nine Months Ended
September 30,
 
     2016      2015      2016      2015  

Total revenues

   $ 60,711       $ 56,622       $ 176,401       $ 159,009   
  

 

 

    

 

 

    

 

 

    

 

 

 

Net income

   $ 2,275       $ 2,573       $ 5,764       $ 5,445   
  

 

 

    

 

 

    

 

 

    

 

 

 

Basic earnings per share

   $ 0.07       $ 0.08       $ 0.18       $ 0.18   
  

 

 

    

 

 

    

 

 

    

 

 

 

Diluted earnings per share

   $ 0.07       $ 0.08       $ 0.18       $ 0.18   
  

 

 

    

 

 

    

 

 

    

 

 

 
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.5.0.2
Business Segments (Tables)
9 Months Ended
Sep. 30, 2016
Segment Reporting [Abstract]  
Business Segment Information Based on Net Revenues

The following is the Company’s business segment information as of and for the three and nine months ended September 30, 2016 and 2015 (in thousands).

 

     Three Months Ended
September 30,
     Nine Months Ended
September 30,
 
     2016      2015      2016      2015  

Revenues, net:

           

Workforce

   $ 43,015       $ 41,092       $ 124,489       $ 118,488   

Patient Experience

     8,931         8,792         25,862         25,545   

Provider

     6,421         3,951         16,886         9,103   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total revenues, net

   $ 58,367       $ 53,835       $ 167,237       $ 153,136   
  

 

 

    

 

 

    

 

 

    

 

 

 
Business Segment Information Based on Operating Income
     Three Months Ended
September 30,
     Nine Months Ended
September 30,
 
     2016      2015      2016      2015  

Income from operations:

           

Workforce

   $ 9,386       $ 10,386       $ 29,034       $ 29,789   

Patient Experience

     471         807         (319      1,737   

Provider

     (959      (852      (681      (1,638

Unallocated

     (7,612      (6,016      (21,946      (18,209
  

 

 

    

 

 

    

 

 

    

 

 

 

Total income from operations

   $ 1,286       $ 4,325       $ 6,088       $ 11,679   
  

 

 

    

 

 

    

 

 

    

 

 

 
Business Segment Information Based on Assets
     September 30,
2016
     December 31,
2015
 

Segment assets *

     

Workforce

   $ 93,350       $ 82,375   

Patient Experience

     35,724         34,902   

Provider

     152,162         100,948   

Unallocated

     112,815         161,344   
  

 

 

    

 

 

 

Total assets

   $ 394,051       $ 379,569   
  

 

 

    

 

 

 

 

* Segment assets include accounts and unbilled receivables, prepaid and other current assets, other assets, capitalized software development, certain property and equipment, and intangible assets. Cash and cash equivalents and marketable securities are not allocated to individual segments, and are included within Unallocated. A significant portion of property and equipment assets are included within Unallocated.
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.5.0.2
Income Taxes - Additional Information (Detail) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Income Tax Disclosure [Abstract]        
Income tax provision $ 461,000 $ 1,739,000 $ 2,487,000 $ 4,862,000
Effective tax rate     38.00% 41.70%
Reduction of gross unrecognized tax benefits     $ (300,000) $ (1,800,000)
Unrecognized tax benefits that would affect effective tax rate   $ 115,000   $ 115,000
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stock Based Compensation - Additional Information (Detail)
1 Months Ended 3 Months Ended 9 Months Ended
Jun. 30, 2015
Employees
shares
Sep. 30, 2016
USD ($)
Mar. 31, 2016
$ / shares
shares
Sep. 30, 2015
USD ($)
$ / shares
shares
Jun. 30, 2015
USD ($)
Employees
shares
Sep. 30, 2016
USD ($)
Incentive_Plan
$ / shares
shares
Sep. 30, 2015
USD ($)
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Number of incentive plans | Incentive_Plan           3  
Restricted share units issued             49,310
Weighted average grant date fair value, restricted share unit | $ / shares             $ 30.42
Stock based compensation expense | $   $ 512,000   $ 440,000   $ 1,516,000 $ 2,787,000
RSUs [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Restricted share units issued           111,808 80,355
Weighted average grant date fair value, restricted share unit | $ / shares           $ 20.49 $ 25.56
Stock Awards [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Number of employees eligible to receive common stock | Employees 600            
Minimum eligible period of service required for the employees to receive common stock 1 year            
Stock based compensation expense | $         $ 1,500,000    
Common stock issued under stock plans, number of shares withheld         17,279    
Total payments to taxing authorities for stock awards | $             $ 526,000
Performance-Based RSUs [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Restricted share units issued       30,000      
Weighted average grant date fair value, restricted share unit | $ / shares     $ 20.20 $ 23.40      
Restricted share units vesting period       5 years      
Restricted share units grant date established     5,000 8,750      
Restricted share units grant date remaining     16,250 16,250      
Chief Executive Officer [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Restricted share units issued         49,310    
Number of common stock contributed         54,241    
Number of employees eligible to receive common stock | Employees         600    
Stock based compensation expense | $         $ 1,500,000    
Chief Executive Officer [Member] | Stock Awards [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Restricted share units issued 49,310            
Number of common stock contributed 54,241            
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stock Based Compensation - Stock Based Compensation Expense Recorded in Condensed Consolidated Statements of Income (Detail) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]        
Total stock based compensation expense $ 512 $ 440 $ 1,516 $ 2,787
Cost of Revenues (Excluding Depreciation and Amortization) [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]        
Total stock based compensation expense 35 29 110 790
Product Development [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]        
Total stock based compensation expense 73 55 200 514
Sales and Marketing [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]        
Total stock based compensation expense 65 61 193 486
Other General and Administrative [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]        
Total stock based compensation expense $ 339 $ 295 $ 1,013 $ 997
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.5.0.2
Earnings Per Share - Additional Information (Detail) - shares
3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Earnings Per Share [Abstract]        
Total number of common equivalent shares excluded from the calculations of diluted earnings per share 21,000 26,000 42,000 13,000
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.5.0.2
Earnings Per Share - Computation of Basic and Diluted Earnings Per Share (Detail) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Numerator:        
Net income $ 1,162 $ 2,614 $ 4,066 $ 6,810
Denominator:        
Weighted-average shares outstanding 31,739 31,643 31,714 29,527
Effect of dilutive shares 368 386 336 378
Weighted-average diluted shares 32,107 32,029 32,050 29,905
Basic earnings per share $ 0.04 $ 0.08 $ 0.13 $ 0.23
Diluted earnings per share $ 0.04 $ 0.08 $ 0.13 $ 0.23
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.5.0.2
Marketable Securities - Fair Value of Available for Sale Marketable Securities (Detail) - USD ($)
$ in Thousands
Sep. 30, 2016
Dec. 31, 2015
Schedule of Available-for-sale Securities [Line Items]    
Available for sale securities, Fair Value $ 60,747 $ 66,976
Level 2 [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Available for sale securities, Adjusted Cost 60,774 77,046
Available for sale securities, Unrealized Gains 9  
Available for sale securities, Unrealized Losses (36) (70)
Available for sale securities, Fair Value 60,747 66,976
Level 2 [Member] | Certificates of Deposit [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Available for sale securities, Adjusted Cost   1,000
Available for sale securities, Fair Value   1,000
Level 2 [Member] | Corporate Debt Securities [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Available for sale securities, Adjusted Cost 43,720 66,046
Available for sale securities, Unrealized Gains 3  
Available for sale securities, Unrealized Losses (36) (70)
Available for sale securities, Fair Value 43,687 $ 65,976
Level 2 [Member] | Government-sponsored Enterprises Debt Securities [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Available for sale securities, Adjusted Cost 17,054  
Available for sale securities, Unrealized Gains 6  
Available for sale securities, Fair Value $ 17,060  
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.5.0.2
Business Combinations - Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended 15 Months Ended
Aug. 08, 2016
Jul. 25, 2016
Jun. 30, 2016
Sep. 30, 2016
Mar. 31, 2016
Mar. 31, 2015
Jun. 30, 2016
Sep. 30, 2016
Dec. 31, 2014
Mar. 31, 2015
Mar. 16, 2015
Nursing Registry Consultants Corporation [Member]                      
Business Acquisition [Line Items]                      
Equity method ownership interest percentage       32.00%       32.00%      
Fair value of minority equity interest   $ 484,000                  
HealthLine Systems LLC [Member]                      
Business Acquisition [Line Items]                      
Acquisition date of assets               Mar. 16, 2015      
Consideration paid for acquisition in cash               $ 90,309,000      
Transaction costs associated with the acquisition           $ 965,000     $ 329,000 $ 1,300,000  
Preliminary purchase price allocation measurement period               1 year      
Net tangible assets include deferred revenue book value at acquisition date       $ 15,000,000       $ 15,000,000      
Net tangible assets include deferred revenue fair value at acquisition date       6,000,000       6,000,000      
Net tangible assets include deferred revenue estimated fair value       5,979,000       5,979,000     $ 5,979,000
Write-down of deferred revenue               9,000,000      
Estimated indemnification asset       300,000       300,000      
Contingent liability       700,000       700,000      
Adjustment to goodwill       2,200,000 $ 2,200,000            
Goodwill indemnification claim       2,400,000              
Goodwill measurement period adjustment       200,000              
Tax indemnification, charge against net income               $ 200,000      
Other Business Combination [Member]                      
Business Acquisition [Line Items]                      
Consideration paid for acquisition in cash     $ 4,000,000                
Additional contingent consideration     $ 500,000       $ 500,000        
Morrisey Associates Inc [Member]                      
Business Acquisition [Line Items]                      
Acquisition date of assets               Aug. 08, 2016      
Consideration paid for acquisition in cash $ 48,000,000                    
Transaction costs associated with the acquisition       $ 805,000     $ 148,000 $ 953,000      
Preliminary purchase price allocation measurement period 1 year                    
Net tangible assets include deferred revenue book value at acquisition date $ 9,100,000                    
Net tangible assets include deferred revenue fair value at acquisition date 4,200,000                    
Net tangible assets include deferred revenue estimated fair value 4,201,000                    
Write-down of deferred revenue $ 4,900,000                    
Nursing Registry Consultants Corporation [Member]                      
Business Acquisition [Line Items]                      
Consideration paid for acquisition in cash   1,000,000                  
Additional contingent consideration   75,000                  
Recorded gain after business combination   $ 225,000                  
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.5.0.2
Business Combinations - Summary of Purchase Price (Detail) - USD ($)
$ in Thousands
9 Months Ended
Aug. 08, 2016
Sep. 30, 2016
HealthLine Systems LLC [Member]    
Business Acquisition [Line Items]    
Total consideration paid   $ 90,309
Morrisey Associates Inc [Member]    
Business Acquisition [Line Items]    
Total consideration paid $ 48,000  
Cash Paid at Closing [Member] | HealthLine Systems LLC [Member]    
Business Acquisition [Line Items]    
Total consideration paid   87,450
Cash Paid at Closing [Member] | Morrisey Associates Inc [Member]    
Business Acquisition [Line Items]    
Total consideration paid 44,120  
Consideration Due to the Seller [Member] | HealthLine Systems LLC [Member]    
Business Acquisition [Line Items]    
Total consideration paid   2,180
Cash Held in Escrow [Member] | HealthLine Systems LLC [Member]    
Business Acquisition [Line Items]    
Total consideration paid   $ 679
Cash Held in Escrow [Member] | Morrisey Associates Inc [Member]    
Business Acquisition [Line Items]    
Total consideration paid $ 3,880  
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.5.0.2
Business Combinations - Summary of Fair Value of Assets Acquired and Liabilities Assumed (Detail) - USD ($)
$ in Thousands
Sep. 30, 2016
Aug. 08, 2016
Dec. 31, 2015
Mar. 16, 2015
Business Acquisition [Line Items]        
Goodwill $ 109,796   $ 83,073  
HealthLine Systems LLC [Member]        
Business Acquisition [Line Items]        
Cash       $ 54
Accounts receivable, net       3,052
Prepaid assets       546
Property and equipment       200
Deferred tax assets       2,523
Goodwill       43,798
Intangible assets       47,200
Accounts payable and accrued liabilities       (1,085)
Deferred revenue $ (5,979)     (5,979)
Net assets acquired       $ 90,309
Morrisey Associates Inc [Member]        
Business Acquisition [Line Items]        
Accounts receivable, net   $ 3,402    
Prepaid assets   187    
Property and equipment   75    
Deferred tax assets   1,548    
Goodwill   20,502    
Intangible assets   27,400    
Accounts payable and accrued liabilities   (913)    
Deferred revenue   (4,201)    
Net assets acquired   $ 48,000    
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.5.0.2
Business Combinations - Components of Identifiable Intangible Assets and Estimated Useful Lives (Detail) - USD ($)
$ in Thousands
9 Months Ended
Aug. 08, 2016
Sep. 30, 2016
Mar. 16, 2015
Morrisey Associates Inc [Member]      
Finite-Lived Intangible Assets [Line Items]      
Total intangible assets subject to amortization $ 27,400    
HealthLine Systems LLC [Member]      
Finite-Lived Intangible Assets [Line Items]      
Total intangible assets subject to amortization     $ 47,200
Customer Relationships [Member] | Morrisey Associates Inc [Member]      
Finite-Lived Intangible Assets [Line Items]      
Estimated useful lives 13 years    
Total intangible assets subject to amortization $ 21,400    
Customer Relationships [Member] | HealthLine Systems LLC [Member]      
Finite-Lived Intangible Assets [Line Items]      
Estimated useful lives   13 years  
Total intangible assets subject to amortization     42,600
Developed Technology [Member] | Morrisey Associates Inc [Member]      
Finite-Lived Intangible Assets [Line Items]      
Estimated useful lives 5 years    
Total intangible assets subject to amortization $ 5,400    
Developed Technology [Member] | HealthLine Systems LLC [Member]      
Finite-Lived Intangible Assets [Line Items]      
Estimated useful lives   5 years  
Total intangible assets subject to amortization     3,700
Trade Names [Member] | Morrisey Associates Inc [Member]      
Finite-Lived Intangible Assets [Line Items]      
Estimated useful lives 6 years    
Total intangible assets subject to amortization $ 600    
Trade Names [Member] | HealthLine Systems LLC [Member]      
Finite-Lived Intangible Assets [Line Items]      
Estimated useful lives   6 years  
Total intangible assets subject to amortization     $ 900
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.5.0.2
Business Combinations - Summary of Unaudited ProForma Financial Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
2 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
HealthLine Systems LLC [Member]            
Business Acquisition [Line Items]            
Total revenues       $ 5,351    
Operating loss       $ (1,899)    
Total revenues   $ 58,644 $ 55,741   $ 168,908 $ 161,954
Net income   $ 1,361 $ 3,760   $ 5,090 $ 10,599
Basic earnings per share   $ 0.04 $ 0.12   $ 0.16 $ 0.36
Diluted earnings per share   $ 0.04 $ 0.12   $ 0.16 $ 0.35
Morrisey Associates Inc [Member]            
Business Acquisition [Line Items]            
Total revenues $ 841          
Operating loss $ (1,023)          
Total revenues   $ 60,711 $ 56,622   $ 176,401 $ 159,009
Net income   $ 2,275 $ 2,573   $ 5,764 $ 5,445
Basic earnings per share   $ 0.07 $ 0.08   $ 0.18 $ 0.18
Diluted earnings per share   $ 0.07 $ 0.08   $ 0.18 $ 0.18
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.5.0.2
Business Combinations - Changes In Carrying Amount of Goodwill (Detail)
$ in Thousands
9 Months Ended
Sep. 30, 2016
USD ($)
Goodwill [Line Items]  
Goodwill, beginning balance $ 83,073
Goodwill, ending balance 109,796
Other Business Combination [Member]  
Goodwill [Line Items]  
Goodwill acquired 4,041
HealthLine Systems LLC [Member]  
Goodwill [Line Items]  
Goodwill acquired 2,180
Morrisey Associates Inc [Member]  
Goodwill [Line Items]  
Goodwill acquired 20,502
Workforce [Member]  
Goodwill [Line Items]  
Goodwill, beginning balance 12,336
Goodwill, ending balance 16,377
Workforce [Member] | Other Business Combination [Member]  
Goodwill [Line Items]  
Goodwill acquired 4,041
Patient Experience [Member]  
Goodwill [Line Items]  
Goodwill, beginning balance 24,154
Goodwill, ending balance 24,154
Provider [Member]  
Goodwill [Line Items]  
Goodwill, beginning balance 46,583
Goodwill, ending balance 69,265
Provider [Member] | HealthLine Systems LLC [Member]  
Goodwill [Line Items]  
Goodwill acquired 2,180
Provider [Member] | Morrisey Associates Inc [Member]  
Goodwill [Line Items]  
Goodwill acquired $ 20,502
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.5.0.2
Business Segments - Business Segment Information Based on Net Revenues and Operating Income (Detail) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Revenues, net        
Revenues, net $ 58,367 $ 53,835 $ 167,237 $ 153,136
Income from operations        
Income from operations 1,286 4,325 6,088 11,679
Operating Segments [Member] | Workforce [Member]        
Revenues, net        
Revenues, net 43,015 41,092 124,489 118,488
Income from operations        
Income from operations 9,386 10,386 29,034 29,789
Operating Segments [Member] | Patient Experience [Member]        
Revenues, net        
Revenues, net 8,931 8,792 25,862 25,545
Income from operations        
Income from operations 471 807 (319) 1,737
Operating Segments [Member] | Provider [Member]        
Revenues, net        
Revenues, net 6,421 3,951 16,886 9,103
Income from operations        
Income from operations (959) (852) (681) (1,638)
Unallocated [Member]        
Income from operations        
Income from operations $ (7,612) $ (6,016) $ (21,946) $ (18,209)
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.5.0.2
Business Segments - Business Segment Information Based on Assets (Detail) - USD ($)
$ in Thousands
Sep. 30, 2016
Dec. 31, 2015
Segment Reporting Information [Line Items]    
Total assets $ 394,051 $ 379,569
Operating Segments [Member] | Workforce [Member]    
Segment Reporting Information [Line Items]    
Total assets 93,350 82,375
Operating Segments [Member] | Patient Experience [Member]    
Segment Reporting Information [Line Items]    
Total assets 35,724 34,902
Operating Segments [Member] | Provider [Member]    
Segment Reporting Information [Line Items]    
Total assets 152,162 100,948
Unallocated [Member]    
Segment Reporting Information [Line Items]    
Total assets $ 112,815 $ 161,344
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.5.0.2
Debt - Additional Information (Detail) - USD ($)
3 Months Ended 9 Months Ended
Jun. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Line of Credit Facility [Line Items]      
Repayment of balances outstanding on the revolving credit facility     $ 28,000,000
SunTrust Bank [Member]      
Line of Credit Facility [Line Items]      
Description of Line of credit facility Covenant   A funded debt leverage ratio (consolidated debt/consolidated EBITDA) of not greater than 3.0 to 1.0 and an interest coverage ratio (consolidated EBITDA/consolidated interest expense) of not less than 3.0 to 1.0.  
SunTrust Bank [Member] | Minimum [Member]      
Line of Credit Facility [Line Items]      
Commitment fee paid per annum   0.20%  
SunTrust Bank [Member] | Maximum [Member]      
Line of Credit Facility [Line Items]      
Commitment fee paid per annum   0.30%  
Revolving Credit Facility [Member] | SunTrust Bank [Member]      
Line of Credit Facility [Line Items]      
Aggregate principal amount of loan agreement   $ 50,000,000  
Maturity date of Loan agreement   Nov. 24, 2017  
Maximum borrowing capacity under credit facility   $ 50,000,000  
Increase in revolving credit facility   $ 25,000,000  
Interest rate under credit facility   The borrowings under the Revolving Credit Facility bear interest at either (1) a rate per annum equal to the highest of SunTrust’s prime rate or 0.5% in excess of the Federal Funds Rate or 1.0% in excess of one-month LIBOR (the “Base Rate”), plus an applicable margin, or (2) the one, two, three, or six-month per annum LIBOR for deposits in the applicable currency (the “Eurocurrency Rate”), as selected by the Company, plus an applicable margin. The applicable margin for Eurocurrency Rate loans depends on the Company’s funded debt leverage ratio and varies from 1.50% to 2.00%. The applicable margin for Base Rate loans depends on the Company’s funded debt leverage ratio and varies from 0.50% to 1.50%  
Principal payments prior to maturity   $ 0  
Balances outstanding on the revolving credit facility   0  
Repayment of balances outstanding on the revolving credit facility $ 28,000,000    
Shares issued during period, public offering 3,869,750    
Revolving Credit Facility [Member] | SunTrust Bank [Member] | Swingline Sub Facility [Member]      
Line of Credit Facility [Line Items]      
Maximum borrowing capacity under credit facility   5,000,000  
Revolving Credit Facility [Member] | SunTrust Bank [Member] | Letter of Credit Subfacility [Member]      
Line of Credit Facility [Line Items]      
Maximum borrowing capacity under credit facility   $ 5,000,000  
Revolving Credit Facility [Member] | SunTrust Bank [Member] | Federal Funds Effective Swap Rate [Member]      
Line of Credit Facility [Line Items]      
Line of Credit Facility, Interest Rate During Period   0.50%  
Revolving Credit Facility [Member] | SunTrust Bank [Member] | Base Rate [Member]      
Line of Credit Facility [Line Items]      
Line of Credit Facility, Interest Rate During Period   1.00%  
Revolving Credit Facility [Member] | SunTrust Bank [Member] | Minimum [Member]      
Line of Credit Facility [Line Items]      
Interest coverage ratio   300.00%  
Revolving Credit Facility [Member] | SunTrust Bank [Member] | Minimum [Member] | Base Rate [Member]      
Line of Credit Facility [Line Items]      
Applicable margin for loans   0.50%  
Revolving Credit Facility [Member] | SunTrust Bank [Member] | Minimum [Member] | Eurodollar [Member]      
Line of Credit Facility [Line Items]      
Applicable margin for loans   1.50%  
Revolving Credit Facility [Member] | SunTrust Bank [Member] | Maximum [Member]      
Line of Credit Facility [Line Items]      
Maximum total leverage ratio   300.00%  
Revolving Credit Facility [Member] | SunTrust Bank [Member] | Maximum [Member] | Base Rate [Member]      
Line of Credit Facility [Line Items]      
Applicable margin for loans   1.50%  
Revolving Credit Facility [Member] | SunTrust Bank [Member] | Maximum [Member] | Eurodollar [Member]      
Line of Credit Facility [Line Items]      
Applicable margin for loans   2.00%  
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.5.0.2
Related Party Transactions - Additional Information (Detail)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2016
USD ($)
Sep. 30, 2015
USD ($)
Jun. 30, 2015
USD ($)
Employees
shares
Sep. 30, 2016
USD ($)
Sep. 30, 2015
USD ($)
shares
Related Party Transaction [Line Items]          
Restricted share units issued         49,310
Stock based compensation expense | $ $ 512 $ 440   $ 1,516 $ 2,787
Chief Executive Officer [Member]          
Related Party Transaction [Line Items]          
Number of common stock contributed     54,241    
Restricted share units issued     49,310    
Number of employees eligible to receive common stock | Employees     600    
Stock based compensation expense | $     $ 1,500    
Common stock unissued shares treated as expense     4,931    
EXCEL 51 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 52 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 53 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 55 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 142 193 1 false 40 0 false 6 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.healthstream.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 103 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.healthstream.com/taxonomy/role/StatementOfFinancialPositionClassified Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.healthstream.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 105 - Statement - Condensed Consolidated Statements of Income (Unaudited) Sheet http://www.healthstream.com/taxonomy/role/StatementOfIncomeAlternative Condensed Consolidated Statements of Income (Unaudited) Statements 4 false false R5.htm 106 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited) Sheet http://www.healthstream.com/taxonomy/role/StatementOfOtherComprehensiveIncome Condensed Consolidated Statements of Comprehensive Income (Unaudited) Statements 5 false false R6.htm 107 - Statement - Condensed Consolidated Statement of Shareholders' Equity (Unaudited) Sheet http://www.healthstream.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome Condensed Consolidated Statement of Shareholders' Equity (Unaudited) Statements 6 false false R7.htm 108 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.healthstream.com/taxonomy/role/StatementOfCashFlowsIndirect Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 109 - Disclosure - Basis of Presentation Sheet http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock Basis of Presentation Notes 8 false false R9.htm 110 - Disclosure - Recent Accounting Pronouncements Sheet http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock Recent Accounting Pronouncements Notes 9 false false R10.htm 111 - Disclosure - Income Taxes Sheet http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock Income Taxes Notes 10 false false R11.htm 112 - Disclosure - Stock Based Compensation Sheet http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Stock Based Compensation Notes 11 false false R12.htm 113 - Disclosure - Earnings Per Share Sheet http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock Earnings Per Share Notes 12 false false R13.htm 114 - Disclosure - Marketable Securities Sheet http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock Marketable Securities Notes 13 false false R14.htm 115 - Disclosure - Business Combinations Sheet http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock Business Combinations Notes 14 false false R15.htm 116 - Disclosure - Business Segments Sheet http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock Business Segments Notes 15 false false R16.htm 117 - Disclosure - Debt Sheet http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock Debt Notes 16 false false R17.htm 118 - Disclosure - Related Party Transactions Sheet http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock Related Party Transactions Notes 17 false false R18.htm 119 - Disclosure - Recent Accounting Pronouncements (Policies) Sheet http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlockPolicies Recent Accounting Pronouncements (Policies) Policies http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock 18 false false R19.htm 120 - Disclosure - Stock Based Compensation (Tables) Sheet http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables Stock Based Compensation (Tables) Tables http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock 19 false false R20.htm 121 - Disclosure - Earnings Per Share (Tables) Sheet http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables Earnings Per Share (Tables) Tables http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock 20 false false R21.htm 122 - Disclosure - Marketable Securities (Tables) Sheet http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables Marketable Securities (Tables) Tables http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock 21 false false R22.htm 123 - Disclosure - Business Combinations (Tables) Sheet http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlockTables Business Combinations (Tables) Tables http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock 22 false false R23.htm 124 - Disclosure - Business Segments (Tables) Sheet http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlockTables Business Segments (Tables) Tables http://www.healthstream.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock 23 false false R24.htm 125 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation Income Taxes - Additional Information (Detail) Details 24 false false R25.htm 126 - Disclosure - Stock Based Compensation - Additional Information (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation Stock Based Compensation - Additional Information (Detail) Details 25 false false R26.htm 127 - Disclosure - Stock Based Compensation - Stock Based Compensation Expense Recorded in Condensed Consolidated Statements of Income (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseRecordedInCondensedConsolidatedStatementsOfIncome Stock Based Compensation - Stock Based Compensation Expense Recorded in Condensed Consolidated Statements of Income (Detail) Details 26 false false R27.htm 128 - Disclosure - Earnings Per Share - Additional Information (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureEarningsPerShareAdditionalInformation Earnings Per Share - Additional Information (Detail) Details 27 false false R28.htm 129 - Disclosure - Earnings Per Share - Computation of Basic and Diluted Earnings Per Share (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureEarningsPerShareComputationOfBasicAndDilutedEarningsPerShare Earnings Per Share - Computation of Basic and Diluted Earnings Per Share (Detail) Details 28 false false R29.htm 130 - Disclosure - Marketable Securities - Fair Value of Available for Sale Marketable Securities (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureMarketableSecuritiesFairValueOfAvailableForSaleMarketableSecurities Marketable Securities - Fair Value of Available for Sale Marketable Securities (Detail) Details 29 false false R30.htm 131 - Disclosure - Business Combinations - Additional Information (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformation Business Combinations - Additional Information (Detail) Details 30 false false R31.htm 132 - Disclosure - Business Combinations - Summary of Purchase Price (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureBusinessCombinationsSummaryOfPurchasePrice Business Combinations - Summary of Purchase Price (Detail) Details 31 false false R32.htm 133 - Disclosure - Business Combinations - Summary of Fair Value of Assets Acquired and Liabilities Assumed (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureBusinessCombinationsSummaryOfFairValueOfAssetsAcquiredAndLiabilitiesAssumed Business Combinations - Summary of Fair Value of Assets Acquired and Liabilities Assumed (Detail) Details 32 false false R33.htm 134 - Disclosure - Business Combinations - Components of Identifiable Intangible Assets and Estimated Useful Lives (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureBusinessCombinationsComponentsOfIdentifiableIntangibleAssetsAndEstimatedUsefulLives Business Combinations - Components of Identifiable Intangible Assets and Estimated Useful Lives (Detail) Details 33 false false R34.htm 135 - Disclosure - Business Combinations - Summary of Unaudited ProForma Financial Information (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureBusinessCombinationsSummaryOfUnauditedProFormaFinancialInformation Business Combinations - Summary of Unaudited ProForma Financial Information (Detail) Details 34 false false R35.htm 136 - Disclosure - Business Combinations - Changes In Carrying Amount of Goodwill (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureBusinessCombinationsChangesInCarryingAmountOfGoodwill Business Combinations - Changes In Carrying Amount of Goodwill (Detail) Details 35 false false R36.htm 137 - Disclosure - Business Segments - Business Segment Information Based on Net Revenues and Operating Income (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureBusinessSegmentsBusinessSegmentInformationBasedOnNetRevenuesAndOperatingIncome Business Segments - Business Segment Information Based on Net Revenues and Operating Income (Detail) Details 36 false false R37.htm 138 - Disclosure - Business Segments - Business Segment Information Based on Assets (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureBusinessSegmentsBusinessSegmentInformationBasedOnAssets Business Segments - Business Segment Information Based on Assets (Detail) Details 37 false false R38.htm 139 - Disclosure - Debt - Additional Information (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureDebtAdditionalInformation Debt - Additional Information (Detail) Details 38 false false R39.htm 140 - Disclosure - Related Party Transactions - Additional Information (Detail) Sheet http://www.healthstream.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation Related Party Transactions - Additional Information (Detail) Details 39 false false All Reports Book All Reports hstm-20160930.xml hstm-20160930.xsd hstm-20160930_cal.xml hstm-20160930_def.xml hstm-20160930_lab.xml hstm-20160930_pre.xml true true ZIP 57 0001193125-16-757218-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-16-757218-xbrl.zip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end